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Abstract
Mutations in the gene CEP290 cause an array of debilitating and phenotypically distinct human diseases,
ranging in severity from the devastating blinding disease Leber congenital amaurosis (LCA) to Senior
LÃ¸ken Syndrome, Joubert syndrome, and the embryonically lethal Meckel-GrÃ¼ber syndrome. The
pathology observed in these diseases is thought to be due to CEP290's essential role in the development
and maintenance of the primary cilium, but despite its critical role in biology and disease we know only
little about CEP290's function. Here we identify four novel functional domains of the protein, showing that
CEP290 directly binds to cellular membranes through an N-terminal domain that includes a highly
conserved amphipathic helix motif, and to microtubules through a domain located within its myosin-tail
homology domain. Furthermore, CEP290 activity was found to be regulated by two novel autoinhibitory
domains within its N- and C-termini, both of which were also found to play critical roles in regulating
ciliogenesis. Disruption of the microtubule-binding domain in the rd16 mouse LCA model was found to be
sufficient to induce significant deficits in cilium formation leading to retinal degeneration. Taking these
findings into account, we developed a novel model that accurately predicts patient CEP290 protein levels
in a mutation-specific fashion. Predicted CEP290 protein levels were found to robustly correlate with
disease severity for all reported CEP290 patients. All these data implicate CEP290 as an integral
structural and regulatory component of the primary cilium and provide insight into the pathological
mechanisms of LCA and related ciliopathies. Our findings also suggest novel strategies for therapeutic
intervention in the treatment of CEP290-based disease that, if fully realized, would be the first treatment
available for the many patients suffering the devastating effects of CEP290 dysfunction.
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ABSTRACT

BRIDGING THE GAP:
DEFINING THE MOLECULAR MECHANISMS OF CEP290 DISEASE PATHOGENESIS

Theodore George Drivas
Dr. Jean Bennett

Mutations in the gene CEP290 cause an array of debilitating and phenotypically distinct
human diseases, ranging in severity from the devastating blinding disease Leber congenital
amaurosis (LCA) to Senior Løken Syndrome, Joubert syndrome, and the embryonically lethal
Meckel-Grüber syndrome. The pathology observed in these diseases is thought to be due to
CEP290’s essential role in the development and maintenance of the primary cilium, but despite
its critical role in biology and disease we know only little about CEP290’s function. Here we
identify four novel functional domains of the protein, showing that CEP290 directly binds to
cellular membranes through an N-terminal domain that includes a highly conserved amphipathic
helix motif, and to microtubules through a domain located within its myosin-tail homology
domain. Furthermore, CEP290 activity was found to be regulated by two novel autoinhibitory
domains within its N- and C-termini, both of which were also found to play critical roles in
regulating ciliogenesis. Disruption of the microtubule-binding domain in the rd16 mouse LCA
model was found to be sufficient to induce significant deficits in cilium formation leading to
retinal degeneration. Taking these findings into account, we developed a novel model that
x

accurately predicts patient CEP290 protein levels in a mutation-specific fashion. Predicted
CEP290 protein levels were found to robustly correlate with disease severity for all reported

CEP290 patients. All these data implicate CEP290 as an integral structural and regulatory
component of the primary cilium and provide insight into the pathological mechanisms of LCA
and related ciliopathies. Our findings also suggest novel strategies for therapeutic intervention
in the treatment of CEP290-based disease that, if fully realized, would be the first treatment
available for the many patients suffering the devastating effects of CEP290 dysfunction.
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PREFACE

This dissertation presents a work of molecular biology, cell biology, biochemistry, and
bioinformatics that attempts to address multiple fundamental questions regarding Centrosomal
protein of 290 kDa, or CEP290, and its role in the function of the primary cilium and in human
disease. It is my hope that the work laid out within these pages should not only contribute to
our understanding of the basic biology of the primary cilium, but that it may someday aid in the
development of novel therapeutic interventions for patients suffering the devastating effects of
CEP290 related disorders.

I began this project by asking a simple question – can I break CEP290 down into individual units
of discrete functionality? This simple question spawned multiple lines of investigation that
resulted in a new understanding of CEP290’s role in the primary cilium. Like the LEGO-obsessed
child I have always been, digging through the LEGO bin for the perfect piece for the project at
hand, I was fascinated by the unique properties of each piece of the protein I had created – a
microtubule binding domain here, a membrane binding domain there. Starting with a protein
broken into five pieces, I had soon generated twelve, then eighteen, and finally thirty-two
CEP290 fragments. The smaller and smaller the pieces got the more I discovered – novel
regulatory domains, new interacting partners, and, of course, more questions.

With my lab notebook overflowing with CEP290 pieces, I began to wonder whether I’d ever be
able to fit any of them together. I began assembling them, like LEGO bricks, and as I assembled I
began to see how different pieces might connect. The pieces began to suggest a critical role for
xix

CEP290 in maintaining the structural integrity of the cilium. Through a little bit of hard work
(and at least as much dumb luck) I demonstrated how the breakdown of this structural integrity
can result in severe retinal degeneration in a mouse model of human disease. With this
newfound knowledge, and in collaboration with fantastic researchers both at UPenn and the
University of Iowa, I formulated and validated a novel model for CEP290 disease pathogenesis
that explains, for the first time, how different mutations in the same gene can result in such
drastically different diseases. More recently my childhood instinct to push the directions aside
and dive straight for the LEGOs took over again as I attempted to assemble all of my CEP290
pieces into a finished product without a complete instruction manual. Even as I write this I find it
hard to exchange the pipette for the pen, and have begun experiments to see how much the

miniCEP290 I pieced together looks like the picture on the box.

What follows is a discussion of much of the work that I have done on CEP290. I begin with a
comprehensive introduction that lays out our understanding of the primary cilium and CEP290
up to the point of the publication of this work. The introduction, divided into three parts, covers
the history, structure, and function of the primary cilium, diseases arising from ciliary
dysfunction, and, finally, the structure, function, regulation, and clinical importance of CEP290.
Following the introduction is a presentation, in three chapters, of the body of work that
comprises this thesis. The first and most substantial chapter describes the discovery of four
novel functional domains within the CEP290 protein and the role that these domains play in
CEP290 function, regulation, and disease. The subsequent chapter details the formulation and
validation of a novel model for CEP290 disease pathogenesis. The third chapter deals with my
recent work in the application of my findings towards the development of a miniCEP290
xx

therapeutic. Finally, in the last chapter, the broad implications and future directions of my
findings are discussed.

As a child I used to save my LEGO creations for as long as possible, until necessity or my mother
dictated that I put them back into the LEGO bin. But inevitably a chunk of bricks would survive as
it was tossed back in and would find itself serving as the foundation for the next bigger, more
ambitious project. I can only humbly hope that some small piece of this work will ultimately find
its way into such a project and help make a difference in the lives of those CEP290 patients and
supporters who have already made a difference in mine.

-Theodore G. Drivas
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CHAPTER 1: INTRODUCTION

Theodore G. Drivas1

1. Cell and Molecular Biology Graduate Group and the F.M. Kirby Center for
Molecular Ophthalmology, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA 19104, USA
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The primary cilium

A brief history
The primary cilium of the mammalian cell was first
described by Zimmerman more than 100 years ago
(Zimmermann, 1898), but it has taken the scientific
community nearly as long to appreciate its
importance. This lone, immotile projection of the
apical membrane found on nearly every vertebrate
cell (Mahjoub, 2013) took a back seat to its more
attention-grabbing cousin, the motile cilium, as
biologists honed in on this organelle as the true
mover and shaker of the microscopic world.
Research quickly progressed in the characterization
of motile cilia and the cells they ornamented while
the primary cilium remained largely ignored.

With the advent of electron microscopy, however,
the similarity between motile and primary cilia
became

sharply

apparent

when

both

were

discovered to be membrane-surrounded organelles
built around a ring of microtubule doublets. In 1952
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Figure 1.1 Schematic representation of
primary and motile cilia in cross
section
A. Representation of a primary cilium
in cross section illustrating the 9+0
arrangement of microtubule doublets
within the ciliary membrane (teal).
B. Representation of a motile cilium in
cross section illustrating the 9+2
arrangement of microtubule doublets,
inner (red) and outer (blue) dynein
arms, nexin connections (black), and
radial spokes (blue), all of which are
required for motility.

Fawcett and Porter famously described the 9+2 arrangement of the motile cilium’s microtubule
axoneme (Figure 1.1B; Fawcett and Porter, 1954), and just a few years later De Robertis,
perhaps less famously, described the 9+0 arrangement of the axoneme of the primary cilium.
(Figure 1.1A; De Robertis, 1956). It soon became apparent that primary cilia were nearly
ubiquitous – Barnes, Dahl, Grillo, Palay, Sorokin and others began publishing report after report
of primary cilia in cell types and tissues as diverse as fibroblasts, neurons, the pituitary gland,
and muscle (Barnes, 1961; Dahl, 1963; Grillo and Palay, 1963; Sorokin, 1962).

However, even with the realization that the primary cilium appeared to be a component of
nearly every cell of the human body, scientists continued to shy away from intense study of the
organelle as the consensus at the time was that it was merely vestigial, a lonely reminder of our
evolutionary past. A few outspoken ciliary biologists, however, began to advocate for a different
hypothesis – perhaps the primary cilium, an outgrowth of the centriole, is formed by dividing
cells to arrest cell division, sequester the centrosome, and enter quiescence (Dingemans, 1969;
Fonte et al., 1971). A number of lines of research seemed to support this presumption and to
this day this is still considered an important aspect of the primary cilium’s function. The vast
importance of the organelle was about to become much more apparent, however, with the
publication of Poole, Flint, and Beaumont’s work on primary cilia in chondrocytes.

In 1985 Poole and colleagues were the first to clearly, if perhaps speculatively, label the primary
cilium a sensory organelle; or, to use their own words, a “cellular cybernetic probe” (Poole et al.,
1985). It was at this point that the field of ciliary biology truly took off. With the realization that
the primary cilium was critical to the cell’s ability to interact with its environment, biologists
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finally began to treat the organelle with the respect it currently commands. It soon became clear
that deficits in cilium formation and function were at the root of a number of human disease
syndromes (Pazour et al., 2000, 2002; Praetorius and Spring, 2001). The more the scientific
community began to learn about these diseases, the ciliopathies, the more they learned about
the essential basic biology of the organelle.

In the past ten years the number of papers published in the field of ciliary biology has exploded
and we are finally beginning to understand the pathways, mechanisms, and components
required by the cell for building and operating the organelle. The pathways involved in
ciliogenesis are remarkably conserved, and thoroughly understanding them will help illuminate
both the role of the cilium in human disease and the role of particular ciliary proteins, such as
CEP290, in human health and pathology.

Ciliogenesis
Ciliogenesis is the name given to the highly orchestrated sequence of events that together give
rise to the primary cilium. Ciliogenesis requires the temporal and spacial coordination of a
number of proteins and subcellular machines, but can be divided into a number of distinct steps
(Sorokin, 1968). While we tend to discuss each of these steps as discrete events, it is almost
certain that many of these steps occur concurrently, at least to a degree, with checkpoints along
the way to ensure proper cilium formation (Miyamoto et al., 2011).

To understand ciliogenesis, however, we must first understand the organelle from which the
cilium is derived. The cilium is, at its most basic level, a membrane-enclosed extension of the
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centriole (Bornens, 2012). Each centriole is composed of a ring of nine microtubule triplets, at
40° angles to each other, that come together to form a short cylinder roughly 0.25 µm in
diameter and a little less than 1 µm long (Gönczy, 2012). Two centrioles, a mother and daughter
(the daughter being built using the mother as a template upon completion of the cell cycle),
come together at a 90° angle within a cloud of dense pericentriolar material to form the
centrosome (Bettencourt-Dias and Glover, 2007). The centrosome is the organelle familiar to
even middle school biology students (I still remember using pieces of Twizzlers to represent the
centrosome for a 6th grade “edible cell” project) as the site of spindle body formation during
mitosis. Spindle formation is a critical step along the way to cell division wherein the
chromosomes, attached to microtubule projections emanating from the centrosome, are
induced to line up along the midline of the cell before being pulled apart to opposite cellular
poles upon the completion of anaphase (Bettencourt-Dias and Glover, 2007).

As important as spindle formation is, the cell spends only a fraction of its time in mitosis. During
the rest of the cell cycle the centrosome is repurposed for the equally important job of acting as
the cell’s microtubule organizing center. It is in this capacity that the centrosome helps to define
cell polarity, position cellular organelles, and pave the roadways that make up the intracellular
highway in the form of the microtubule network (Bettencourt-Dias and Glover, 2007).

But just as the cell spends only a small portion of the cell cycle in mitosis, most cells in the
human body spend only a small fraction of their time in the cell cycle (Vermeulen et al., 2003).
Upon terminal differentiation, cells can choose to exit the cell cycle and enter a phase of their
lives known as G0. It is during G0 that we return to the story of ciliogenesis (Goto et al., 2013).
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While we can never know the motivation behind any evolutionary “decision,” it has been
proposed that the primordial differentiated cell choose to sequester its centriole at the cell
surface to guard against aberrant reentry into the cell cycle. Perhaps this was the case, or
perhaps the evolutionary drive for a highly specialized cellular antenna was the motivating
factor (Cavalier-Smith, 2010; Satir et al., 2008), but regardless of etiology evolution dictated
that, upon entry into G0, the vertebrate cell sequester its centrosome in the structure we know
as the primary cilium (Kobayashi and Dynlacht, 2011).

Figure 1.2. A schematic diagram of the events involved in ciliogenesis.
(A) The centrosome acts as the microtubule organizing center of the cell during the cell cycle,
helping to position the nucleus and other organelles. (B) As the cell enters G1/0 the centrosome
begins to migrate towards the cell surface. (C) The mother centriole docks with a Golgi-derived
ciliary vesicle by means of the ciliary transition fibers. (D) Axoneme extension begins into an
invagination in the ciliary vesicle while the whole complex docks at the apical cellular membrane
(E) The ciliary vesicle fuses with the plasma membrane, the axoneme completes extension, and
ciliogenesis is complete.
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Ciliogenesis, then, begins at G0 (it is worth mentioning that eukaryotic cells sometimes also
produce cilia during the G1 phase of the cell cycle through the same process discussed below)
when a signal, which has not yet been fully elucidated, induces the centrosome to begin
migrating towards the apical surface of the cell (Figure 1.2A; Kobayashi and Dynlacht, 2011).
During this journey the mother centriole encounters and docks with a Golgi-derived ciliary
vesicle (Figure 1.2B; Sorokin, 1962, 1968). Dense, proteinaceous transition fibers begin to
extend from the mother centriole, anchoring the centrosome (now referred to as a basal body)
to the ciliary vesicle that will ultimately give rise to the ciliary membrane (Figure 1.2C; Anderson,
1972; Deane et al., 2001). It is at this point that two critical steps occur: the basal body must
nucleate the outgrowth of the microtubules that will go on to make up the core of the primary
cilium (Figure 1.2D; Sorokin, 1962), and the ciliary vesicle must dock at and fuse with the plasma
membrane (Figure 1.2E; Sorokin, 1962, 1968).

Once each of these critical steps is accomplished, ciliogenesis is complete. The ciliary axoneme
will continue to elongate until it reaches a stable length of about 3-8 µm (Besschetnova et al.,
2010), driven by the trafficking of axonemal components to the ciliary compartment and by the
opposing inward and outward forces of intraflagellar transport (Ishikawa and Marshall, 2011;
Rosenbaum and Child, 1967).

The structure of the cilium
The fully-formed primary cilium can be divided into a number of distinct domains. Below is a
discussion of each region of the cilium, moving from proximal to distal, along with a brief
description of the structure, components, and hypothesized roles of each. Figure 1.3 serves to
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illustrate many of these same points and, while it will be specifically referenced at different
points in the following text, it also provides a good stand-alone summary of ciliary structure.

Basal body
During the process of ciliogenesis the centrosome migrates to the cell surface where it matures
into the basal body of the nascent primary cilium. While the basal body consists of both the
mother and daughter centriole of the centrosome, it is only the mother centriole that acts in the
attachment to the cell cortex and the nucleation of the microtubules that will ultimately make
up the core of the ciliary axoneme (Beisson and Jerka-Dziadosz, 1999).

Figure 1.3. A diagram
of the structure of the
primary cilium
An illustration of the
different domains of
the cilium in profile and
in cross section. The
microtubules of the
basal
body
are
indicated
by
grey
cylinders.
The
microtubules of the
axoneme are indicated
by green cylinders. The
distal appendages are
indicated
by
blue
wedges. The ciliary Ylinks are depicted in
red while the ciliary
necklace is depicted by
yellow dots. At each
distinct level of the
cilium a cross section of
the
organelle
is
provided.
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The basal body is, not surprisingly, nearly identical in structure to the centriole. It is
characterized by a ring of 9 microtubule triplets, each containing a fully formed A microtubule
and two incomplete microtubules, the B and C tubules (Figure 1.3, Basal Body; Avidor-Reiss and
Gopalakrishnan, 2012; Azimzadeh and Marshall, 2010). The mother centriole of the basal body is
distinguished from the daughter by the presence of the distal appendages, ancillary structures
found at the distal end of the mother centriole (Paintrand et al., 1992). In the basal body, these
distal appendages are extended and elaborated to form the dense propeller-like array of
transition fibers, the strong physical connectors between the basal body and the cell cortex
(Ringo, 1967; Sorokin, 1968).

Although often considered a more-or-less static structure, important more for the structural
stability of the cilium than anything else, the basal body also serves as a waypoint for ciliary
transport, acting as a loading dock for ciliary cargo (Deane et al., 2001; Hsiao et al., 2009). The
basal body, even while attached to the cilium, also continues to act as the major microtubule
organizing center for the cell (Basten and Giles, 2013). Thus, cilium-directed trafficking of
proteins and vesicles is accomplished by means of dynein-mediated transit along the
microtubule network towards the microtubule minus ends and the basal body. Cargos then
accumulate at the basal body before being transported into the cilium and across the diffusion
barrier at the ciliary transition zone (Cole et al., 1998; Stephan et al., 2007).

Transition zone
Just past the basal body lies the transition zone of the cilium. Here the A and B microtubules of
the nine basal body microtubule triplets elongate, giving rise to the 9+0 arrangement of
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microtubule doublets characteristic of the transition zone and ciliary axoneme (Czarnecki and
Shah, 2012; Reiter et al., 2012). The aptly named transition zone is the point of transition from
basal body to true axoneme. As such, it contains a number of important protein complexes that
both define its structure and play critical roles in the regulation of cilium formation and function
(Szymanska and Johnson, 2012).

Perhaps the most striking feature of the transition zone, when compared to the rest of the
ciliary axoneme, is the presence of the dense, proteinaceous ciliary Y-links and the punctate
ciliary necklace (Figure 1.3, Transition Zone). The Y-links span the distance between the
microtubule core of the transition zone and the overlying membrane (Craige et al., 2010).
Immediately abutting the ciliary Y-links is the ciliary necklace, a circumferential collection of
several parallel strands of intramembranous particles that stud the ciliary membrane (Gilula and
Satir, 1972; Torikata, 1988). These two structures contain dozens of proteins that appear critical
for ciliary function. It is thought that these two structures act together to form a ciliary pore and
diffusion barrier, both of which are responsible for maintaining the ciliary milieu (Kee et al.,
2012; Ounjai et al., 2013). In fact, when either of these structures is disrupted, protein
trafficking into the cilium becomes highly dysregulated with non-ciliary proteins gaining access
to the organelle and ciliary proteins unable to enter (Craige et al., 2010).

As one might imagine, mutations in many of the protein components of the ciliary transition
zone can result in severe human disease. This is thought to be due to the critical nature of the
transition zone in establishing and supporting intraflagellar transport (IFT), the highly regulated
process whereby ciliary proteins are transported into and along the axoneme (Hsiao et al.,
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2012). Even small defects in the transition zone can have deleterious effects further down the
axoneme since transition zone dysfunction can lead to the detainment or complete exclusion of
protein components destined for the ciliary compartment.

The ciliary pocket
Immediately adjacent to the transition zone is a structure known as the ciliary pocket. This
region of the organelle, found in most, but not all, vertebrate cilia, consists of a depression in
the plasma membrane in a ring immediately surrounding the ciliary axoneme at the point where
the regular plasma membrane transitions to the well-defined ciliary membrane (this structure is
not shown in Figure 1.3 but is present in Figure 1.2E; (Benmerah, 2013; Molla-Herman et al.,
2010)). The ciliary pocket is thought to be critical in the trafficking of ciliary membrane proteins
into the organelle for axonemal extension and ciliary function (Molla-Herman et al., 2010). In
some cilia, such as those of endothelial cells, the ciliary pocket can be as deep as the axoneme is
long, such that the axoneme barely projects past the surface of the cell (Geerts et al., 2011). In
other cells, such as the epithelial cells of the renal tubules, the ciliary pocket is so small it is
barely noticeable (Geerts et al., 2011).

Ciliary axoneme
The ciliary axoneme begins where the transition zone leaves off. The microtubule doublets of
the transition zone continue to extend distally, past the Y-links and ciliary necklace, to produce
the canonical membrane-enveloped 9+0 organization of the primary cilium (Figure 1.3, Proximal
Axoneme; De Robertis, 1956). The organelle continues to extend in this fashion, projecting
outward and into the environment surrounding the cell. In the very distal region of the organelle
11

the B tubule of the microtubule doublet ceases to elongate, leading to a short stretch of 9 single
microtubule extensions that finally end, a few micrometers away from the basal body, at the
terminus of the organelle (Figure 1.3, Distal Axoneme; Sorokin, 1968).

One might say that the ultimate goal of ciliogenesis is the formation of the ciliary axoneme. As
important as the basal body and transition zone are, both to ciliary function and in human
disease, the function of the cilium is truly accomplished distally to both these regions.
Intraflagellar transport (IFT) drives the accumulation of innumerable signaling molecules, G
protein-coupled receptors, and downstream effector molecules within the axonemal lumen and
membrane, and it is the high concentration of these molecules that allows the cilium to perform
its function as the cell’s antenna (Boekhoff et al., 1990; Elias et al., 2004; Jenkins et al., 2006).
But exactly how do these molecules make their way into the cilium and along the axoneme?

Trafficking to the cilium
Proteins cannot be synthesized within the ciliary lumen and thus all the components of the
cilium must be specifically shuttled into the organelle from the cytosol (Rosenbaum and Child,
1967). Both soluble and membrane-associated proteins accumulate at the base of the cilium by
means of the network of microtubules that emanates from the ciliary basal body, the primary
microtubule organizing center for ciliated cells (Guo et al., 2006). Proteins can also reach the
base of the cilium by diffusion, both through the cytosol for soluble proteins and laterally across
the plasma membrane for transmembrane proteins, but recent evidence suggests that active
trafficking along microtubules plays a much more prominent role in ciliary trafficking
(Dammermann and Merdes, 2002; Quintyne and Schroer, 2002; Wright et al., 2011).
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Having completed their journey towards the ciliary base, proteins and vesicles accumulate
around the basal body awaiting the next step in their journey (Dammermann and Merdes, 2002;
Kubo et al., 1999). From here, soluble proteins must transit across the ciliary basal body and
transition zone to enter the organelle. The entry of proteins into the cilium is an active process,
the tight regulation of which is accomplished by a ciliary diffusion barrier that excludes all
proteins larger than 10kD and allows only the specific translocation of cilium-destined cargo in a
highly selective fashion (Calvert et al., 2010; Hu and Nelson, 2011; Kee et al., 2012; Najafi et al.,
2012). Recent evidence suggests that this is accomplished by a pore-like complex at the
transition zone of the cilium (Kee et al., 2012; Ounjai et al., 2013). This pore appears to share
much in common with the nuclear pore complex and, as with nuclear transport, ciliary transport
has recently been demonstrated to be dependent on a gradient of RanGTP/RanGDP, importin
and exportin proteins that act as shuttling chaperones, and even nuclear pore protein
components themselves (Dishinger et al., 2010; Kee et al., 2012). Just as nucleus-destined
proteins contain specific nuclear localization signals, proteins destined for the cilium appear to
contain some kind of ciliary localization signal (CLS) that mediates their entry into the organelle.
A number of CLSs have been identified, but no single canonical CLS sequence has yet been
defined (Berbari et al., 2008a; Dishinger et al., 2010).

These same CLSs also appear to serve in the targeting of membrane proteins to the ciliary
compartment (Geng et al., 2006; Ward et al., 2011). The specifics of membrane protein
translocation through the ciliary diffusion barrier are still debated, but it has been convincingly
demonstrated that Golgi-derived vesicles containing proteins destined for the cilium are
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recognized by means of their CLSs (Geng et al., 2006; Jenkins et al., 2006; Ward et al., 2011) and
chaperoned to the base of the cilium by the exocyst and BBSome, two complexes of proteins
critical in ciliary membrane trafficking (He and Guo, 2009; Mazelova et al., 2009). Ciliary
membrane transport is aided by a number of additional vesicular trafficking proteins such as
Clathrin, Rab8, Rab11, and the SNARE family of proteins (Kaplan et al., 2010; Mazelova et al.,
2009; Westlake et al., 2011). Once at the base of the cilium it is thought that these vesicles fuse
with the periciliary membrane and the transmembrane protein cargo then transits the ciliary
diffusion barrier by mechanisms not yet completely elucidated (Hu et al., 2010; Ou et al., 2007).

Intraflagellar transport
After successfully navigating the ciliary pore and diffusion barrier, proteins are transported
along the length of the cilium by means of a highly regulated process known as intraflagellar
transport (IFT). IFT was first observed by differential interference light microscopy in the

Chlamydomonas flagellum, the algal ortholog of the mammalian cilium (Kozminski et al., 1993).
Here small particles could be seen moving along the flagellar axoneme in opposite directions,
both towards and away from the tip of the organelle (Pedersen and Rosenbaum, 2008). The IFT
particles were noted to be closely associated with both the microtubules of the flagellar
axoneme and with the flagellar membrane and it wasn’t long before it was discovered that the
movement of these IFT particles was coordinated by a set of dynein and kinesin microtubule
motor proteins (Kozminski et al., 1995; Pazour et al., 1998). The microtubules of the cilium are
always organized with their plus ends projecting from the cell towards the tip of the organelle
(Binder et al., 1975), and thus it quickly became apparent that the anterograde motion of IFT
particles is driven by the kinesin class of microtubule motor proteins in association with
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Figure 1.4. A schematic summary of ciliary trafficking and IFT
(A) Cargos destined for the cilium (green) transit towards the basal body either by diffusion or
by means of the microtubule network, driven by cytoplasmic dynein (orange). Membrane
proteins destined for the cilium (black) can be transported in the same fashion, packaged in
golgi-derived vesicles, or can diffuse laterally along the plasma membrane towards the cilium.
Cargos then accumulate at the ciliary base before translocating through the ciliary pore at the
transition zone (red and yellow). Once within the cilium, ciliary components are shuttled along
the length of the axoneme by the process of IFT. Anterograde transport is accomplished by the
microtubule motor protein kinesin (pink), while retrograde transport is accomplished by the
axonemal dynein motor proteins (orange)
(B) While the specifics of ciliary pore translocation have not yet been fully worked out, the
import of many proteins has been shown to be dependent on the same class of importin
proteins (dark grey) that shuttle cargos into the nucleus. A gradient of RanGTP(red background)
and RanGDP (blue background) is established across the ciliary pore and this gradient helps
drive directional ciliary transport. An importin molecule, bound to RanGDP (red triangle,
phosphates in yellow) on the cytoplasmic side of the ciliary pore binds to a cilium-destined cargo
(green) by recognizing a ciliary localization signal contained within the protein’s amino acid
sequence. This complex then navigates the ciliary pore, exchanges RanGDP for RanGTP (red
square, phosphates in yellow) within the ciliary lumen, causing a conformation change in the
importin freeing the cargo protein. RanGTP-bound importin then exits the cilium, hydrolyzing
RanGTP to RanGDP within the cytoplasm to free inorganic phosphate (yellow) and affect a
comformational change returning the importin to its original state for the next round of import.
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the IFT-B subcomplex (Kozminski et al., 1995), while the retrograde movement of IFT particles
is driven by dynein family members in association with the IFT-A subcomplex of proteins (Pazour
et al., 1998; Pedersen and Rosenbaum, 2008).

IFT particles are loaded onto the IFT highway by a vast array of proteins, many of which are
certainly still unknown, but a key player in this process is the protein machine known as the
BBSome. The BBSome is a complex of a number of ciliary proteins that aid in the ciliary targeting
of membrane-associated proteins, the loading of cargo into IFT particles, and the recycling of
particles at the ciliary tip (Wei et al., 2012; Zhang et al., 2013). IFT particles, loaded onto the IFT
highway by the BBSome at the basal body, appear to move in a continuous loop – particles make
their way to the tip of the cilium, unload their cargo, begin retrograde transport, and are finally
recycled at the base for another round of transport (Wei et al., 2012). These cycles of IFT
accomplish multiple purposes. First, anterograde transport accomplishes the delivery of
retrograde transport machinery to the ciliary tip (Piperno et al., 1996), while retrograde
transport accomplishes the recycling of anterograde transport machinery to the ciliary base
(Pazour et al., 1999; Signor et al., 1999). Defects in transport in either direction will ultimately
lead to a breakdown in ciliary structure, either through the inability to initiate anterograde
transport and axoneme extension or by the depletion and accumulation of anterograde
transport machinery at the tip of the cilium with no means of recycling it (Engel et al., 2012).

Perhaps even more importantly, IFT is completely responsible for the shuttling of axonemal
subunits, signaling molecules, and all the components required for ciliary function to different
locations along the length of the organelle (Zhao and Malicki, 2011). Without IFT the growth and
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maintenance of the ciliary axoneme would be impossible, and the specialized signaling
environment of the cilium would not exist. All of the many transmembrane receptors, effector
proteins, and downstream signaling molecules that are critical to the cilium’s function as a
sensory organelle must be specifically trafficked into and along the cilium by IFT. In fact, failure
of important components of the IFT machinery can, as will become apparent, result in significant
human disease (Blacque et al., 2008).

Ciliary function
The principle that structure follows function (while obviously not adhered to in the organization
of the sections of this introduction) is certainly a truism for most biological systems. The cilium is
no exception – the great lengths that the cell goes to to produce and maintain such a highly
structured organelle is not without explanation. Much as the antennas we use to receive and
transmit electromagnetic waves have evolved over time to produce a shape most conducive to
this activity, the primary cilium has evolved into a highly specialized, highly efficient cellular
antenna. The unique signaling environment afforded by the cilium’s rigorously maintained
structure is critical to its function and allows for its participation in the coordination of
numerous cellular activities.

The cilium is critical in development, repair, homeostasis, and growth. These activities are all
triggered or inhibited by extracellular stimuli that the cilium senses and transduces to the rest of
the cell. It accomplishes this both by means of the large concentration of signaling molecules
within its membrane and lumen and by means of its strategic location on the apical surface of
the cell, the side most often in contact with the cellular environments critical for cellular
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function (Basten and Giles, 2013; Oh and Katsanis, 2012). The epithelial cells of the kidney
project cilia into the lumen of the renal tubules to detect and respond to fluid flow (McAteer et
al., 1986). Acinar cells of secretory organs project cilia into the acinar lumen where they are
critical in the development of the glandular structure and in maintaining and regulating
secretion (van Asselt et al., 2013). The endothelial cells of the circulatory system produce cilia,
submerged deep within profound ciliary pockets, which are thought to be essential in detecting
and responding to blood flow and serum composition (Geerts et al., 2011). Perhaps most
intriguingly, recent evidence has begun to suggest that the immune synapse that forms between
circulating T-cells and antigen presenting cells is driven by IFT machinery in a process that shares
much in common with ciliogenesis (Finetti et al., 2011).

While it is clear that primary cilia are present in and essential to nearly every organ system of
the human body, some signaling pathways and organ systems are more dependent on ciliary
function than others. Below is a discussion of some of the specialized functions that primary cilia
play in these diverse pathways and tissues.

Hedgehog signaling
The Hedgehog signaling pathway is critical during embryogenesis and plays an essential role in
the homeostasis of many adult tissues. Hedgehog signaling is mediated by the membrane
receptor Patched that actively inhibits the transmembrane protein Smoothened, resulting in the
proteolytic processing of the Gli family of transcription factors (Lum and Beachy, 2004). In the
processed state, the Gli proteins act to inhibit transcription at a number of genomic loci. When
the Patched receptor is bound by its ligand, Shh, inhibition of Smoothened is relieved – the Gli
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family proteins thus remain unprocessed, actively promoting transcription at the same genomic
loci (Lum and Beachy, 2004).

The proper function of the primary cilium is critical in each of these steps. The Gli proteins are
specifically trafficked to the tip of the cilium where they are processed and released to act as
transcriptional repressors in the nucleus (Haycraft et al., 2005). In the absence of Shh ligand,
Patched is confined to the ciliary membrane (Rohatgi et al., 2007), actively excluding
Smoothened from the ciliary compartment. The binding of Patched to Shh ligand results in its
exit from the cilium and the concurrent entry of the Smoothened effector molecule (Corbit et
al., 2005). Once inside the cilium Smoothened gains access to the Gli proteins at the ciliary tip,
arresting their proteolytic processing and releasing them to the nucleus in their transcriptionpromoting forms (Haycraft et al., 2005).

Defects in cilium formation have a catastrophic effect on embryogenesis and development, and
much of this is thought to be due to deficiencies in Hedgehog pathway regulation (Fliegauf et al.,
2007; Wang et al., 2007). Neural tube closure defects, abnormal brain morphology, and limb
patterning defects, all hallmarks of deficiencies in Shh signaling, are also seen in human
ciliopathy patients and mouse models of ciliary disease (Huangfu et al., 2003). The precise role
that the Hedgehog pathway plays in the maintenance and function of adult tissues is still being
worked out, but it is clear that it is essential in the proliferation of adult hematopoietic and
neural stem cells and in the processes of growth and regeneration in general (Bhardwaj et al.,
2001; Han et al., 2008; Ruiz i Altaba et al., 2002). It will be interesting to see the role the primary
cilium plays in regulating these processes as we continue to learn more about the organelle.
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Wnt signaling
While the exact role that the primary cilium plays in Shh signaling has been more or less
resolved, the organelle’s role in Wnt signaling is still being debated. The Wnt family of ligands
represents a class of secreted lipid-modified proteins that affect numerous critical processes
within the cell. This is accomplished by the interaction of Wnt ligands with the Frizzled class of
receptor proteins that, in the canonical Wnt pathway, results in activation of the cytoplasmic
pool of the protein Disheveled, ultimately acting to inhibit the protein Axin. (Komiya and Habas,
2008). Axin normally localizes to the destruction complex where it works to target the
transcription factor β-Catenin for degradation, but with Axin’s inhibition β-Catenin accumulates
and enters the nucleus, affecting numerous changes in the transcriptional regulation of the cell
(MacDonald et al., 2009; Rao and Kühl, 2010). In the noncanonical Wnt signaling pathway,
activated Frizzled receptor binds directly to cytoplasmic Disheveled, resulting in its activation
and accumulation at the plasma membrane. Here Disheveled initiates a β-Catenin-independent
signaling cascade that ultimately results in major cytoskeletal changes (Gordon and Nusse,
2006).

A number of different lines of evidence have begun to implicate the primary cilium as critical in
the regulation of both of these pathways. Numerous studies have suggested that the primary
cilium acts to restrain canonical Wnt signaling through the sequestration of β-Catenin and
Disheveled at the ciliary basal body (Gerdes et al., 2007). In support of this model, knock down
of a number of proteins essential for ciliogenesis results in increased nuclear β-Catenin (Basten
and Giles, 2013; Corbit et al., 2008; Kishimoto et al., 2008). At the same time, however, many
groups have begun publishing reports of the primary cilium mediating both activation and
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repression of the non-canonical Wnt signaling pathway (Gerdes et al., 2007; Leitch et al., 2008;
Ross et al., 2005). While the details of the cilium’s role in Wnt signaling are not yet settled, it
seems that the organelle may be playing a role in the switch between the canonical and noncanonical pathways (Simons et al., 2005). Regardless of the specific mechanisms involved, it is
clear that the cilium has strong input on Wnt pathway regulation.

Fluid flow
One of the more interesting roles that the cilium plays is in the sensing of fluid flow in the renal
tubules. The renal tubules connect the glomeruli (the sites of blood filtration) to the collecting
ducts (the sites of urine collection) of the kidney. It is in the renal tubules that components of
the filtrate, including water, sugar, salt, and amino acids, are reabsorbed by the body and the
urine is concentrated (Torres and Harris, 2006).

While the importance of the renal tubule epithelial cells’ ability to sense fluid flow for the
proper function of the kidney seems apparent, what is less obvious is how this ability is essential
for renal development and growth. Many ciliopathies result in the development of renal cysts
that, in some cases, are severe enough to result in embryonic lethality (Torres and Harris, 2006).
These cysts are a direct result of the renal epithelial cells’ inability to sense fluid flow during
kidney development. Normally these cells divide in a coordinated fashion along the same plane
as fluid motion, working to elongate the renal tubules (Fischer et al., 2006). When ciliary
mechanotransduction is impaired, these cells are no longer able to coordinate their division in
the direction of fluid flow and begin dividing in a haphazard fashion, resulting in the formation
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of cystic structures that continue to enlarge over time and with repeated cell divisions (Luyten et
al., 2010).

Deficits in many different ciliary proteins can result in such a phenotype – as one might imagine,
any mutation that blocks ciliogenesis has a good chance of eliciting renal cyst formation
(Lancaster and Gleeson, 2009; Nishio et al., 2010). Such deficits are
often also accompanied by extrarenal disease manifestations, as a
properly functioning cilium is critical to many different tissues
(Lancaster and Gleeson, 2009). The specific dysfunction of ciliary
components essential only to mechanosensation, however, can result
in an isolated renal phenotype. Two examples of such components
are the polycystic kidney disease proteins Polycystin-1 and Polycystin2. Deflection of the cilium by fluid flow stresses the ciliary membrane
and causes a conformational change in these membrane proteins
creating a pore for the influx of calcium ions (Nauli et al., 2003). This
is an essential step in the detection of fluid flow and the key
underlying deficit in polycystic kidney disease and related disorders.

Figure 1.5. Schematic
representation of a rod
Just as the renal tubule epithelial cells produce cilia highly photoreceptor
A. Rod outer segment
specialized for mechanotransduction, the photoreceptor cells of the B. Connecting cilium
C. Rod inner segment
retina are characterized by a cilium highly specialized for D. Nucleus
E. Synaptic body
phototransduction. The main function of the photoreceptor is to
Phototransduction
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transform incident light energy into an electrical impulse to be transmitted to the brain. This is
accomplished through a complicated system of photopigments and enzymes, all of which must
be strictly compartmentalized for phototransduction to occur (Deretic et al., 1995). The process
of phototransduction is also highly energetically demanding. As such, the photoreceptor is a
very rigorously structured cell with different compartments dedicated to different activities
(Masland, 2001).

The photoreceptor cell can be divided into many different segments (Figure 1.5). The inner
segment of the cell serves as the cell’s powerhouse. Overflowing with mitochondria, this
segment is dedicated to the production of energy to make phototransduction possible (Mustafi
et al., 2009). The outer segment of the cell, on the other hand, is dedicated to light capture.
Here stacks of membranous disks full of photopigment sit, ready to capture incident photons
(Mustafi et al., 2009). These two compartments are separated by a structure known as the
connecting cilium. This structure, a derivative of the primary cilium, serves as the only passage
from the inner to outer segment (Röhlich, 1975). In fact, the entire outer segment can be
thought of as a highly elaborated primary cilium specialized for the process of
phototransduction (Louvi and Grove, 2011). As no protein production takes place within the
outer segment, all of its many components must transit through the connecting cilium to
assume functional positions within the outer segment disks – no small feat when one considers
that the entire outer segment is recycled every 10 days (Kevany and Palczewski, 2010). It is
precisely because of this high turnover rate and their complete dependence on the connecting
cilium and IFT that photoreceptors are so often affected by mutations in ciliary disease genes.
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Ciliary dysfunction
As one might suspect having read through the long list of cell types and cellular processes that
cilia are so intimately involved in, dysfunction of the primary cilium can lead to a whole host of
human diseases. These diseases are collectively known as ciliopathies and the organ systems
that they affect and the symptoms that they produce are as varied as the many different genes
involved in their pathogenesis.

Below is a discussion of the ciliopathies. I have divided this discussion into two main headings –
dysfunction of motile cilia and dysfunction of primary cilia. While the dysfunction of motile cilia
is clinically an important topic, the mutations that affect only motile cilia are less relevant to the
work presented in this thesis. For this reason I will spend less time discussing this class of
diseases.

Dysfunction of the primary cilium, on the other hand, receives much more attention in this
chapter. In addition to a general discussion of primary cilium dysfunction I have included
individual sections describing the details of many of the specific, diagnosable ciliopathies, such
as Joubert syndrome and Meckel-Gruber syndrome. Included at the end of the discussion on
primary cilium dysfunction is a section on the emerging evidence for the cilium’s involvement in
common chronic diseases, such as insulin resistance, type 2 diabetes, and obesity (Berbari et al.,
2008b; Girard and Petrovsky, 2011; Guo and Rahmouni, 2011). In explaining how defects in
ciliary function result in human disease, I hope to also illustrate some of the basic underlying
aspects of ciliary biology.

24

Motile cilium dysfunction
Disorders of the motile cilia go by many names. A disease triad – situs inversus, chronic sinusitis,
and bronchiectasis – was first defined by Kartagener in 1933, giving rise to the term Kartagener’s
syndrome as a diagnosis for patients suffering from these symptoms (Kartagener, 1933). With
the realization that the major deficits in these patients stemmed from an inability of their cilia to
beat in an organized fashion, the term Kartagener’s syndrome was replaced with either
immotile ciliary syndrome (ICS) or primary ciliary dyskinesia (PCD), both referring to the same
condition (Afzelius, 1976; Eliasson et al., 1977).

As a ciliopathy, PCD is unique in that ciliogenesis and primary cilium structure are not perturbed
– PCD is, instead, purely a disease of the machinery of ciliary motion (Sturgess et al., 1979).
Mutations in genes affecting the dynein arms, radial spokes, and central doublet of the motile
cilium (Figure 1.1) have all been identified in PCD patients (Bartoloni et al., 2002; Olbrich et al.,
2002; Pennarun et al., 1999). While each of these components is critical to the motile cilium,
they are each dispensable for primary cilium formation and function.

The symptoms of PCD, then, are not surprising. Issues with mucociliary clearance, the result of
dysfunctional motile cilia of the airway epithelia, give rise to chronic sinus infections,
pneumonia, rhinitis, and otitis media (Carlén and Stenram, 2005). The same mutations that
affect the normal rhythmic beating of motile cilia also affect the motion of the sperm flagellum,
resulting in significant infertility in male PCD patients (Carlén and Stenram, 2005). Perhaps most
interestingly, situs inversus, or a complete reversal of the normal left-right axis of the body,
occurs in 50% of PCD patients. The left-right body axis is defined early in development by the
25

coordinated beating of cilia in the developing embryo. Without ciliary movement, the layout of
the left-right axis is left completely to chance (Carlén and Stenram, 2005).

While not particularly common, with an incidence of no more than 1 in 16,000 (Kuehni et al.,
2010), PCD has made for an interesting study in the importance of ciliary motion to mammalian
health. It is also a compelling reminder of the fact that sometimes the best studied scientific
questions turn out to be of only minimal biologic importance – the motile cilium, which received
so much attention in the early days of cell and molecular biology, is involved in only a few mild
human diseases. The primary cilium, on the other hand, mostly ignored for more than a century,
has proven to be involved in various and devastating human disease syndromes and may even
play an important role in the pathogenesis of diseases of great public health concern, such as
diabetes and obesity (Berbari et al., 2008b; Girard and Petrovsky, 2011; Guo and Rahmouni,
2011).

Sensory cilium dysfunction
While disorders of ciliary motility result in only relatively few symptoms, disorders of ciliary
structure and sensory function can lead to a plethora of human disorders, many of which are
still being characterized and many of which are certainly still unknown. The list of ciliopathies is
long, and while each syndrome is characterized by a unique set of signs and symptoms there are
certain characteristics that all or most of the ciliopathies have in common.

First, and this likely goes without saying, all ciliopathies result from dysfunction of the primary
cilium (retinitis pigmentosa, discussed later in this chapter, can be caused by mutations in either
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ciliary genes or genes important for the visual cycle. It is considered a ciliopathy only if due to
ciliary dysfunction (Adams et al., 2007)).

Second, because each cell type of the body depends on the primary cilium to a different extent,
certain organ systems are more commonly affected by ciliary diseases than others. In reviewing
the list of ciliopathy disease syndromes bellow, it will become apparent that the retina, kidney,
and central nervous system (CNS) appear to be the three organ systems most susceptible to
ciliary dysfunction (Waters and Beales, 2011).

Third, and perhaps most interesting, ciliary disease seems to exist on a continuous spectrum
(Figure 1.6). The clinical cutoffs that separate the ciliopathies into discrete syndromes are useful

Figure 1.6 The spectrum of ciliopathy disease
The spectrum of affected organ systems and disease symptoms along with the clinical diagnoses
applied to patients who fall within each category. RP, retinitis pigmentosa; NPH,
nephronophthisis; SLS, Senior Løken syndrome; JSRD, Joubert syndrome and related disorders;
MKS, Meckel-Gruber syndrome.
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from a diagnostic perspective but can obscure the fact that incremental increases in ciliary
dysfunction lead to incremental increases in disease severity with no obvious distinction
between different syndromes (van Reeuwijk et al., 2011). This point is hammered home by the
fact that different mutations in certain ciliopathy genes, such as CEP290 (Coppieters et al.,
2010), can produce phenotypes anywhere along the ciliopathy disease spectrum from isolated
retinal degeneration to multi-organ system dysfunction and embryonic lethality. It is clear that
ciliary defects do not result in all-or-none ciliopathy disease.

The ciliopathies described below are organized in order of severity, with those diseases affecting
only single organ systems described first and with the syndromes affecting multiple organ
systems described last. While this list is certainly not exhaustive, it presents a representative
Figure
1.7
Different
ciliopathy disease genes
cause different overlapping
ciliopathy phenotypes
Many ciliopathy disease
genes are known causes of
multiple clinically distinct
ciliopathies. Each ellipse
represents
a
different
ciliopathy phenotype. The
genes inscribed within each
ellipse are known causes of
that phenotype. Note that
CEP290 has been associated
with each of the ciliopathies
shown.
NPH, nephronophthisis; SLS,
Senior-Loken syndrome; RP.
Retinitis pigmentosa; BBS,
Bardet Biedl syndrome; MKS,
Meckel-Gruber syndrome;
JSRD, Joubert syndrome and
related disorders
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cross-section of ciliary disease and serves to illustrate certain key points regarding the specific
pathologic effects of the dysfunction of different ciliary processes. The particular syndromes
described were also chosen, in part, because the gene CEP290, the focus of this dissertation, has
been implicated in the pathogenesis of each (Figure 1.7; Coppieters et al., 2010).

Nephronophthisis
First described in 1945, nephronophthisis (NPH) is a rare autosomal recessive medullary cystic
kidney disease and the most common cause of childhood renal failure (Hildebrandt et al.,
2009). Patients typically present with polyuria, polydipsia, secondary eneurisis, and anemia
within the first decade of life and progress to end stage renal failure, necessitating dialysis or
renal transplant, by the third decade of life. Prevalence is estimated to be about 1 in 1 million in
the United States, with the disorder diagnosed in about 1 in 50,000 live births in Canada
(Hildebrandt et al., 2009).

The basic pathology of the disease results in the proliferation of multiple renal cysts that
ultimately destroy the structure of the kidney. As with polycystic kidney disease (discussed
above in the section “fluid flow”), cystic proliferation is due to an inability of the renal epithelial
cells to sense the direction of fluid flow within the renal tubules, resulting in uncoordinated cell
division and cyst formation instead of renal tubule extension (Fischer et al., 2006). Renal
epithelial cells depend on their primary cilia to sense fluid flow and, not surprisingly, mutations
in genes involved in ciliary structure and function have been discovered to be at the root of
NPH.
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To date 14 different genes have been implicated in NPH. They are NPHP1, NPHP2/inversin,

NPHP3, NPHP4, NPHP5/IQCB1, NPHP6/CEP290, NPHP7/GLIS2, NPHP8/RPGRIP1L, NPHP9/NEK8,
NPHP10/SDCAAG8, NPHP11/TMEM67, NPHP12/TTC21B, NPHP13/WDR19, and NPHP14/ZNF423
(Hildebrandt et al., 2009). While the roles than many of these genes play in cilium formation and
function remain unclear, it is apparent that they have important jobs in processes as diverse as
ciliary structural maintenance, ciliary membrane biogenesis, and ciliary mechanotransduction,
implying that deficits in any aspect of primary cilium biology can lead to NPH.

Many of the NPHP disease genes, as will become apparent in the discussion of the other
ciliopathies bellow, are also implicated in the ciliary diseases of other organ systems (Figure 1.7).
Perhaps not surprisingly, then, more than 10% of NPHP patients are diagnosed with extrarenal
disease manifestations such as hepatic fibrosis, CNS malformations, and retinitis pigmentosa
(Hildebrandt et al., 2009). Why ciliary dysfunction results only in renal disease in a majority of
NPH patients, however, remains unknown.

Retinitis pigmentosa
Retinitis pigmentosa (RP) is a progressive degeneration of the photoreceptors of the retina that
can occur either by itself or as a symptom of various syndromic disorders (Ferrari et al., 2011).
Unlike all of the other ciliopathies discussed in this thesis, isolated RP is only sometimes the
result of the dysfunction of the primary cilium. A number of different mutations affecting
cellular processes as diverse as transcription, RNA splicing, and photopigment recycling can all
result in RP, and each particular affected gene is associated with a characteristic disease
progression and time course (Ferrari et al., 2011). The list of genes associated with non30

syndromic RP is long and rapidly growing, but of the many genes involved only about 10% have
been shown to have any role in the function of the primary cilium. Syndromic RP, on the other
hand, is almost always caused by mutations in genes affecting ciliary integrity. Mutations in
these genes result in photoreceptor degeneration secondary to ciliary dysfunction.

RP affects about 1 in 5,000 people around the world. Of these patients, roughly 20% present
with symptoms characteristic of syndromic disorders such as Usher syndrome, Joubert
syndrome, and Bardet Biedl syndrome (Ferrari et al., 2011). The pace of retinal degeneration
varies with the causative gene – in the most severe cases, retinal degeneration begins before
birth and leads to complete blindness within the first two decades of life in a form of congenital
RP known as Leber congenital amaurosis (LCA) (Chung and Traboulsi, 2009). Although a
distinction is sometimes made between LCA and RP, they are both characterized by very similar
signs, symptoms, and clinical time courses, only with different ages of onset.

Regardless of etiology, most RP and LCA patients experience, at some point in the disease
process, night blindness, and tunnel vision, and will be found to have retinal atrophy with bone
spicule-shaped pigment deposits upon ophthalmoscopy – findings that originally gave RP its
name (Chung and Traboulsi, 2009; Ferrari et al., 2011). The disease normally begins with the
degeneration of rod photoreceptors within the periphery of the retina. As the disease
progresses the retina begins to atrophy from the periphery towards the macula, the area of
central vision, until patients are left with only a very narrow cone photoreceptor-dominated
visual field. In the end stages of retinal degeneration cone photoreceptors, for reasons that are
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not entirely clear, also begin to degenerate, resulting, in some cases, in complete blindness
(Chung and Traboulsi, 2009; Ferrari et al., 2011).

The fact that RP can be a symptom of so many different ciliopathies only reinforces the idea that
the retina is one of the tissues most susceptible to ciliary dysfunction. This is not altogether
surprising since the photoreceptors of the retina are probably the cells in the body most
dependent on their cilia for normal function (see the section “phototransduction”, above). It is
not difficult to imagine why even small deficits in ciliary function might cause devastating
changes in normal photoreceptor function and health.

Senior Løken syndrome
The kidneys and retina being the organs most susceptible to ciliary dysfunction, it is not
surprising that pathology of both organ systems can be seen together in a syndrome known as
Senior Løken Syndrome (SLS). SLS is diagnosed upon the discovery of nephronophthisis in a
patient presenting with Leber congenital amaurosis (Ronquillo et al., 2012). In fact, this is often
the way the diagnosis is made – patients or parents notice the retinal deficits first and the renal
dysfunction is discovered by a suspicious clinician, aware of the possibility of the two symptoms
occurring together, during a renal workup. The natural history and pathophysiology of each of
the two aspects of the syndrome (i.e. the retinal and renal degeneration) are identical to the
pathophysiology and disease course of LCA and NPH (Ronquillo et al., 2012). Put another way,
SLS can truly be thought of as a combined diagnosis of LCA and NPH.
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SLS is a rare disease, affecting fewer than 1 in 1 million people, and only very few families with
the disease have been described (Ronquillo et al., 2012). To date 6 SLS genes have been
identified – NPHP1, NPHP3, NPHP4, NPHP5/IQCB1, NPHP6/CEP290, and NPHP10/SDCAAG8
(Ronquillo et al., 2012). As is apparent from their names, all of the genes responsible for SLS are
also associated with other ciliopathies. In fact, all known SLS genes can also cause NPH and all of
them are also capable of causing RP, either by itself or in the context of some other ciliopathy
syndrome.

Joubert syndrome
The syndrome that we now know as Joubert syndrome (JS) was first described in 1969 by Marie
Joubert upon the discovery that the severe ataxia and hyperpnea displayed by four siblings she
had been evaluating was due to congenital agenesis of the cerebellar vermis (Brancati et al.,
2010). This deficit is the cardinal symptom of Joubert syndrome and is most often detected in
imaging studies of the brain where it presents as the “molar tooth sign,” an abnormality of the
brain stem in transverse section that bears an uncanny resemblance to a molar tooth. JS is
diagnosed in about 1 in 90,000 live births, although it is thought that this number is artificially
low due to underdiagnosis (Brancati et al., 2010).

Infants with JS most often present, not unlike the siblings studied by Dr. Joubert, with
hypotonia, episodic hyperpnea, and abnormal eye movements, all of which are due to the
dysfunction of the cerebellum. The hypotonia progresses to ataxia as the patient ages while the
hyperpnea tends to improve over time, with resolution generally by six months of age (Brancati
et al., 2010). Many JS patients also present with mild to moderate developmental delay,
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particularly with regard to language and motor skills, are more prone to seizures, and
sometimes present with occipital encephalocele, signs and symptoms thought to be due to the
highly irregular structure of the JS brain (Brancati et al., 2010). Most JS patients, however, are
capable of attending school, learning specific job skills, and can work in protected environments.
It must be noted that developmental delay is not universal and some, although few, JS patients
appear completely cognitively normal.

To date, every gene that has been linked to JS (there are already more than 20) has been shown
to be critical in primary cilium structure and function. It is thought that these mutations lead to
deficiencies in ciliary structure that result in significant deficits in ciliary Hedgehog signaling (see
the section “Hedgehog signaling,” above; Brancati et al., 2010). The impairment, in JS patients,
of Hedgehog signaling, so critical for neural crest formation, neurodevelopment, and embryonic
patterning, results in the various CNS symptoms characteristic of the disease (Aguilar et al.,
2012).

A substantial percent of JS patients present with symptoms outside of the CNS. The organ
systems that can be affected are many, but the two most commonly hit, not surprisingly, are the
retina and kidneys. The same mutations that adversely affect ciliary structure and hedgehog
signaling in the CNS are thought to result in deficiencies in the ciliary structure of the
photoreceptors and renal epithelial cells, leading to significant pathology in these tissues.
Approximately 25% of all JS patients are found to display signs of NPH, with cystic renal
degeneration and end stage renal failure early in life (Brancati et al., 2010). Another substantial
portion of JS patients present with RP or LCA. In fact, numerous JS patients have been identified
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that suffer from SLS, with both retinal and renal degeneration in addition to their cerebellar
deficits, truly illustrating how much overlap exists between the different ciliopathies and making
even more apparent the continuous spectrum of ciliopathy disease (Brancati et al., 2010).

Because the clinical features of JS are so broad it has become common practice to refer to all
patients presenting with agenesis of the cerebellar vermis, regardless of what other symptoms
they may manifest, as having one of the Joubert syndrome related disorders (JSRD). The
syndromes formally known as cerebello-oculo-renal syndrome, Dekaban-Arima syndrome,
COACH syndrome, Varadi-Papp syndrome, and Malta syndrome are now all considered to fall
under the JSRD umbrella (Brancati et al., 2010).

Bardet Biedl syndrome
While Joubert syndrome is the result of mild hedgehog signaling impairment, Bardet Biedl
syndrome (BBS) is a study in the complete dysfunction of ciliary signaling. The syndrome we
know as Bardet Biedl syndrome was first described in 1865 (a full thirty years before the
discovery of the primary cilium) as the manifestation of three symptoms: obesity, retinal
degeneration, and cognitive deficits (Tobin and Beales, 2007). In the 1920s George Bardet and
Artur Biedl independently expanded on this triad, adding polydactyly and hypogonadism to the
list of symptoms characteristic of the syndrome that would ultimately bear their names. These
five signs and symptoms remain the cardinal features of the syndrome to this day (Tobin and
Beales, 2007).
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BBS affects roughly 1 in 150,000 Americans and is up to ten times more prevalent in some
particular populations in Canada and Kuwait. Not every patient diagnosed with BBS manifests all
five of the cardinal symptoms, and the list of BBS associated symptoms is much longer than the
cardinal five. Of the cardinal symptoms, 98% of patients present with hypogonadism, 93% with
retinal degeneration, 72% with obesity, 69% with polydactyly, and 50% with developmental
delays (Tobin and Beales, 2007). Patients diagnosed with BBS also often present with anosmia
(60% of patients), speech delay (54%), ataxia (40%), renal anomalies (24%), hearing loss (20%),
and diabetes (6%) (Tobin and Beales, 2007).

It is immediately clear that the symptoms of BBS significantly overlap with those of JSRD. What
is not readily apparent is that the genes that cause BBS are never responsible for JSRD, and vice
versa (Figure 1.7) (with the exception of CEP290, and even then only one BBS patient has ever
been found to harbor mutations in the CEP290 gene). All of the 16 identified BBS disease genes
(Figure 1.7) are critical to ciliary function, but in ways different from the genes that are
responsible for JSRD. Recent scholarship has indicated that most of the genes responsible for
BBS cooperate to form a subcellular complex known as the BBSome (Jin et al., 2010). This
complex has critical functions in the ciliary transport of membrane proteins such as the Shh
receptor/effector proteins Patched and Smoothened. Hence, the major deficits of BBS are
primarily due not to deficits in ciliary structural integrity, as is the case with many of the NPH
and RP genes, but to deficits in ciliary signaling by transmembrane receptor proteins. Deficits in
ciliary leptin signaling within the hypothalamus of BBS patients lead to uncontrollable eating and
obesity (Guo and Rahmouni, 2011); abnormalities in the insulin signaling pathway lead to
diabetes (Marion et al., 2012); deficits in Shh signaling during development result in polydactyly,
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CNS abnormalities, and developmental delays (Zhang et al., 2012). The renal, retinal, and
olfactory phenotypes of BBS, on the other hand, are likely secondary to defects in ciliary
structure due to inadequate trafficking of structural ciliary membrane proteins due to BBSome
dysfunction.

Thus it becomes clear that defects of the cilium can be divided into two broad, phenotypically
distinct categories – those that disrupt ciliary receptor trafficking and those that disrupt ciliary
structure and IFT. Organs, such as the kidney and retina that depend heavily on the structural
integrity of the cilium are more severely affected by deficits in ciliary structure, while organ
systems that depend more on ciliary signaling, such as the developing brain, skeletal system,
and endocrine system, are more severely affected by deficits in ciliary receptor trafficking.

Meckel-Gruber syndrome
We have so far examined ciliopathies that can be traced back to deficits predominantly in either
ciliary structure (RP, LCA, NPH) or ciliary signaling (JSRD, BBS). There do exist, however, human
mutations that result in significant deficits in both ciliary structure and function, and these
almost invariably result in the perinatal lethal condition known as Meckel-Gruber syndrome
(MKS). MKS, with an incidence estimated to be somewhere between 1 in 9,000 and 1 in
140,000, depending on the population, was first reported by the German anatomist Friedrich
Meckel in 1822 (Chen, 2007). Meckel described a case of two siblings, both of whom died
shortly after birth, presenting with severe occipital meningoencephalocele, polycystic kidneys
that filled the abdomen, polydactyly, and cleft palette. Similar cases continued to be reported in
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the medical literature until Opitz and Howe, in 1969, definitively delineated the clinical features
of the syndrome that they named for its discoverer (Chen, 2007).

The cardinal symptoms of MKS are severely dysplastic kidneys, growing to between 10 and 20
times their normal size (present in 95% of patients), occipital encephalocele (60-85%), and
postaxial polydactyly (55-96%) (Chen, 2007). MKS patients are also often diagnosed with
microcephaly, cerebral and cerebellar hypoplasia, anencephaly, microphthalmia, hepatic
fibrosis, cryptorchidism, and shortened limbs (Chen, 2007). Thus, it is apparent that MKS
combines the worst features of NPH, BBS and JSRD into one devastating syndrome. It is not
surprising, then, that every one of the 10 genes (Figure 1.7) that is known to cause MKS is also
capable of causing NPH, JSRD or BBS.

The dysfunction of the primary cilium seen in MKS is likely due to severe deficits that cause
catastrophic changes in both ciliary trafficking and structure. It is easy to image how extreme
deficiencies in either ciliary structure or trafficking could easily result in deficiencies in the other
– without trafficking of ciliary components to the basal body and into the cilium, no axoneme
can be extended; without a structurally sound axoneme and ciliary compartment, properly
trafficked ciliary proteins have no organelle to populate. MKS, then, can be thought of as the
result of complete dysfunction of the cilium, due to debilitating mutations in proteins that play
key roles in either ciliary structure or trafficking. The structural deficits in the cilium lead to renal
and retinal disease while deficits in Shh and Wnt signaling (Aguilar et al., 2012), secondary to
disrupted ciliary trafficking, lead to the dramatic malformations of the brain and limbs
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characteristic of MKS. The lethal nature of the syndrome serves to illustrate exactly how
important the cilium is to human health and development.

Non-syndromic disorders of the primary cilium
Up until now we have focused on syndromic, clearly heritable disorders of the primary cilium,
but recent evidence has also begun to implicate the cilium in the pathogenesis of many much
more common diseases. Renal failure, diabetes, obesity, neurologic deficits, and retinal
degeneration, all characteristics of multiple ciliopathy disease syndromes, are also aspects of
what we consider the common pathology of aging and chronic disease. In the past few years the
role of the cilium in the pathogenesis of each of these chronic conditions has begun to be
investigated.

The cilium’s role in the pathogenesis of obesity in particular has become a significant area of
research in the scientific community. Multiple lines of data have implicated ciliary deficits in the
hypothalamus as resulting in hyperphagia and increased appetite (Feuillan et al., 2011; Guo and
Rahmouni, 2011), and an equal number of studies have also indicated that ciliary signaling plays
a critical role in the differentiation and growth of adipocytes (Marion et al., 2009; Romano et al.,
2008; Zhu et al., 2009). Insulin sensitivity also appears to be highly regulated by receptors
confined to the primary cilium (Hearn et al., 2005; Iwanaga et al., 2011; Romano et al., 2008), an
important finding when one considers the huge number of Americans suffering the
consequences of insulin resistance and diabetes.
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While the relationship of the primary cilium to these common chronic disease is still tenuous, it
is tantalizing to think that this organelle might be the key link between so many of the ailments
that currently burden our healthcare system. Perhaps a better understanding of this overlooked
organelle will help us continue to make strides against these diseases and pave the way for new
therapeutics, better patient outcomes, and improved public health.
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CEP290
With the conclusion of that wide-ranging discussion of ciliary structure, function, and disease,
we can now finally turn to the true subject of this dissertation, centrosomal protein 290 kDa, or
CEP290. CEP290 is a key component of the primary cilium and a central player in ciliogenesis
and ciliopathy pathogenesis. It has been shown to be critical to the processes of IFT, ciliary
signaling, and in the maintenance of ciliary structure (Coppieters et al., 2010). It is the only gene
capable of causing NPH, LCA, JSRD, BBS, and MKS, and mutations in the CEP290 gene are
thought to be the most common cause of LCA in North America and Europe (den Hollander et
al., 2006). For a protein clearly so important to human disease and ciliary biology we know
surprisingly little about what it does and about how mutations in the CEP290 gene can lead to
human disease. Below is an in-depth discussion of all the CEP290 biology that was known up
until the point of publication of the work presented in this thesis.

A history of CEP290
The story of the gene that we know today as CEP290 begins in a human brain cDNA library from
Japan. CEP290 had been completely unknown to the scientific community until the late 1990s
when a group of researchers at the Kazusa DNA Research Institute, interested in identifying
novel brain-related mRNAs, cloned and described 100 new transcripts of unknown significance.
One of these transcripts happened to be CEP290 (Nagase et al., 1997). They named the CEP290
transcript they had identified KIAA0373, published its sequence, and moved on to other
experiments.
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Just three years after its discovery in the human brain, another group of researchers
independently identified a fragment of the CEP290 protein as the major antigen of the 3H11
antibody (Chen and Shou, 2001), a monoclonal antibody specific for cancerous cells of many
different lineages (Shou et al., 1997). Unaware of the KIAA0373 transcript, they named this
protein 3H11Ag and began to characterize its function in the cell. It was noted that the 3H11Ag
tumor antigen localized to both the cytoplasm and nucleus, and that its nuclear localization was
conferred by the N-terminal region of the protein (Guo et al., 2004). Despite the compelling
nature of this study, 3H11Ag’s role within the nucleus and in cancer pathogenesis was never
actively pursued, and the protein was again shelved, awaiting its third and final renaming.

In 2003 CEP290 was again independently discovered, this time by a group of researchers
examining the protein makeup of the centrosome. In one of the first attempts to better define
the protein milieu of the organelle, this group subjected purified centrosomal material to
analysis by mass spectroscopy in the hopes of discovering novel centrosomal components. Of
the many proteins they identified, one of the more common hits was KIAA0373/3H11Ag
(Andersen et al., 2003). Following the conventions of the time they renamed this protein
centrosomal protein of 290kDa, referencing both its subcellular localization and molecular
weight and giving rise to the definitive CEP290 gene name and symbol.

With the discovery that CEP290 was a protein closely associated with the centrosome/basal
body, it wasn’t long before the gene was discovered to be involved in ciliopathy disease.
Interestingly, the discovery that mutations in CEP290 could result in significant pathology was
observed, for the first time, not in a human patient, but in a naturally occurring mouse model of
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CEP290 deficiency. In a collaboration between researchers at Jackson Labs and the University of
Michigan the genetic deficit responsible for the rapid retinal degeneration of the rd16 mouse
was finally identified as a large deletion within the Cep290 gene (Chang et al., 2006). The mouse
mutation was found to result in perturbations of the connecting cilium of the rod
photoreceptors causing deficiencies in the ciliary trafficking of proteins critical for
phototransduction. This discovery opened the floodgates for research into CEP290’s role in
human disease – CEP290 was soon discovered to be the causative gene in a number of cases of
Joubert syndrome (Valente et al., 2006) , then Leber congenital amaurosis (den Hollander et al.,
2006), and finally even Meckel syndrome (Baala et al., 2007).

Reports of new CEP290 patients and new CEP290 disease syndromes continued to pour in, but
still no one had any idea of exactly what the protein was doing at the primary cilium or how
deficits in protein function might lead to human disease. Hints would occasionally appear –
CEP290 seemed important in the regulation of ciliogenesis (Tsang et al., 2008) and appeared to
be a component of the numerous protein complexes at the transition zone of the cilium (Gorden
et al., 2008; Kim et al., 2008), but it wasn’t until Craige et al. published their work on CEP290 in
the Chlamydomonas model system that CEP290’s role in the cell finally began to come into
focus.

In an elegant structural study of the flagellum of Chlamydomonas reinhardtii, Craige et al. (2010)
demonstrated that CEP290 was a critical structural component of the ciliary Y-links. Their data
indicated that CEP290 was instrumental in maintaining the physical integrity of these links
between the ciliary membrane and microtubule axoneme, and that in the absence of CEP290
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these structures were significantly compromised, resulting in the dysregulation of the protein
milieu of the ciliary compartment. This was the first direct evidence of the mechanistic
underpinnings of CEP290’s critical role both in ciliary structure and IFT. In the years since the
publication of this work numerous other studies have emerged identifying novel CEP290
interacting partners but no other major insights have been gained into CEP290’s function.

CEP290 Structure
CEP290 is a behemoth of a protein, weighing in at 290 kilodaltons, as its name suggests. It is
encoded by a 93 kilobase gene on human chromosome 12 containing a roughly 8 kilobase open
reading frame composed of 54 exons (Coppieters et al., 2010). From the time of its initial
discovery researchers have employed all the bioinformatic tools available to them in an attempt
to gain some insight into the structure and function of the gene, searching for predicted
structural domains, known protein motifs, and regions of homology to other proteins (Figure
1.9). While this line of investigation has not led to any major discoveries, it has uncovered a
number of interesting facts about the gene, some of which may ultimately aid in the
identification of domains critical to the protein’s function and help complete our understanding
of the protein’s role in the cell.

Predicted structure
To date no crystal structure has been solved for any piece of the CEP290 protein. What we have
to work with, instead, are predicted structural motifs. It is abundantly clear from any number of
bioinformatic tools that CEP290 lacks both a signal peptide and any kind of canonical
transmembrane domain. This squarely localizes CEP290 to the “regular” pool of non-membrane,
44

non-luminal proteins that make up about 60% of the protein content of the cell. There is not
much else that can be gleaned from bioinformatic structural analysis of the CEP290 amino acid
sequence except this: nearly the entire protein is predicted to fold into a coiled coil (Figure 1.8).

Coiled coils are a common motif in biology, utilized by nature to perform many varied processes
such as transcriptional regulation, vesicular fusion, and intracellular signaling (Chapman et al.,
1994; Chen et al., 1995; Zhang et al., 2000). Regardless of the cellular pathways they are
involved in, the mechanism by which coiled-coil domains accomplish their diverse tasks is the
same – two or more alpha helices wrap around each other to form a thermodynamically
favorable and structurally stable coil (Mason and Arndt, 2004). This bundling action can be used
to mediate hetero- or homodimerization and is occasionally employed to achieve intramolecular
interactions within a single protein (Hammond et al., 2010). Coiled coil domains aren’t only
used for mediating protein-protein interactions, however. The motif can also be employed in
Figure 1.8. More than
80% of CEP290 is
predicted to form
coiled coils.
The x-axis represents
the position along
CEP290’s amino acid
sequence and the yaxis represents the
probability that the
amino acid sequence
analyzed will form a
coiled coil. Nearly all of
CEP290 is predicted to
fold into coiled coils.
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Adapted from
http://embnet.vitalit.ch/software/COILS_f
orm.html

the creation of rigid, spring-loaded, structurally-stable domains as is the case with the myosin
tail (Schwaiger et al., 2002). It is intriguing that CEP290 is, at its most basic structural level, a
large coiled coil, but only time and continued research will tell exactly what these coils are
doing.

Predicted domains
While the bioinformatic prediction of structural domains within the CEP290 protein yields only
few results, the list of predicted functional domains, protein motifs, and regions of homology is
long. I have opted not to go through each in detail, especially as most have not been
experimentally verified or investigated, but to instead list each of the identified domains, taking
time to discuss only those that seem relevant to CEP290 protein function. Let us then begin by
discussing regions of homology between CEP290 and other proteins.

Portions of the CEP290 amino acid sequence have been discovered to share significant
homology with tropomyosin, structural maintenance of chromosomes (SMC) proteins, and the
tail domain of the myosin class of microtubule motors (Chang et al., 2006). These different
regions are distributed throughout the protein – the three tropomyosin homology domains are
found within CEP290’s N-terminus, the SMC homology domain is found near the center of the
CEP290 protein, and the myosin tail homology domain comprises most of the C-terminus of the
protein. To date no significant function has been ascribed to any of these domains within
CEP290, but it is fun to speculate as to what they may be doing. In particular, it is interesting to
note that of the 5 homology domains identified 4 are related to proteins involved in generating
and maintaining the microtubule organization of the cell. As the cilium is so integrally associated
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with the microtubule network, it stands to reason that these domains might allow CEP29 to
interact with or modulate the microtubules of the cilium.

The SMC homology domain at first seems a little more perplexing. The SMC proteins are
involved in the regulation of mitosis, binding directly to the DNA sequences of different
chromosomes during cell division (Carter and Sjögren, 2012). While there is some evidence for
CEP290 localization to the nucleus, trying to imagine what a known ciliary protein might be
doing binding to DNA is difficult. Consideration of the structure of the SMC proteins, however,
provides a hint to the role that the SMC-homology domain might be playing in CEP290 function.
The SMCs are composed of two coiled coil arms on either side of a molecular hinge (Melby et
al., 1998). The SMC protein’s hinge and arms can be selectively swung open or closed (the exact
mechanism of how this happens has not yet been completely worked out) to bind to and gather
the cell’s chromosomes. Perhaps the mechanism of SMC action, but not its teliologic purpose, is
conserved in CEP290. The SMC homology domain would then provide a molecular hinge for
CEP290, the function of which might be useful in ciliogenesis, the maintenance of ciliary
structure, or the regulation of IFT.

In addition to homology domains, CEP290 is predicted to contain a number of known short
protein motifs. These include protein kinase inducible domains, ATP/GTP-binding motifs, at least
one bipartite nuclear localization signal, and multiple sites predicted to be prime targets for Nglycosylation, tyrosine sulfation, phosphorylation, N-myristoylation, and amidation (Coppieters
et al., 2010). It is unclear what any of these motifs may be doing, let alone whether they are true
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sites or just artifacts of the prediction algorithms used to detect them. What is clear, however, is
that much work remains before we can hope to fully elucidate CEP290’s structure and function.

CEP290 Localization
A number of papers have investigated the subcellular localization of CEP290 to varying degrees
of specificity and with varying results. The first such paper, published when the gene was still
known as 3H11Ag, found that the CEP290 protein localizes to both the cytoplasm and nucleus
with the nuclear localization of the protein conferred by a region within its N-terminus (Guo et
al., 2004). These findings were later corroborated by Sayer et al. (2006) when they discovered
that CEP290 is capable of physically interacting with and activating the transcription factor ATF4.
Sayer et al. never explicitly showed that CEP290 was capable of gaining access to the nuclear
compartment, but claimed to have evidence for this in unpublished data.

Sayer et al.’s examination of CEP290 localization didn’t stop at the nucleus, however. They went
on to investigate the localization of the protein during various phases of the cell cycle and found
that throughout all of interphase CEP290 clearly localizes to the centrioles. During mitosis,
however, the protein appeared to localize more diffusely throughout the cytoplasm until
eventually returning to the centrioles upon the completion of cell division. This is in contrast to a
study, published at about the same time, that found CEP290 to consistently localize to the
centrioles throughout all stages of mitosis (Chang et al., 2006).

No other groups have since investigated the nuclear localization of CEP290, but a number have
gone on to more specifically define the localization of CEP290 at the centrioles. Chang et al.
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(2006), for instance, provided conclusive proof of CEP290 localization not only to the centrioles
but specifically to the primary cilia of cultured cells and to the connecting cilia of mouse
photoreceptors. This finding was corroborated by a number of groups, many of whom more
finely localized CEP290 to the basal body/transition zone of the cilium (Gorden et al., 2008; Kim
et al., 2008).

The definitive study of CEP290 localization, however, was performed by Craige et al. in the

Chlamydomonas model system (Craige et al., 2010). In a number of elegant ultrastructural
studies Craige et al. conclusively demonstrated that CEP290 localizes to the transition zone of
the cilium. In particular, they demonstrated that CEP290 localizes to the ciliary Y-links, the
structures that link the microtubule axoneme to the ciliary membrane. Using antibodies raised
against different regions of the protein they were able to show that the middle portion of
CEP290 seems to localize specifically to the ciliary membrane whereas the C-terminal end of
CEP290 was found to be more generally localized within the transition zone with perhaps a small
preference for the ciliary axoneme. Of course the major caveat of this work is that it was
performed in the Chlamydomonas model system, but the high degree of similarity between
human and Chlamydomonas CEP290 and the highly conserved structure of the cilium across all
species would seem to indicate that Craige et al.’s findings should apply more generally to all
ciliated organisms.

CEP290 interacting partners
While we are limited in our knowledge of CEP290 structure, function, and localization, an
abundance of studies have investigated and identified numerous CEP290 interacting partners.
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The number of proteins that associate with CEP290, either directly or indirectly, is already more
than a dozen and the number continues to grow by the month. The proteins identified vary in
function from transcriptional regulation to membrane trafficking and centriolar structure
stabilization. Below are listed each of CEP290’s known interacting partners along with a brief
description of each protein’s function (if one is known) and the nature of the interaction with
CEP290.

ATF4
ATF4 is a well characterized transcription factor important in modulating the cell stress response
(Ye and Koumenis, 2009). Although ATF4 was one of the first CEP290-interacting proteins
identified, the importance of the ATF4-CEP290 interaction has not been extensively researched.
In 2006 Sayer et al. presented data showing that CEP290 is capable of binding to and activating
ATF4, but how this interaction fits into CEP290’s greater role in the cell remains completely
unknown.

Sayer

and

colleagues

demonstrated,

both

by

yeast

two-hybrid

and

coimmunoprecipitation, that the C-terminus of CEP290 is the region of the protein responsible
for ATF4 binding and activation and that knockdown of CEP290 results in decreased baseline
ATF4 activity. In the 7 years since the publication of these findings no headway has been made
in the characterization of CEP290’s role in activating ATF4 or its role in the nucleus in general.
The presence of multiple bipartite nuclear localization signals within CEP290 make it seem at
least feasible that the protein plays an important and potentially completely overlooked role in
the nucleus of the cell and it will be interesting to see if and how this story pans out in the
coming years.
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CC2D2A and NPHP5
It is not surprising that a rigorously structured organelle such as the cilium should be dependent
on multiple structural subunits for its assembly. CC2D2A and NPHP5 (IQCB1) both appear to be
such structural subunits and each has been shown to interact with CEP290 (Gorden et al., 2008;
Schäfer et al., 2008). Why these proteins interact with CEP290 and what these interactions
accomplish is not yet known, but understanding how they interact and what happens when
these interactions are disrupted may help to provide some insight into CEP290’s role in cilium
function.

CC2D2A is a protein, like CEP290, composed of numerous coiled coils (Noor et al., 2008). The
interaction between CC2D2A and CEP290 has been characterized on many levels – the proteins
have been shown to colocalize by confocal microscopy and to directly interact with each other
both by yeast two hybrid and in vitro pull down assays (Gorden et al., 2008). It was determined
that the domain of CEP290 responsible for this interaction was a region of the protein from
amino acids 703-1103. The two proteins were found to interact functionally as well – in
zebrafish morpholino experiments knockdown of both proteins was demonstrated to result in a
more severe phenotype than would be expected from the additive knockdown of either
separately (Gorden et al., 2008).

In many ways the story of NPHP5 is very much like the story of CC2D2A. Like CC2D2A, NPHP5 is
a protein composed of a number of coiled coils (Otto et al., 2005) that has been shown to
colocalize and coimmunoprecipitate with CEP290 (Schäfer et al., 2008). Like CC2D2A, there is a
functional interaction between NPHP5 and CEP290, with knockdown of both synergistically
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resulting in a phenotype more severe than would be expected from knockdown of either
together (Schäfer et al., 2008).

The ciliary transition zone, the region of the cilium where CC2D2A, NPHP5, and CEP290 are
found, is characterized by a dense web of proteinaceous material that serves as a diffusion
barrier and ciliary pore (Kee et al., 2012). It is probably not a coincidence that each of these
three proteins contains numerous coiled coil domains, motifs often utilized for maintaining
structural integrity and strong protein-protein interactions. It is likely that both NPHP5 and
CC2D2A cooperate with CEP290 to play important, non-redundant (as evidenced by the
phenotypic synergism displayed in zebrafish knockdown experiments) roles in the organization
and structure of the transition zone, perhaps serving as key structural components of the ciliary
pore and diffusion barrier. It is not surprising, then, that human mutations in both CC2D2A and
NPHP5 result in severe human disease (Gorden et al., 2008; Stone et al., 2011). As we continue
to learn more about the nature of these proteins and their interactions with CEP290 we may
also begin to learn more about the organization and function of the ciliary transition zone.

Figure 1.9 Schematic representation of CEP290 homology domains, protein motifs, and
interacting partners
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RPGRIP1, RPGR, and Rab8a
While RPGRIP1 (RPGR interacting protein 1), RPGR, and Rab8a have all been independently
described as interacting partners of CEP290 (Chang et al., 2006; Kim et al., 2008), it is almost
certain that they exist as a single complex, collectively recruited to the primary cilium by
CEP290. Once properly localized to the ciliary transition zone these proteins can affect their end
goal of regulating ciliogenesis and ciliary membrane transport, processes critical to basic ciliary
biology and human health (Doherty et al., 2010; Zhao et al., 2003).

Even in the first description of CEP290’s involvement in the primary cilium it was noted that the
protein exists in a complex with RPGRIP1 and RPGR (Chang et al., 2006). RPGR, in turn, has been
shown to directly bind Rab8a – in fact RPGR is critical in the recruitment of Rab8a to the ciliary
membrane (Murga-Zamalloa et al., 2010). A more recent study suggests that CEP290 amino
acids 1280-1695 serve to recruit Rab8a to the cilium, but no direct interaction between CEP290
and Rab8a was described (Tsang et al., 2008). Regardless, it was noted early on that knockdown
of CEP290 results in the drastic mislocalization of RPGRIP1, RPGR, and Rab8a, implying that
CEP290 is critical in the ciliary recruitment of each of these proteins.

Taken together these data point towards a model where CEP290, localized to the transition zone
of the cilium, binds to and recruits RPGRIP and RPGR. RPGR, in turn, binds to and recruits Rab8a
to the ciliary membrane. The ultimate recruitment of Rab8a to the cilium may, in fact, be one of
the most important functions of CEP290 – Rab8a is an absolutely critical component of the
membrane trafficking machinery of the cell, responsible for the targeting of vesicles from the
trans-Golgi network to the cilium and other membranous organelles (Sato et al., 2007). In fact,
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ciliogenesis and ciliary function are completely reliant on the delivery of membrane and
membrane proteins to the nascent cilium, a process which is regulated by and dependent on
Rab8a (Tsang et al., 2008).

FAM161A
FAM161A is one of the newest players in the field of retinal degeneration with the recent
discovery that mutations in the FAM161A gene can lead to inherited retinitis pigmentosa
(Langmann et al., 2010). Even newer, however, is the discovery that FAM161A interacts with a
number of ciliary transition zone/basal body components including CEP290 (Di Gioia et al.,
2012). The C-terminus of FAM161A was shown to bind directly to CEP290 in both yeast twohybrid and coimmunoprecipitation experiments, but exactly what this interaction accomplishes
remains unknown (Di Gioia et al., 2012). In fact, not much is known about FAM161a in general.
In addition to interacting with a number of ciliary disease proteins, FAM161A protein has been
shown to localize to the ciliary transition zone where it binds to microtubules, helping to
mediate their acetylation (Zach et al., 2012). The large number of high-profile interacting
partners that bind to FAM161A hints that the protein may be playing a central role in ciliary
biology, but more research is clearly needed to fully understand exactly what it is doing as a
component of the ciliary transition zone.

CEP72, CEP123, CEP162, PCM-1
The relationships between these four proteins and CEP290 are probably the most tenuous of
those discussed in this chapter. Each of these proteins localizes to the centrosome/basal body
and seems to play an important role in the recruitment of ciliary proteins in the initiation of
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ciliogenesis (Sillibourne et al., 2013; Stowe et al., 2012; Wang et al., 2013). Each of these
proteins has also been shown to associate with CEP290 in coimmunoprecipitation experiments,
but whether these associations are indicative of direct or indirect interactions remains to be
seen (Kim et al., 2008; Sillibourne et al., 2013; Stowe et al., 2012; Wang et al., 2013). That is not
to say that these proteins should be written off as peripheral to the processes of ciliogenesis and
ciliary function – in fact each has proven critical to both – but only that whatever interactions
they exhibit with CEP290 have not yet been convincingly shown to be critically relevant to
CEP290’s role in the cilium.

What is known is that CEP162, in particular, appears to be able to mediate the spindle pole
microtubule and centriolar satellite localization of CEP290 (Wang et al., 2013). Knockdown of
CEP162 results in decreased CEP290 localization to both these areas, although the phenotype
was not necessarily clear-cut – for instance, it is difficult to say how much, if any, CEP290
localized to spindle pole microtubules even before CEP162 knockdown (Wang et al., 2013).
PCM-1 was similarly shown to be necessary for CEP290 localization to the centriolar satellites,
although CEP290 localization to the transition zone of the cilium was not affected by PCM-1
knockdown (Kim et al., 2008). CEP72 was also found to either directly or indirectly associate
with CEP290, and in this case this interaction was found to be important in the recruitment of
BBSome components to the ciliary transition zone (Stowe et al., 2012). It will be exciting to see
what new insights into CEP290 biology can be gained as the interactions between CEP290 and
these novel interacting partners are better characterized.
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CP110
Up until this point we have focused on CEP290’s interactions with proteins that aid in promoting
ciliogenesis or maintaining ciliary structure. There is, however, one known CEP290 interacting
protein, CP110, that acts to inhibit CEP290 activity and ciliogenesis (Tsang et al., 2008).

CP110 was first discovered as a component of the centriole with important functions in
regulating centriolar length and duplication (Chen et al., 2002). It soon became apparent,
however, that CP110’s functions extended beyond the centriole when it was discovered that the
protein plays a critical role in the regulation of ciliogenesis (Spektor et al., 2007). CP110, it turns
out, directly binds to the N-terminus of CEP290 and actively inhibits ciliogenesis (Tsang et al.,
2008). Overexpression of CP110 prevents cells from forming primary cilia, while knockdown of
CP110 results in aberrant cilium formation (Tsang et al., 2008).

It isn’t known exactly how CP110 binding to CEP290 inhibits CEP290 function, but the process of
CP110 removal from CEP290 is now beginning to be worked out. During the cell cycle CP110
remains bound to CEP290 at both the mother and daughter centrioles, inhibiting axoneme
extension and IFT (Tsang et al., 2008). Once the centrosome docks with a ciliary vesicle,
however, the processes of axoneme extension and IFT are initiated by the kinase TTBK2. TTBK2
is recruited to the tip of the mother centriole where it specifically affects the removal of CP110
from CEP290 (Goetz et al., 2012). Once this step has occurred, axoneme extension and IFT
begin. It seems that the interaction between CP110 and CEP290 is one of the last critical
checkpoints in the ciliogenesis pathway. We will need to learn much more about how these
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interactions are regulated and how CEP290 is activated, however, before we can begin to
understand and manipulate the process of ciliogenesis for potential therapeutic gain.

CEP290
Perhaps the most interesting interacting partner of CEP290 is CEP290 itself. In 2008 researchers
investigating CEP290’s interaction with NPHP5 made the surprising discovery that purified
regions of CEP290 were capable of homodimerization and heterodimerization (Schäfer et al.,
2008). In particular, they found that two regions of the protein, one encompassing its N-terminal
695 amino acids and the other spanning a C-terminal portion of the protein from amino acids
1966-2479, were each capable of binding themselves and each other. The researchers didn’t
investigate this phenomenon any further, but noted in their discussion that such interactions
present multiple possibilities for CEP290 tertiary/quaternary structure at the cilium. Numerous
models, with CEP290 molecules forming thick bundles, long filaments, or even rings can be
supported by these findings. There is even the possibility of intramolecular interactions, with a
single CEP290 molecule folding over on itself and binding itself in a head-to-tail fashion.

CEP290’s role in ciliogenesis and cilium function
Given its prime location at the transition zone of the primary cilium it is reasonable to assume
that CEP290 might play a critical role in mediating ciliogenesis and ciliary function. In fact, we
have already discussed some of the ways that CEP290 appears critical to these processes: CP110
inhibits CEP290 as a final checkpoint in the pathway to ciliogenesis, CEP290 binds to numerous
ciliary proteins that play critical roles in initiating ciliogenesis and maintaining IFT, and CEP290 is
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a critical component of the ciliary-links. But what do we know specifically about CEP290’s direct
affect on ciliogenesis and cilium function?

A number of labs have looked into this and have discovered that CEP290 is a critical regulator of
ciliogenesis and a key player in the maintenance of the ciliary compartment. Knockdown of
CEP290 in cultured cells results in dramatic decreases in cell ciliation, implying that CEP290 is
absolutely critical for normal ciliogenesis (Tsang et al., 2008). In fact, overexpression of CEP290
alone is enough to induce cells to aberrantly form primary cilia, indicating just how strong a
promoter of ciliogenesis CEP290 can be (Tsang et al., 2008). Those cells that do form cilia after
CEP290 knockdown are often noted to display significant perturbations of the microtubule
network, both within the cell in general and specifically within the ciliary axoneme (Kim et al.,
2008; McEwen et al., 2007).

But CEP290’s role in ciliogenesis and cilium formation are not limited to structural and
regulatory defects. Numerous groups have found that mutation or knockdown of CEP290 results
in significant deficiencies in the trafficking or proteins that should normally localize to the cilium.
RPGR, PCM-1, Rab8A, and olfactory G-proteins are all mislocalized in the absence of properly
functioning CEP290 (Chang et al., 2006; Kim et al., 2008; McEwen et al., 2007). Altogether these
data indicate an important structural and regulatory role for CEP290 within the ciliary
compartment and illustrate exactly how important the gene is to normal ciliary function.
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Animal models of CEP290 disease
Researchers working to elucidate the molecular functionality of CEP290 are lucky to benefit
from two naturally occurring models of CEP290 deficiency. The first CEP290 animal model to be
identified was the rd16 mouse, a strain characterized by rapid and near-complete
photoreceptor degeneration within the first month of life (Chang et al., 2006). This naturally
occurring mutant was discovered in 2003 at the Jackson Laboratories and, in a collaboration
with researchers at the University of Michigan and elsewhere, the molecular basis for the
phenotype was discovered only three years later (Chang et al., 2006). Chang et al. showed that
the underlying cause of the retinal degeneration was a deletion of exons 35-39 of the mouse

Cep290 gene, resulting in the in-frame deletion of 897 base pairs of the Cep290 mRNA and in a
Cep290 protein lacking 299 amino acids. They went on to show that the deletion perturbs
Cep290’s interaction with other ciliary proteins, resulting in paradoxically increased association
between Cep290 and RPGR. Subsequent studies by other groups went on to show that the
hypomorphic rd16 Cep290 results in the abnormal accumulation of high levels of Raf-1 kinase
inhibitory protein in the mouse photoreceptors and in the mistrafficking of ciliary-destined
proteins (McEwen et al., 2007; Murga-Zamalloa et al., 2011).

It is interesting that the rd16 mouse phenocopies the retinal pathology of LCA (albeit at a much
more rapid pace than in human patients) while producing no pathology in any other organ
system. It has been said that engineered mouse strains completely lacking the Cep290 gene are
uniformly embryonic lethal with significant pathology observed in the developing kidneys, liver,
and CNS, but no papers on this model have yet been published. This finding may point to the
importance of different regions of the protein in the pathology of different organ systems.
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In addition to the rd16 mouse, one other animal model of CEP290 deficiency has been reported.
This is the Abyssinian cat rdAc model of late-onset photoreceptor degeneration. In 2007
researchers finally linked the phenotype of this cat model to a mutation in intron 50 of the cat

CEP290 gene (Menotti-Raymond et al., 2007). This mutation creates a strong canonical splice
donor resulting in a 4 base pair addition and frame shift in exon 51 of the CEP290 gene. The
more mild phenotype of the rdAc cat (compared to the rd16 mouse) may be a result of the
mutation occurring so late in the open reading frame (perhaps enough of the CEP290 message is
translated that the protein maintains some residual function) or perhaps only a small percent of
transcripts actually include the additional 4 bases (similar to the most common human CEP290
mutation, where only 50% of transcripts include the cryptic exon (see following section on
human CEP290 mutations)), but more work is clearly needed to work out the molecular basis of
retinal degeneration in the rdAc cat. Regardless, the existence of a large animal model of
CEP290 deficiency can only serve to hasten the path to testing novel CEP290-based
therapeutics.

Patient CEP290 mutations
Mutations in CEP290 have been identified as the molecular cause of each of the ciliopathies
described above (see the section titled “Sensory cilium dysfunction”), Leber congenital
amaurosis, nephronophthisis, Senior-Loken syndrome, Joubert syndrome, Bardet-Biedl
syndrome, and Meckel syndrome (Baala et al., 2007; den Hollander et al., 2006; Valente et al.,
2006). In fact, CEP290 is the only gene that has been implicated in the pathogenesis of so many
diverse ciliopathy diseases. The number of CEP290 patients and novel CEP290 mutations
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continues to grow, but exactly how different CEP290 mutations lead to such different
phenotypes remains to be discovered.

To date over 120 unique mutations have been identified within the CEP290 gene (Coppieters et
al., 2010). None of these mutations seems to cluster to any particular area, but are instead
widely distributed anywhere from exon 1 to 54. Interestingly, of the mutations discovered fewer
than 10 are missense mutations. The rest are frame shift, splicing, or nonsense mutations
predicted to result in severely truncated CEP290 protein or no protein at all through the process
of nonsense mediated decay. The significance of the preponderance of pathologic truncating
mutations in the CEP290 gene is still unknown, but it is certainly an interesting aspect of CEP290
disease.

While all the identified mutations are interesting from a scientific perspective, one stands out as
both the most common and perhaps the most treatable. This is the c.2991+1655A>G mutation
within intron 26 of the CEP290 gene. Buried deep within the intronic sequence, this mutation
creates a strong splice-donor site that results in the inclusion of a cryptic exon between exons
26 and 27 in the fully spliced CEP290 mRNA (den Hollander et al., 2006). This cryptic exon
contains a stop codon that terminates translation just halfway through the CEP290 mRNA.
Interestingly, only 50% of transcripts produced will contain the cryptic exon, resulting in about
half-normal levels of full length CEP290 message (den Hollander et al., 2006). The hypomorphic
nature of the c.2991+1655A>G mutation may explain why it has only been identified in LCA
patients and never in patients with more severe disease.
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The c.2991+1655A>G mutation is widespread, particularly within Europe and the United States,
accounting for roughly 20% of all identified pathologic CEP290 mutations (Perrault et al., 2007).
The common nature of this mutation makes it an excellent target for therapeutic intervention –
a drug or biologic that successfully corrects even only the c.2991+1655A>G mutation could
stand to significantly alleviate the burden of CEP290-based disease.

CEP290 as a target for therapeutic intervention
The end goal of much of biomedical science is the development of treatments for human
disease. Unfortunately the development of therapeutic interventions for CEP290-based disease
has not yet reached even the early stages of animal testing. This is in part due to the large size of
the CEP290 gene. With a nearly 8 kilobase open reading frame the CEP290 cDNA is much too
large to package in traditional adeno-associated virus (AAV) vectors (Tal, 2000), the current
darlings of the gene therapy field and the only viral vectors proven safe and effective in the
treatment of retinal diseases (Maguire et al., 2009). A considerable amount of effort in the gene
therapy community has been spent trying to package larger-than-normal genomes within AAV,
and any developments in this field would be a major breakthrough for CEP290 patients. In fact,
it was reported in 2008 that packaging of full length CEP290 cDNA had been achieved in AAV
serotype 5 (Allocca et al., 2008), but to date no one has been able to replicate these results and

CEP290 patients remain without any effective treatments.

In the absence of a catch-all treatment for CEP290 disease a number of researchers have been
investigating strategies to correct at least the most common CEP290 mutation, the
c.2991+1655A>G cryptic splicing event (Collin et al., 2012; Gerard et al., 2012). All of these
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approaches revolve around the vectored delivery of a small antisense oligonucleotide (AON)
complementary to the cryptic exon splice site. The hope is that the AON might bind to and mask
the cryptic splice site, skewing the ratio of mutant to normal transcript more in the favor of
normal and potentially ameliorating the retinal degenerative phenotype of CEP290

LCA

patients. This strategy is still being actively pursued, but no results in animal models have yet
been published.

Finally, a third approach to the treatment CEP290-based disease is also in the works. This
approach relies on the vectored delivery of a tuncated version of the CEP290 gene small enough
to fit within AAV vectors but still large enough to maintain some or all of the full-length gene’s
function. This is not a completley novel idea – a mini-gene approach has met some success in
the treatment of muscular dystrophy. The functionality of dystrophin, a large structural protein
that is at the root of all cases of Duchenne muscular dystrophy, was found to be preserved in a

miniDystrophin gene that, when delivered to a mouse model of the disease was able to effect at
least some improvement in the muscular phenotype (Koppanati et al., 2010). Recently one
group has reported the rescue of the retinal degeneration phenotype in an induced zebrafish
model of CEP290 disease using just such a miniCEP290 (Baye et al., 2011). To date, however,
there have been no publications on the efficacy of this miniCEP290 in any other models of
disease.
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Concluding thoughts
So, this was the state of the field when I began my work to elucidate CEP290 function. I was
lucky to begin my dissertation in a field that had only recently emerged but, at the same time,
was beginning to move forward at a rapid pace. I had a chance to experience the strange mix of
excitement and anxiety whenever a new publication with the word “CEP290” was loaded onto
PubMed but the good fortune to have made it to this stage of the game without being scooped.

I hope that this introduction has adequetly explained the background necessary to understand
the work that follows while at the same time has impressed upon the reader the drastic need
for a better understanding of ciliary biology and the immense need for novel ciliopathy
therapeutics. It was also my intent to begin to establish certain ideas and paradigms in this
introduction that will be more thoroughly fleshed out by the presentation of my work that
follows. It is my hope that the reader, following these common threads through the next three
chapters and into the discussion, finds the story that my dissertation tells novel, compelling, and
exciting.
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Abstract
Mutations in the gene CEP290 cause an array of debilitating and phenotypically distinct human
diseases, ranging from the devastating blinding disease Leber congenital amaurosis (LCA) to
Senior Løken Syndrome, Joubert syndrome, and the lethal Meckel-Grüber syndrome. Despite its
critical role in biology and disease, we know only little about CEP290’s function. Here we identify
four novel functional domains of the protein, showing that CEP290 directly binds to cellular
membranes through an N-terminal domain that includes a highly conserved amphipathic helix
motif, and to microtubules through a domain located within its myosin-tail homology domain.
Furthermore, CEP290 activity was found to be regulated by two novel autoinhibitory domains
within its N- and C-termini, both of which were also found to play critical roles in regulating
ciliogenesis. Disruption of the novel microtubule-binding domain in the rd16 mouse LCA model
was found to be sufficient to induce significant deficits in cilium formation leading to retinal
degeneration. These data implicate CEP290 as an integral structural and regulatory component
of the cilium and provide insight into the pathological mechanisms of LCA and related
ciliopathies, illustrating how disruption of particular CEP290 functional domains might lead to
particular disease phenotypes, and suggesting novel strategies for therapeutic intervention.
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Introduction
Upon exit from the cell cycle and entry into G0 nearly every human cell sequesters its
centrosome in a structure known as the primary cilium (Kobayashi and Dynlacht, 2011). Until
recently the functional role of the primary cilium, a single antenna-like projection of the apical
membrane, had not been well studied or appreciated. It is now clear that this organelle has
important sensory roles affecting multiple cellular processes (Davenport et al., 2007; Han et al.,
2009; Wong et al., 2009) and that defects in primary cilium formation and function are
responsible for a variety of human diseases and developmental disorders, collectively termed
ciliopathies (Waters and Beales, 2011).

While the ciliopathies are diverse in both phenotype and etiology, specific genes, including

CEP290, have been implicated as having causative roles in multiple cilium-associated disorders
(D’Angelo and Franco, 2009). CEP290 mutations have been described in up to 20% of cases of
the devastating inherited blinding disease Leber congenital amaurosis (den Hollander et al.,
2008; Perrault et al., 2007) and in numerous cases of other more debilitating ciliopathies, such
as Joubert syndrome (Brancati et al., 2007; Sayer et al., 2006; Valente et al., 2006), Senior Løken
Syndrome (Helou et al., 2007), and Meckel-Grüber syndrome (Baala et al., 2007). How the many
identified mutations in CEP290 contribute to these diverse pathologies remains unknown, and
the protein’s normal biological role has not been well-characterized.

Throughout the cell cycle CEP290 localizes to both the mother and daughter centrioles (Chang et
al., 2006; Sayer et al., 2006) where it is maintained in an inhibited state by the protein CP110
(Tsang et al., 2008). During G0 the kinase Ttbk2 mediates the removal and degradation of CP110
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from CEP290 at the mother centriole (Goetz et al., 2012; Spektor et al., 2007) leading to
ciliogenesis, the formation of the primary cilium. Ciliogenesis is driven by the highly regulated
and specific transport of ciliary proteins into the ciliary compartment through a process known
as intraflagellar transport (IFT) (Pedersen and Rosenbaum, 2008). Numerous studies have
demonstrated that CEP290’s function is critical for this process – in CEP290 knockdown
experiments proteins that would normally localize to the cilium fail to do so (Chang et al., 2006;
Craige et al., 2010) and cilium formation is disrupted (Kim et al., 2008; Stowe et al., 2012).

Once the cilium is formed, CEP290 is found at the ciliary transition zone, the region of the
organelle just proximal to the microtubule axoneme. Elegant structural work in the

Chlamydomonas model system has localized CEP290 to the ciliary Y-links (Craige et al., 2010),
dense, proteinaceous structures within the transition zone that closely couple the ciliary
membrane to its microtubule core (Williams et al., 2011). The Y-links are thought to form a
barrier to passive diffusion between the cilium and the cytosol (Hu and Nelson, 2011) and
possibly act as a scaffold for the cellular machinery responsible for IFT (Kee et al., 2012). CEP290
likely plays an important role in the organization of this diffusion barrier and “ciliary pore”
through the recruitment of a number of interacting partners, such as CC2D2A (Gorden et al.,
2008), NPHP5 (Schäfer et al., 2008), and Rab8 (Kim et al., 2008), all of which are also involved in
cilium function and disease. However, despite our expanding knowledge of CEP290 interacting
partners and localization, the precise role CEP290 plays in ciliogenesis, IFT, and as a component
of the Y-links is still unclear. No functional domains for the protein have been identified, and
how mutations in particular regions of the gene affect protein function and cause disease
remains completely unknown.
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In this paper we present evidence that CEP290 directly binds to cellular membranes through a
highly conserved region in its N-terminus and to microtubules through a domain located near its
C-terminus. CEP290 activity was found to be regulated by autoinhibitory domains located within
its N- and C-termini, both of which were found to play a critical role in regulating ciliogenesis.
Furthermore, we show that the microtubule-binding domain we identified is completely
disrupted In the rd16 mouse LCA model (Chang et al., 2006), resulting in significant deficits in
cilium formation leading to retinal degeneration. These findings implicate CEP290 both as a key
structural component of the ciliary Y-links and as a terminal regulator in the pathway leading to
ciliogenesis. Our study also provides the first evidence of a mechanistic and pathological basis
for CEP290-related LCA and related ciliopathies and suggests novel strategies for therapeutic
intervention.
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Results
Mutations in the CEP290 gene have been implicated in a variety of human diseases (Moradi et
al., 2011), but their effects on protein function have not yet been characterized. Mutations
clustering in particular regions of the gene might be indicative of important functional domains,
but no mutational hotspots or functional domains have been identified to date (Figure 2.1A)
(Coppieters et al., 2010). To better understand the role CEP290 plays in cilium function,
ciliogenesis, and human disease, we performed a structure-function analysis using a panel of
truncation constructs spanning the full length of CEP290 to identify and define domains of novel
functionality.

CEP290 associates with ARL13B-positive cellular membranes via its N-terminus
The first two CEP290 truncations we tested displayed distinct localization patterns. When
overexpressed as GFP fusion proteins the N-terminal fragment of CEP290 (spanning aa 1-580)
showed an exclusively punctate localization pattern while the C-terminal fragment of CEP290
(from aa 580 to the end of the protein, aa 2479) showed a striking fibrillar localization (Figure
2.1B). Both of these patterns were occasionally observed in cells overexpressing the full-length
CEP290 construct, but not with the same frequency as in cells expressing the truncations (data
not shown). We generated two additional truncations of the N-terminal region of the protein to
better define the domain responsible for the punctate localization. The truncation spanning
CEP290 aa 1-362 showed a punctate pattern similar to that observed for the complete Nterminal fragment, while the truncation spanning aa 380-580 was present only diffusely
throughout the cytoplasm (Figure 2.1B). Further truncation of the protein was not effective in
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resolving the domain responsible for punctate localization beyond aa 1-362, implying either that
this is the minimum region needed for punctate staining or that further truncation significantly
interferes with protein function.

The CEP290-positive puncta observed by microscopy were found to display robust co-staining
with ARL13B (Figure 2.1B), a membrane protein important in the trafficking of vesicles to the
primary cilium (Barral et al., 2012; Cevik et al., 2010; Li et al., 2010), suggesting that these
puncta might be cilium-destined cellular vesicles. Detergent-free post-nuclear supernatants of
cells expressing our CEP290 truncations were prepared and ARL13B-positive membranes were
magnetically immunoprecipated and analyzed by western blotting. Both CEP290 aa 1-580 and
CEP290 aa 1-362 were significantly enriched in the ARL13B membrane immunoprecipitate, while
neither CEP290 aa 380-580 nor GFP alone were found in significant quantities (Figure 2.2B).
Thus, CEP290 aa 1-362 were found to be necessary and sufficient to mediate CEP290 localization
to ARL13B-positive membranes. In only very few cases did the CEP290-positive puncta exhibit
any co-staining with LAMP2, a marker of the lysosomal compartment (Figure 2.2D), suggesting
that CEP290 membrane localization was not an artifact of protein overexpression.

To confirm that the puncta observed by microscopy were truly membranous organelles we
performed a series of membrane co-flotation assays on cells expressing CEP290 aa 1-580.
Roughly 40% of total CEP290 aa 1-580 was found to co-float in the membrane-associated
fractions (Figure 2.2A, fractions 1-3), indicating that a substantial portion of the protein was, in
fact, associated with cellular membranes. ARL13B, the Na/K ATPase, and Annexin A2 were all
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found to similarly co-float in the membrane-associated fractions, while Tubulin was found
almost exclusively in the soluble fraction (Figure 2.2A).

The dual distribution of CEP290 aa 1-580 within both the membrane-associated and soluble
fractions along with the absence of a signal peptide from CEP290’s amino acid sequence was
suggestive of peripheral, rather than integral, membrane association (Mu et al., 1995; Seaman
et al., 1996). To confirm this, membrane fractions of cells transfected with our CEP290
truncations were prepared and peripheral membrane proteins were eluted from the membrane
with a high pH buffer. The remaining integral membrane proteins were subsequently solubilized
with detergent. For both CEP290 aa 1-580 and aa 1-362 the majority of each truncation was
found in the peripheral membrane protein fraction (Figure 2.2C). This same pattern was
observed for the peripheral membrane protein Annexin A2 (Klee, 1988), while the majority of
the Na/K ATPase, an integral membrane protein, was found in the integral membrane protein
fraction (Figure 2.2C). CEP290 aa 380-580, on the other hand, was not found in significant
amounts in either fraction. Taken together, these data indicate that CEP290 aa 1-362 are
necessary and sufficient for robust peripheral membrane association.

CEP290’s capacity for membrane association is increased by truncation of its Cterminus
To further investigate CEP290’s membrane association, we performed a series of subcellular
fractionation experiments on cells expressing each of our CEP290 truncations. The CEP290
truncation spanning aa 580-2479 that produced a fibrillar localization pattern by microscopy
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was found almost exclusively in the cytoskeletal fraction, while truncations lacking this region
were completely absent from the cytoskeletal fraction (Figure 2.13A). On the other hand,
truncations that included CEP290 aa 1-362 were again found to be significantly present in the
membrane fraction when compared to either GFP-alone or our fractionation controls (Figure
2.13A). Roughly 30% each of both CEP290 truncations aa 1-580 and aa 1-362 were found to be
associated with cellular membranes while roughly 10% of full-length CEP290 was also found in
the membrane fraction (Figure 2.13B). This distribution agrees with what was observed by
fluorescence microscopy – specifically, that full-length CEP290 occasionally displayed vesicular
localization, but to a lesser extent than CEP290 truncations lacking the C-terminus of the protein
but containing aa 1-362.

CEP290 directly binds membranes in vitro and contains a highly conserved membranebinding amphipathic α-helix motif
To determine whether CEP290’s membrane association was mediated by a direct or indirect
interaction we performed a series of liposome co-flotation assays on purified recombinant
CEP290 aa 1-580 (Figure 2.14A). CEP290 aa 1-580 associated with liposomes robustly, with a
majority of the protein found in the liposome-associated fraction (Figure 2.3A). Flotation of the
truncation occurred only in the presence of liposomes, and liposome co-flotation was not
observed for a control protein, BSA (Figure 2.3A). The ability of this region of CEP290 to directly
bind liposomes suggests that the observed association between the N-terminus of CEP290 and
cellular membranes is mediated by a direct interaction
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Projecting CEP290 aa 1-362 onto an α-helical wheel, a segment from aa 257 to 292 was
predicted to form a canonical amphipathic α-helix (Figure 2.3B). Such helices have been shown
to be critical in mediating robust interactions between peripheral membrane proteins and
various cellular membranes (Cornell and Taneva, 2006). Comparing this stretch of the protein
across a variety of species, we found the amphipathic helix motif to be very highly conserved.
Where there was divergence in the amino acid sequence, there was usually conservation of
polarity and charge between the divergent residues (Figure 2.3C). Taken together, these data
suggest that the highly conserved amphipathic helix located within the membrane binding
region of CEP290 may be mediating CEP290’s novel membrane binding function.

CEP290 aa 1695-1966 mediate colocalization with microtubules
CEP290 aa 580-2479 appeared both by microscopy and subcellular fractionation to be
associated with the cytoskeleton (Figures 2.1B, 2.2D, 2.13A). To further investigate this
phenomenon, we constructed a library of additional CEP290 truncations to thoroughly
interrogate CEP290’s cytoskeletal association (Figure 2.4). Overexpression of these truncations
as GFP fusions revealed that those truncations containing CEP290 aa 1695-1966, referred to as
region M, displayed a fibrillar localization pattern similar to that which was observed for CEP290
aa 580-2479 while truncations lacking CEP290 region M never display any fibrillar localization
(Figure 2.5A-B). These fibrils were noted to co-localize with the microtubule network implicating
CEP290 region M as necessary and sufficient for microtubule co-localization.
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The degree to which different CEP290 truncations displayed a fibrillar localization pattern was
found to be dependent upon which regions of the protein were included in the truncation. The
full-length CEP290 construct was noted to produce a fibrillar localization pattern in only about
10% of transfected cells (Figure 2.5B). Truncations lacking either the N- or C-terminus of CEP290,
on the other hand, were found to display a fibrillar localization in roughly 20% and 60% of
transfected cells, respectively. The truncation lacking both termini was found to display a
fibrillar localization pattern in nearly 80% of transfected cells. These data indicated that the Nand C-termini of the protein have an inhibitory or regulatory effect on CEP290’s microtubule
binding ability.

It is interesting to note that all of our truncations displayed co-localization with pericentrin, a
marker of the centriole (the normal site of CEP290 localization) (Figure 2.5A, insets). Homotypic
interactions between endogenous CEP290, present at the centrioles, and our truncations
(through CEP290’s homo/heterodimerization domains (Schäfer et al., 2008)) might explain the
observed centriolar localization of a number of our truncations. However, those truncations
lacking both homo/heterodimerization domains are apparently still capable of localizing to the
centriole, implying that multiple regions throughout CEP290 are capable of affecting centriolar
localization.

CEP290 microtubule association results in microtubule acetylation and bundling
In cells transfected with CEP290 constructs containing region M there was a dramatic increase in
the intensity of acetylated α-tubulin staining, with bundles of acetylated microtubules looping
throughout the cells (Figure 2.6A). These increases were not seen for truncations lacking region
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M. The degree to which different CEP290 truncations increased the acetylation and bundling of
microtubules was dependent upon which regions of the protein were included in the truncation.
Full-length CEP290 and CEP290 truncations lacking either the N- or C-terminus increased
microtubule acetylation and bundling in nearly 40% of transfected cells while CEP290
truncations lacking both the N- and C-terminus of the protein increased microtubule acetylation
and bundling in nearly 75% of cells (Figure 2.6B). Less than 15% of cells transfected with
truncations lacking region M were noted to have any change in microtubule acetylation or
bundling.

CEP290 directly binds microtubules in vitro
A series of microtubule co-sedimentation assays performed on our CEP290 truncation
constructs revealed that truncations containing region M were capable of significant
microtubule association in vitro (Figure 2.7A-B). Again, the degree to which different CEP290
truncations associated with microtubules was found to be dependent on the inclusion of the Nand C-termini. Less than 50% of the full-length CEP290 construct and CEP290 constructs lacking
either terminus were found to associate with microtubules, while nearly 100% of CEP290
constructs lacking both termini associated with microtubules (Figure 2.7B).

To test whether CEP290 region M’s microtubules association was mediated by direct
microtubule binding we recombinantly expressed and purified CEP290 region M (Figure 2.14B)
and subjected this protein to a series of microtubule co-sedimentation assays using increasing
concentrations of microtubules (Figure 2.7C-D). Region M was found to directly and robustly
bind to microtubules in a concentration dependent manner (Figure 2.7D). The calculated KD of
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this interaction was found to be approximately 100nM, an affinity comparable to those of other
microtubule binding proteins (Gustke et al., 1994; Kikkawa et al., 2000).

The N- and C-termini of CEP290 cooperate to inhibit protein function and regulate
ciliogenesis
The observation that the N- and C-termini of CEP290 appeared to act in inhibiting the
membrane and microtubule binding activity of the protein (Figures 2.4, 2.5B, 2.6B, 2.7B, 2.13B)
suggested that these regions might be regulatory domains mediating the autoinhibition of the
protein. To test this hypothesis, we transduced hTERT-RPE1 cells with lentiviral vectors encoding
either the N- or C-terminus of the protein and observed the cells for deficits in primary cilium
formation. To our surprise, we found that overexpression of either of these regulatory regions
resulted not in deficiencies in primary cilium formation, but instead in significant increases in
the percent of cells forming primary cilia, with more than twice as many cells forming primary
cilia than those cells treated with a control vector (Figure 2.8A-B). The length of cilia formed by
cells overexpressing either regulatory region was also significantly increased by more than 25%
compared to cells treated with the control vector (Figure 2.8C-D). These increases were only
observed in cells maintained in media supplemented with serum, a condition in which CEP290 is
normally inhibited (Stowe et al., 2012), implying that these regulatory domains act through the
same pathway that mediates normal CEP290 inhibition. It is also interesting to note that
dysregulation of CEP290 by overexpression of either regulatory region was sufficient to initiate
aberrant primary cilium formation, suggesting that there is no further downstream regulation of
ciliogenesis beyond CEP290.
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Interestingly, in both the serum starved and serum fed state it was noted that occasional cells
transduced with the N-terminus of CEP290 appeared to produce multiple ciliary axonemes at
the same centrosome (Figures 2.8A, 2.9A-C). These axonemes always emanated from a single
focus of pericentrin (Figure 2.8B) and were often found at 90˚ to each other. In some, but not all
cases, one or more of these axonemes co-stained with ARL13B (Figure 2.9A), a protein
associated with the ciliary membrane (Cevik et al., 2010), indicating that at least some of these
multi-axoneme structures were fully formed cilia.

The rd16 mouse Cep290 gene encodes a version of the protein deficient in microtubule
binding
The rd16 mouse is a retinal disease model of CEP290 deficiency characterized by a rapid and
near-complete degeneration of photoreceptors. The rd16 Cep290 gene encodes a protein
containing an in-frame deletion of 298 amino acids (Chang et al., 2006) that significantly
overlaps the region of human CEP290 we identified as being critical for microtubule binding
(Figure 2.10A).

We generated two truncation mutants of human CEP290 containing either the region of the
microtubule binding domain deleted in the rd16 mouse, or the region of the microtubule
binding domain spared by the mouse deletion (Figure 2.10A). To our surprise, when
overexpressed in hTERT-RPE1 cells both truncations displayed a diffuse localization pattern
indicative of a primarily cytosolic localization (Figure 2.10B). In neither case was any significant
co-localization with the microtubule network observed. We confirmed that neither of these
constructs was capable of associating with microtubules by subjecting them to microtubule co78

sedimentation assays (Figure 2.10C). Neither construct was found to significantly co-sediment
with microtubules (Figure 2.10D), indicating both that the rd16 deletion perturbs microtubule
binding and that microtubule binding is conferred by a larger portion of the CEP290 gene than
was included in either of our truncations.

To confirm that rd16 Cep290 was in fact deficient in microtubule binding we subjected brain
lysates from wild type (WT) and rd16 mice to microtubule co-sedimentation assays (Figure
2.10E). WT Cep290 showed very significant microtubule association, with roughly 60% of the
protein associating with microtubules (comparable to full-length human CEP290 (Figure 2.7B)),
while rd16 Cep290 was found to be completely deficient in microtubule binding (Figure 2.10F).

The rd16 mouse is deficient in cilium formation and structure
While the retinal phenotype of the rd16 mouse has been well documented (Cideciyan et al.,
2011), no cellular phenotype regarding primary cilium formation or structure has yet been
reported. To investigate the effect that ablation of Cep290 microtubule binding might have on
primary cilium formation, we assayed primary dermal fibroblasts from rd16 and WT mice for
deficiencies in cilium formation and structure. In both serum starved and serum fed conditions,
rd16 fibroblasts were found to be significantly deficient in primary cilium formation, with
roughly 50% fewer cells forming cilia than WT controls (Figure 2.11C-D). The cilia produced by
rd16 fibroblasts were also found to be more than 25% shorter than those produced by WT
fibroblasts (Figure 2.11A-B), further suggesting that the microtubule binding functionality of
CEP290 is critically important in the maintenance and formation of the primary cilium and, when
disrupted, capable of causing severe retinal disease.
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Discussion
CEP290 plays a critical role in the formation and function of the primary cilium and, when
mutated, is responsible for a variety of devastating human diseases (Coppieters et al., 2010).
Our understanding of the protein’s function has been, until now, inadequate to explain how
disruption of CEP290 might lead to human pathology (Moradi et al., 2011). The findings
presented here begin to implicate CEP290 as a vital structural and regulatory element of the
ciliary transition zone, elucidate some of its molecular functionality, and place it at the center of
the critically important and disease-relevant pathways of ciliogenesis and IFT.

CEP290 as a bridge between the ciliary membrane and the microtubule axoneme
To date, how CEP290 functions as a component of the ciliary Y-links has been unclear. Here we
have shown that CEP290 is capable of directly binding to both cellular membranes and
microtubules, possibly anchoring the two to each other and likely playing a key structural role in
the maintenance of the cilium. Furthermore, we have described the particular domains of
CEP290 responsible for mediating these specific functions. The N-terminus of the protein,
containing a highly conserved amphipathic helix, mediates CEP290’s membrane binding activity.
Such helices have previously been shown to be critical in mediating robust, reversible
interactions between various membrane binding proteins and cellular membranes (Cornell and
Taneva, 2006). Multiple experiments determined that a region near the C-terminus of CEP290,
encompassing much of the protein’s myosin-tail homology domain, was necessary and sufficient
to mediate microtubule binding. Myosin-tail homology domains have been reported to be
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critical in mediating the microtubule binding activity of several other cytoskeleton-associated
proteins (Moen et al., 2011; Weber et al., 2004).

The location of these two functional domains at opposite ends of CEP290 immediately suggests
a potential structural role for the protein, anchoring the ciliary membrane to the axoneme at a
fixed distance. Our data also indicate that, in addition to binding microtubules, CEP290 is
capable of mediating their acetylation and bundling, two hallmarks of the microtubules that
make up the ciliary axoneme (Alieva et al., 1999), suggesting that CEP290 might play an
important role in the stabilization, bundling, and organization of microtubules during
ciliogenesis.

A novel mechanism for the inhibition of CEP290
An overarching theme that emerged from our analysis of CEP290’s membrane and microtubule
binding activities was that the full-length protein exhibited attenuated activity when compared
to truncation mutants lacking the N- or C-terminus. Confirming a role for these domains in the
regulation of the protein’s function and ciliogenesis, we found that overexpression of either
domain interfered with the normal regulation of CEP290 and was sufficient to initiate aberrant
primary cilium formation, suggesting that there is no further downstream regulation of
ciliogenesis beyond CEP290. Overexpression of the regulatory regions in serum-starved cells,
where CEP290 is known to be relieved of inhibition, did not result in any increase in CEP290
activity, implying that these regulatory domains act through the same pathway that mediates
normal CEP290 inhibition.
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These data present at least two possibilities for a mechanism of CEP290 regulation. Both
regulatory loci might be acted upon by extraneous inhibitory factors to mediate CEP290
inhibition. In fact, it has been shown that the protein CP110 acts as just such an inhibitory
factor, binding to the N-terminus of CEP290 and inhibiting protein activity (Spektor et al., 2007;
Tsang et al., 2008). Accordingly, we found that, in some cells, overexpression of CEP290’s Nterminus led to the growth of multiple ciliary axonemes. This is consistent with what would be
expected upon competition between endogenous CEP290 and the overexpressed N-terminal
fragment for CP110, normally removed from only one end of the mother centriole to initiate
ciliogenesis (D’Angiolella et al., 2010). Nonspecific depletion of CP110 from both ends of both
centrioles by the overexpressed N-terminus could have resulted in the growth of multiple ciliary
axonemes in the cells we observed.

Our data cannot, however, be fully explained by this mechanism alone. If inhibition were solely
dependent on the binding of a finite pool of endogenous inhibitory factor, then overexpression
of the full-length protein should result in competition for the inhibitory factor and only minimal,
if any, observed inhibition of the overexpressed protein. Additionally, we would not expect to
see inhibition of the full-length construct in in vitro assays where inhibitory factors should not
be present at meaningful concentrations. In all our experiments assessing protein activity, we
found that full-length CEP290 was significantly inhibited compared to truncation mutants
lacking the novel inhibitory regions, arguing against extraneous factors such as CP110 being
solely responsible for CEP290 regulation.
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We propose an alternative model for CEP290 regulation that is more consistent with our
findings and with previous data showing that both the N- and C-termini of CEP290 are capable
of binding both themselves and each other (Schäfer et al., 2008). Perhaps the two novel
regulatory regions of the protein cooperate to inhibit CEP290 function, binding to each other
and causing a conformational change in the protein, stabilized by the binding of CP110, that
obscures important functional domains and decreases protein function (Figure 2.12). Thus, the
overexpression of either regulatory domain would saturate endogenous CEP290 regulatory
domains, resulting in a paradoxical increase in protein function, and the full-length protein, of its
own accord, would be expected to display innate inhibition regardless of experimental
conditions. These are exactly the results we observed in all of our experiments.

Interestingly, this mechanism of inhibition has been described for a variety of other proteins,
such as Vinculin, Ezrin, and the ERM domain proteins, all of which act to link the cell membrane
to the actin cytoskeleton (Smith et al., 2003; Song et al., 2012). These proteins depend on
amphipathic helices for their membrane binding activity, and these helices have also been
shown to act in the inhibition of these proteins, binding to and obscuring their actin-binding
domains (Cornell and Taneva, 2006). It is plausible that this mechanism of autoinhibition,
conserved among membrane-to-actin cytoskeleton bridging proteins, is operative and
conserved for membrane to microtubule bridging proteins as well. CEP290 would be the first
protein in this class shown to rely upon this mechanism of inhibition. This model is also
supported by observations made in the rd16 mouse, such as the apparent increased affinity of
rd16 Cep290, compared to WT, for RPGR (Chang et al., 2006). The rd16 deletion of the
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microtubule binding/regulatory region may thus result in decreased autoinhibition and a higher
affinity of Cep290 for its interacting partners, as was observed.

Implications for human disease
As we continue to learn more about the key functional domains of CEP290 we will begin to
better understand how mutations in particular protein domains contribute to pathology. The
microtubule binding function of CEP290 is clearly of critical importance to the function of the
protein on a cellular level and, as we have shown, critical in disease. The rd16 mouse Cep290
gene was found to encode a version of the protein completely deficient in microtubule binding,
resulting in deficiencies in primary cilium formation and structure in cultured fibroblasts. While
rd16 photoreceptors do seem capable of forming connecting cilia, the function and
maintenance of the connecting cilium and photoreceptor outer segment is perturbed in these
animals, resulting in dramatic and rapid retinal degeneration, implying that deficiencies in
CEP290 microtubule binding can lead to significant pathology. Over 24 unique mutations
identified in human CEP290 patients map to the microtubule binding domain we report here
(Figure 2.1A). Almost all of these mutations are expected to have truncating effects on the
protein (Coppieters et al., 2010), which, as in the rd16 mouse, would result in significant
deficiencies in microtubule binding, potentially explaining the mechanism underlying the disease
phenotype seen in these individuals.

Perhaps most interesting, however, are the implications that the discovery of novel regulatory
domains of CEP290 has for the development of therapeutic interventions. The extension, to
CEP290 patients, of recombinant adeno-associated virus (AAV)-based therapeutics, which have
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proven safe and effective in the treatment of another genetic cause of LCA (Maguire et al.,
2009), has been hindered by CEP290’s large size, precluding it from packaging in AAV (Wu et al.,
2010). Truncation mutants of CEP290 lacking the novel inhibitory domains we have described
but maintaining the other functional regions of the protein may exhibit normal, or even
enhanced, CEP290 function, while at the same time being small enough to fit in AAV. The
delivery of such a therapeutic to terminally differentiated tissues, such as the retina, where
permanent activation of CEP290 would not be expected to be problematic, might prove
effective in the treatment of CEP290-related diseases such as LCA.

85

Methods
Plasmid construction
CEP290 truncations were generated by PCR amplification using Gateway® cloning (Invitrogen)
compatible primers from a human codon-optimized CEP290 plasmid synthesized by DNA 2.0.
Amplified products were cloned into pDONR221 (Invitrogen) by Gateway® cloning to generate
entry clones. For cell transfection and in vitro transcription and translation assays, entry clones
were shuttled into the plasmid pcDNA-DEST53 (Invitrogen) by Gateway® LR clonase reactions to
create N-terminally-tagged GFP fusions. For bacterial expression, entry clones were shuttled
into pDest-527 (a gift of Dominic Esposito (Frederick National Laboratory for Cancer Research,
Frederick, MD. Addgene plasmid #11518)) to create N-terminally-tagged 6xHis fusions. For
lentivirus production, entry clones were shuttled into pLXnGFP, a modified version of pLX302 (a
gift of David Root (The Broad Institute, Cambridge, MA. Addgene plasmid #25896)), to create Nterminally-tagged GFP fusion lentivirus production plasmids. Restriction digest and DNA
sequencing were used to confirm the integrity of each expression construct.

Cell culture and treatments and lentivirus production
Wild type and rd16 mouse primary dermal fibroblasts and 293T cells were grown in DMEM
supplemented with 10% FBS. hTERT RPE-1 cells were grown in DMEM:F12 supplemented with
10% FBS and 0.075% sodium bicarbonate. All cells were grown at 37˚ C in a humidified 5% CO2
atmosphere. Transfections were performed with FuGENE 6 reagent (Promega) according to the
manufacturer’s protocol. Cells were induced to form primary cilia by serum starvation with OptiMEM I (Invitrogen) for 48-72 hours.
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Lentiviral vectors were produced by transfection of 80% confluent 293T cells in T25 culture
flasks with 1 µg of lentivirus construct, 750 ng of PsPAX2 packaging plasmid, and 250 ng of
pMD2.G envelope plasmid. Media was replaced after 24 hours, and lentiviral supernatants were
harvested at 48 and 72 hours, combined, filtered through a 0.45 µm filter, and snap-frozen at 80° C. For lentivirus transduction, hTERT RPE-1 cells were plated in media containing 8 µg/mL
polybrene. Filtered media containing the appropriate lentivirus particles was added and 24
hours after transduction cells were switched to selective media containing 10µg/mL puromycin.

Primary dermal fibroblast isolation
Primary dermal fibroblasts were isolated by washing neonatal mouse skin in 70% ethanol
followed by 5 washes in PBS. The skin was minced in a culture vessel, covered with DMEM
supplemented with 10% FBS, penicillin, and streptomycin, and incubated at 37˚ C in a humidified
5% CO2 atmosphere. One week after harvesting the skin was removed and discarded and
fibroblasts were passaged into a larger vessel.

Antibodies, immunofluorescence, and immunoblotting
Antibodies used in this study were rabbit anti-human CEP290 (Abcam, ab105383), rabbit antimouse Cep290 (Abcam, ab128231), mouse anti-α tubulin (Abcam, AB7291), rabbit antipericentrin (Abcam, AB4448), mouse anti-GFP (Roche 11 814 460 001), mouse anti-Bovine
serum albumin (Thermo, MA5-15238), rabbit anti-6xHis (Abcam, AB1187), rabbit anti-GAPDH
(Sigma, SAB2103104), mouse anti-Na/K ATPase α-1 (Novus, NB300-146), mouse anti-Lamin A/C
(Sigma, SAB4200236), mouse anti-Acetylated α-tubulin (Sigma, T7451), rabbit anti-LAMP2
(Novus, NBP1-71692), rabbit anti-Annexin A2 (Cell Signaling, 8235), rabbit anti-ARL13B
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(Proteintech, 17711-1-AP), HRP-conjugated goat anti-mouse (GE, NA931V), HRP-conjugated goat
anti-rabbit (GE, NA934V), Cy5 conjugated goat anti-rabbit (KPL, 072-02-15-06), and AlexaFluor
594-conjugated goat anti-mouse (Invitrogen, A1100S).

For immunofluorescence, cells were grown in chamber slides and fixed with 3% PFA in PBS for
20 minutes at 37˚ C. Cells were permeabilised with 1% Triton X-100 in PBS for 5 minutes, and
blocked in 2% BSA in PBS for 30 minutes prior to incubation with primary antibody. Secondary
antibodies used were donkey anti-mouse or anti-rabbit, conjugated to Cy5 or AlexaFluor 594.
Slides were mounted in mounting medium containing DAPI. Confocal imaging was performed
with an LSM510 META NLO laser scanning confocal on a Zeiss Axiovert 200M inverted
microscope using a Plan-Apo 63x/1.4 oil objective and the LSM510 4.2 software. Laser lines used
were 488nm (for green labeling, from argon laser), 543nm (for red labeling, HeNe laser), 633nm
(for cy5 channel, HeNe laser), and 740nm (for DAPI channel, from a Coherent Chameleon
tunable two photon laser). For normal fluorescence microscopy, slides were imaged using an
Axio Imager.M2 microscope using an either EC Plan-Neofluar 40x/0.75 M27 or an EC PlanNeofluar 63x/1.25 Oil M27 objective and captured using an AxioCamMR3 camera and the
AxioVs40 software, version 4.8.2.0. Primary cilium length was measured using the same
AxioVs40 software.

For immunoblotting, samples were subjected to SDS-PAGE and transferred to nitrocellulose
membrane using standard techniques. Membranes were blocked in 5% nonfat milk for 1 hour at
room temperature and subsequently incubated in primary antibody overnight at 4° C.
Membranes were washed three times with PBST (0.1% Tween-20 in PBS), incubated with HRP88

conjugated secondary antibody for 1 hour at room temperature, washed, and developed using
ECL2 reagent (Pierce), and scanned on a Typhoon 9400 instrument (GE). Immunoblots were
densitometrically quantified using ImageJ 1.44p.

Membrane

flotation,

membrane

protein

fractionation,

and

vesicle

immunoprecipitation
Cultured cells were washed three times with ice cold PBS. Cells were resuspended in a 250mM
Sucrose solution containing 4mM immidazole and a protease inhibitor cocktail and passaged
through a 25G needle 20 times. The resulting lysate was centrifuged at 1,000x g for 10 minutes
at 4˚C to pellet nuclei and unlysed cells and the resulting post-nuclear supernatant was
centrifuged at 100,000x g for 60 minutes at 4˚C to pellet the membrane-enriched fraction.

Membrane flotation was performed by resuspending the membrane-enriched fraction in 250 µL
of 80% sucrose in PBS. This solution was added to the bottom of a 2mL centrifuge tube, overlaid
with 1.5 mL of 50% sucrose in PBS and with 250 µL of 5% sucrose in PBS. Sucrose gradients were
then centrifuged at 100,000x g for 16 hours at 4˚C. Equal fractions were subsequently taken
from the top to the bottom of the gradient and analyzed by western blotting as indicated.

Peripheral membrane proteins were extracted from membrane preparations by resuspending
and incubating the membrane-enriched fraction of cultured cells in a high pH buffer (100nM
Na2CO3, pH 11.3) for 30 minutes at 4˚C. The membranes were pelleted at 100,000x g for 60
minutes at 4˚C and the resulting supernatant was saved as the peripheral membrane fraction.
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Integral membrane proteins were subsequently extracted by resuspending and incubating the
resulting membrane pellet in 4% Triton-X100 in PBS for 30 minutes at 4˚C.

Vesicle immunoprecipitation was performed on post-nuclear supernatants of hTERT-RPE1 cells
expressing various CEP290 truncations. A sample of the total post nuclear extract was saved as
the input fraction. Protein G Dynabeads (Invitrogen) were washed and incubated with 2 µg of
anti-ARL13B antibody for 20 minutes at room temperature, magnetically collected, and washed
in PBS. 350 µL of post-nuclear supernatant was added to the antibody-dynabead complex and
incubated with gentle agitation for 20 minutes at room temperature. The beads and
immunoprecipitated complexes were magnetically collected and washed three times with PBS.
A sample of the unbound fraction was saved and the immunoprecipitated material was eluted
by resuspension in 4X SDS PAGE sample buffer.

Subcellular fractionation
Subcellular fractionation was performed using the QProteome Cell Compartment kit (Qiagen)
according to the supplied protocol.

Recombinant protein expression and purification
6xHis tagged CEP290 truncation M and N were expressed from pDest-527 in E.coli
BL21(DE3)pLysS (Invitrogen) and purified using the Ni-NTA Fast Start Kit (Qiagen) according to
the manufacturer’s protocol. Purified protein products were subjected to SDS-PAGE and stained
with Coomassie Brilliant Blue to assess purity and determine protein concentration.
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Liposome flotation assay
100 nm liposomes (total lipid concentration of 5mg/mL in PBS) with a lipid composition of a
60:40 molar ratio of phosphatidylserine to cholesterol were purchased from Encapsula
NanoSciences and used within 2 weeks of formulation. 20 µL (1.5 µg) of recombinant CEP290
truncation N, or an equivalent amount of BSA, was incubated with 230 µL of liposomes, or an
equal volume of PBS alone, at 37˚ C for 30 minutes. Each reaction was then mixed 1:1 with a
solution of 80% sucrose in PBS and added to the bottom of a 2mL ultracentrifuge tube.
Reactions were overlaid with 1.3 mL of 30% sucrose in PBS and with 200 µL of PBS and
centrifuged at 100,000x g for 90 minutes at 30˚ C. Five 400 µL fractions were taken, starting at
the top of sucrose gradient, and equal amounts of each were analyzed by SDS-PAGE and
western blotting.

In vitro transcription and translation reactions
Plasmid DNA was transcribed and translated using the TNT T7 reticulocyte lysate system
(Promega) according to the manufacturer’s protocol.

Microtubule polymerization
Pure bovine tubulin (Cytoskeleton) was diluted 1:1 in BRB80 buffer (80mM Pipes, 1mM MgCl2,
1mM EGTA, pH 6.8) and cleared of insoluble material by centrifugation at 20,000x g for 10
minutes. The soluble fraction was supplemented with 1 mM GTP and incubated at 37˚ C for 15
minutes to polymerize microtubules. The polymerized microtubules were treated with 10 µM
taxol and incubated at room temperature for an additional 15 minutes to stabilize the
microtubules. Microtubules were pelleted at 48,000x g for 30 minutes at 30˚ C and resuspended
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in BRB80 supplemented with 1mM GTP and 10 µM taxol. Microtubules were used within one
week of preparation.

Microtubule Binding Assays
Crude TNT T7 reaction products were diluted 1:1 in BRB80 supplemented with 1mM GTP and 10
µM taxol. The diluted products were then incubated at 30˚ C for 30 minutes in either the
presence or absence of pure, pre-polymerized microtubules. Reactions were centrifuged
through a 40% sucrose cushion at 48,000x g for 30 minutes, the supernatant was collected, and
the pellet washed once with warm BRB80 and resuspended in 1x SDS PAGE sample buffer. Both
fractions were subjected to SDS-PAGE and transferred to nitrocellulose. The presence of tubulin
in the pellets was confirmed by Ponceau staining.

For microtubule binding assays performed on mouse brain homogenate, 0.5 g of mouse brain
was mechanically homogenized in 0.5 mL of 1% NP40 in BRB80 buffer containing a protease
inhibitor cocktail. The homogenate was cleared of insoluble material by centrifugation at
48,000x g for 30 minutes at 4˚ C, and the resulting supernatant was either used immediately or
snap-frozen at -80˚ C for later use. Homogenates were incubated either at 37˚ C for 30 minutes
with 1mM GTP and 10µM taxol to promote microtubule polymerization, or at 4˚ C for 30
minutes to inhibit microtubule polymerization. The resulting reactions were then layered over a
40% sucrose cushion, centrifuged at 48,000x g for 30 minutes to pellet the microtubules and
microtubule-associated proteins, and processed as above.
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For the direct microtubule binding assay, 1µM of recombinantly expressed and purified 6xHis
tagged CEP290 truncation M was incubated at 30˚ C for 30 minutes with increasing amounts of
pure, pre-polymerized microtubules. Reactions were centrifuged and subjected to SDS-PAGE as
above, and tubulin and CEP290 truncation M were detected by Coomassie blue staining.

Bioinformatic Analysis
The helical wheel projection in Figure 2.3B was adapted from the Helical Wheel Projection
applet available at http://rzlab.ucr.edu/scripts/wheel/wheel.cgi. The multiple sequence
alignment presented in Figure 2.3C was adapted from GeneDoc 2.7.000.

Statistical analysis
The statistical significance of the difference between two means was determined using a twotailed Student’s t-test. The statistical significance of the difference between three or more
means was determined using a two-way ANOVA and Tukey’s HSD test. Statistical analysis was
performed using GraphPad Prism Software 5.0b. p-values < 0.05 were considered significant.

Study approval
The genetics and cell studies were approved by the University of Pennsylvania IRB, Philadelphia,
PA (protocol 808828, J. Bennett, PI). The animal studies were approved by the University of
Pennsylvania IACUC, Philadelphia, PA (protocol 802901, J. Bennett, PI).

93

Acknowledgments
We are grateful to Dr. Jeannette Bennicelli, Dr. George T. Drivas, Dr. Michael P. Hart, and Adam
Wojno for their many suggestions, conversations, and critical reading of this manuscript. We
would also like to thank Jasmine Zhao for her technical support. Plasmids purchased from
Addgene were kindly deposited by Dominic Esposito and David Root. Studies in this work were
supported by the Wyk Grousbeck Family Foundation and were performed in collaboration with
Project CEP290. Additional support was provided by Foundation Fighting Blindness, Research to
Prevent Blindness, NIH R24Ey019861, 8DP1EY023177, TreatRush (European Union), the Mackall
Foundation Trust, the Penn Genome Frontiers Institute, and the F.M. Kirby Foundation.

94

Figure 2.1. CEP290 aa1-362 mediate punctuate localization
(A) Scale representation of human CEP290. Known human CEP290 mutations are noted by red
tick marks. The indicated domains and mutations are adapted from (Coppieters et al., 2010).
(B) Fluorescence microscopy images showing the localization pattern of GFP fusions of fulllength (FL) and truncated CEP290 constructs in cycling hTERT-RPE1 cells. Cells were stained with
an antibody against ARL13B and with DAPI. Scale bars are 5 µm. Insets show 3x magnified views
of areas (in boxes) of colocalization between CEP290 truncations and ARL13B. Pearson
correlation coefficient for colocalization between ARL13B and CEP290 aa 1-580 is 0.53 and for
CEP290 aa 1-362 is 0.65.
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Figure 2.2. CEP290 aa1-362 mediate peripheral membrane association
(A) Equal amounts of each of five fractions, beginning from the top (1) and ending at the bottom
(8) of the sucrose gradient of a membrane flotation assay performed on hTERT-RPE1 cells
overexpressing CEP290 aa 1-580. Sucrose percentages and the percent of CEP290 aa 1-590
found in each fraction are indicated. Blots were probed for GFP to detect CEP290 aa 1-580 and
for the indicated controls.
(B) ARL13B positive membranes immunoprecipitated from postnuclear supernatants of hTERTRPE1 cells expressing the indicated GFP-fused CEP290 truncations or GFP alone were probed
with an anti-GFP antibody. 15% of the input fraction, 15% of the unbound fraction (UB) and the
entire immunoprecipitated fraction (IP) were loaded.
(C) The peripheral (Peri.) and integral (Int.) membrane protein fractions of hTERT-RPE1 cells
expressing the indicated GFP-fused CEP290 truncations were isolated and probed for GFP and
for the indicated controls.
(D) Fluorescence microscopy images showing the localization pattern of GFP-fused full-length
(FL) and truncated CEP290 constructs in hTERT-RPE1 cells stained for LAMP2 and with DAPI
(blue). Scale bars are 5 µm. Insets show 3x magnified views of areas (in boxes) illustrating lack of
colocalization between CEP290 truncations and LAMP2.
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Figure 2.3. CEP290 aa1-362 mediates direct membrane binding
(A) Liposome co-flotation assays performed on purified CEP290 aa 1-580, both with and without
liposomes, and with BSA as a control. Equal amounts of each of five fractions, beginning from
the top (1) and ending at the bottom (5) of the sucrose gradient were analyzed. Sucrose
percentages and the expected protein composition of each fraction are indicated.
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(B) Helical wheel projection of CEP290 aa 257-292. Red circles represent negatively charged
amino acids, blue circles represent positively charged amino acids, grey circles represent polar,
uncharged amino acids, and green circles represent nonpolar amino acids.
(C) Multiple sequence alignment of CEP290’s predicted amphipathic helix. Amino acids are
color-coded using the same scheme as in panel F.
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Figure 2.4. Schematic of CEP290 truncations
Scale representations of the CEP290 truncations tested in Figures 2.5, 2.6, and 2.7. Included is a
summary of the extent of colocalization with tubulin, rated on a scale ranging from negative (-)
to highly positive (+++).
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Figure 2.5. CEP290 region M mediates microtubule
colocalization
(A) Fluorescence confocal microscopy images showing
the localization pattern of GFP-fused full-length (FL)
and truncated CEP290 constructs expressed in
hTERT-RPE1 cells. Samples were stained for αtubulin, pericentrin, and with DAPI (blue). Scale bars
are 10 µm. Insets show 10x magnified views of areas
of colocalization between CEP290 truncations and
pericentrin. (B) The percent of transfected hTERTRPE1 cells in which GFP-fused truncatiosn displayed a
fibrillar localization pattern. At least 100 cells were
counted per experiment. Data are presented as mean
± SD, n=3.
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Figure 2.6. CEP290 region M mediates tubulin acetylation
(A) Representative confocal fluorescence microscopy images of GFP-fused full-length (FL) and
truncated CEP290 constructs expressed in hTERT-RPE1 cells stained for acetylated α-tubulin and
with DAPI (blue). Scale bars are 10 µm.
(B) Percent of 293T cells showing an increase in the intensity of acetylated α-tubulin staining
following transfection with CEP290 constructs. 100 transfected cells were counted per
experiment. Data are presented as mean ± SD, n=5. Means with different letters are significantly
different.
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Figure 2.7. CEP290 region M mediates direct microtubule binding
(A) Microtubule co-sedimentation assays for in vitro transcribed and translated CEP290
truncations. The supernatants (S) and microtubule pellets (P) are shown for assays performed
both with (+MT) and without (-MT) microtubules.
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(B) Percent of each truncation co-sedimenting with microtubules. Data are presented as mean ±
SD, n=3. Means with different letters are significantly different.
(C) Coomassie-stained gel of microtubule co-sedimentation assays performed with purified
CEP290 truncation M and increasing concentrations of microtubules. The supernatants (S) and
microtubule pellets (P) are shown.
(D) Binding curve of microtubules cosedimentation assays as in panel E. The fraction of
truncation M present in the pellet in the absence of microtubules was subtracted from all data
points. Data are presented as means ± SD, n=3.
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Figure 2.8. Overexpression of either N- or C-terminal regulatory region of CEP290 ablates
normal CEP290 inhibition
(A) Fluorescence microscopy fields of hTERT-RPE1 cells transduced with lentiviral empty vector
(EV), or vectors encoding either the N- (aa 1-580) or C-terminus (aa 1966-2479) of CEP290. Cells
were stained for acetylated α-tubulin (red) and pericentrin (green) to detect primary cilia and
with DAPI. Arrowheads indicate primary cilia. Arrows indicate cells with multiple axonemes
originating from the same focus of pericentrin. Scale bars are 10 µm.
(B) Percent of lentivirus-treated cells forming primary cilia. Data are presented as mean ± SD,
n=3. 100 cells were counted per experiment.
(C) Fluorescence microscopy images of hTERT-RPE1 cells transduced with lentiviral vectors as in
panel A. Cells were stained for acetylated α-tubulin to detect primary cilia and with DAPI. Scale
bars are 5 µm.
(D) Average primary cilium length for hTERT-RPE1 cells as in panel C. Data are presented as
mean ± SD, n=3. A total of at least 150 cilia were measured per condition.
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Figure 2.9. Overexpression of the N-terminal regulatory region of CEP290 results in multiple
ciliary axonemes
(A-B) Fluorescence microscopy images of hTERT-RPE1 cells that formed multiple cilia after
transduction with lentiviral vector encoding the N-terminus of CEP290. Cells were stained for
either ARL13B or pericentrin, and for acetylated α-tubulin and with DAPI (blue). Scale bars are
5µm.
(C) Percent of lentivirus transduced hTERT-RPE1 cells forming multiple cilia. At least 100 cells
were counted per experiment. Data are presented as mean ± SD, n=3.
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Figure 2.10. An in-frame deletion in Cep290 in the rd16 mouse ablates Cep290’s microtubule
binding activity
(A) Schematic representation of the microtubule binding region of human CEP290 in relation to
the rd16 mouse deletion (Chang et al., 2006). Truncations of CEP290 representing the part of
the microtubule binding region deleted in the rd16 mouse and the part of the microtubule
binding region maintained in the rd16 mouse were created as shown.
(B) Confocal fluorescence microscopy images showing the localization pattern of GFP-tagged
“Maintained” and “Deleted” CEP290 truncations. Cells were stained for α-tubulin (red),
pericentrin (white) and with DAPI (blue). Scale bars are 10 µm.
(C) Microtubule co-sedimentation assays for in vitro transcribed and translated “Maintained”
and “Deleted” CEP290 truncations. The supernatant (S) and microtubule pellet (P) fractions are
shown in assays performed both with (+MT) and without (-MT) microtubules.
(D) Percent of each truncation co-sedimenting with microtubules. Data are presented as mean ±
SD, n=2.
(E) Microtubule co-sedimentation assays performed on full-length WT and rd16 Cep290 from
mouse brain homogenate. The supernatant (S) and microtubule pellet (P) fractions are shown in
assays performed on samples induced to polymerize microtubules (+MT) and samples treated to
prevent microtubule polymerization (-MT).
(F) Percent of WT and rd16 Cep290 co-sedimenting with microtubules. Data are presented as
mean ± SD, n=3. Asterisks indicate statistical significance over –MT samples.
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Figure 2.11. rd16 mouse fibroblasts are deficient in primary cilium formation
(A) Fluorescent microscopy images of serum-starved WT and rd16 primary dermal fibroblasts
stained for acetylated α-tubulin (red) to identify primary cilia, and stained with DAPI (blue).
Scale bars are 5 µm.
(B) Average cilium length of serum starved WT and rd16 primary dermal fibroblasts.
Quantification was based on separate experiments on fibroblasts coming from 3 different
animals per genotype. At least 50 cilia were measured per experiment, and a total of 400 cilia
were measured for both the WT and rd16 fibroblasts. Data are presented as mean ± SD, n=5.
(C) Fluorescence microscopy fields of WT and rd16 primary dermal fibroblasts stained for
acetylated α-tubulin (red) to identify primary cilia, and stained with DAPI (blue). Fibroblasts
were grown in media with (Fed) or without (Starved) serum. Arrowheads indicate primary cilia.
Scale bars are 10 µm.
(D) Percent of WT and rd16 primary dermal fibroblasts that form primary cilia in serum fed and
serum starved conditions. Quantification was based on separate experiments on fibroblasts
coming from 3 different animals per genotype. At least 100 cells were counted per experiment.
Data are presented as mean ± SD, n=5.
107

Figure 2.12. A speculative model for CEP290 activity at the primary cilium
CEP290 is maintained in a closed, inhibited state by its N- and C-termini and CP110 during the
cell cycle (A). Upon degradation of CP110 at the mother centriole (B), a conformational change
in the protein frees and activates CEP290’s membrane binding (orange) and microtubule binding
(green) domains (C) and CEP290 is able to recruit additional interacting partners to initiate IFT
and ciliogenesis (D).
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Figure 2.13. Truncation of CEP290’s C-terminus increases CEP290 membrane association
(A) Subcellular fractionation experiments performed on 293T cells expressing CEP290
constructs. Cells were fractionated into cytoplasmic (C), membrane (M), nuclear (N), and
cytoskeletal (S) fractions and analyzed by western blotting. Relevant molecular weight markers
are shown in kDa.
(B) Percent of each truncation present in the membrane fraction. Data are presented as mean ±
SD, n=3. Asterisks indicate statistical significance over GFP-alone.
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Figure 2.14. Expression and purification of CEP290 truncation mutants in bacterial cells
CEP290 regions M (A) and aa 1-580 (B) were expressed from pDest-527 in E.coli BL21(DE3)pLysS
by IPTG induction and purified by nickel affinity chromatography. WCL is the whole bacterial cell
lysate. FT is the fraction of lysate that did not bind to the Ni-NTA resin. W1 and W2 are the
material that washed off the resin during the first and second washes, respectively. E1 is the
first elution fraction. E2 is the second elution fraction. Relevant molecular weights are indicated
in kDa
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Introduction
Mutations in the ciliopathy disease gene CEP290 are associated with a spectrum of devastating
and phenotypically distinct human disease syndromes ranging in severity from isolated retinal
degeneration to embryonic lethality.(Perrault et al., 2007) The pathology observed in these
diseases is due to CEP290’s essential role in the development and maintenance of the primary
cilium (D’Angelo and Franco, 2009), but how different mutations in the same gene can lead to
such dramatically different phenotypes remains unknown. Here we have developed a novel
model that, taking into account the phenomenon of basal exon skipping, accurately predicts
patient CEP290 protein levels in a mutation-specific fashion. Predicted CEP290 protein levels
were found to robustly correlate with disease severity for all reported CEP290 patients. Applying
our model to CC2D2A, another similar ciliopathy disease gene, we found the same correlation to
hold true. Our model establishes a new paradigm for the pathogenesis of the ciliopathies and,
for the first time, helps to explain the diversity of ciliopathy disease in general.

112

Results
Rationale
Mutations in the gene CEP290 are associated with a spectrum of devastating and phenotypically
distinct human syndromes ranging in severity from the isolated retinal degeneration of Leber
congenital amaurosis (LCA) (den Hollander et al., 2008; Perrault et al., 2007) to the cerebellar,
renal, and retinal disease of the Joubert syndrome related disorders (JSRD)(Brancati et al., 2007;
Sayer et al., 2006; Valente et al., 2006) and the multi-organ system pathology and embryonic
lethality of Meckel syndrome (MKS) (Baala et al., 2007). The varied pathology seen in these
disease states is thought to be due to CEP290’s essential role in the development and
maintenance of the primary cilium,(D’Angelo and Franco, 2009; Waters and Beales, 2011) a
cellular organelle critical for signaling and growth,(Davenport et al., 2007; Han et al., 2009;
Wong et al., 2009) but how different mutations in the same gene can cause such drastically
different phenotypes remains unknown.

CEP290 pathology is almost always associated with truncating, rather than missense
mutations.(Coppieters et al., 2010) This has lead to a number of theories as to how different
truncating mutations might lead to different diseases, none of which, unfortunately, have
proven true. It has also been reported that the truncating p.R151X mutation in exon 7 of the

CEP290 gene induces skipping of the mutated exon, resulting in the production of small
amounts of a near-full-length CEP290 message containing an intact open reading frame (Littink
et al., 2010). We speculated that such nonsense-induced alternative splicing, or NAS (Chang et
al., 2007; Puisac et al., 2013; Vuoristo et al., 2004; Wang et al., 2002; Figure 1a), might lead to
selective exon skipping and the partial correction of truncating mutations in CEP290 patients in
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general, with levels of full-length and near-full-length CEP290 protein correlating with disease
severity.

Formulating a model
To formulate and assess our model we first classified all 142 known human CEP290
mutations(Coppieters et al., 2010; Halbritter et al., 2012; Otto et al., 2011; Papon et al., 2010;
Wiszniewski et al., 2011; Yzer et al., 2012) based on their predicted coding effects (Figure 1b).
Mutations were divided into three categories – mild, moderate, and severe. Mild mutations
(green) were those that were predicted to have only small or moderate effects on the levels of
CEP290 protein. These included all known CEP290 missense mutations and the common intronic
c.1655A>G mutation, which results in only a roughly 50% reduction in normal CEP290 transcript
(den Hollander et al., 2006).

All truncating mutations were classified as either moderate or severe. Moderate mutations
(orange) were those that resulted in the introduction of a premature stop codon (due either to a
missense, frame-shift, or splicing mutation) within an exon beginning and ending in the same
reading frame. Transcripts including the mutated exon and premature stop codon should be
subject to nonsense mediated decay (NMD) (Baker and Parker, 2004; Maquat, 2004), resulting
in little or no protein production, whereas those few transcripts skipping the mutated exon,
through the process of NAS, should result in the production of low levels of near-full-length
CEP290 (Figure 1a.I-II).

114

Severe mutations (red), on the other hand, were those that resulted in the introduction of a
premature stop codon within an exon beginning and ending in different reading frames. Thus
transcripts either including the mutated exon or those skipping the mutated exon (resulting in a
frame-shift) should both contain premature stop codons and be subject to NMD, resulting in no
full length or near-full-length CEP290 protein (Figure 1a.III-IV).

Accurate correlation of CEP290 patient phenotype with genotype
Using this classification system we established a model for the prediction of total full-length and
near-full-length CEP290 protein levels for any patient, given both CEP290 disease alleles (Figure
1c). Hypothesizing that the predicted protein levels might correlate with different CEP290
disease phenotypes, we categorized different phenotypes by predicted protein level as part of
our model. Applying our model to all 231 published CEP290 patients(Coppieters et al., 2010;
Halbritter et al., 2012; Otto et al., 2011; Papon et al., 2010; Wiszniewski et al., 2011; Yzer et al.,
2012) a striking correlation was immediately apparent -- predicted protein levels were
significantly associated with disease severity with p < 0.0001 (Fisher’s exact test). More than
90% of patients with LCA, the least severe CEP290 phenotype, were predicted to have high to
medium levels of CEP290. CEP290 levels in Senior Løken syndrome and Joubert syndrome
patients were predicted to be more evenly distributed, from high to low, whereas 100% of
Meckel-like and Meckel syndrome patients, with the most severe phenotypes, were predicted
to have low to absent CEP290 levels (Figure 2a).
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Identification of domains critical to CEP290 function
While predicted protein levels clearly and significantly correlated with the severity of CEP290
disease, 48 patients presented with phenotypes and genotypes not completely consistent with
our model. Examining the mutations harbored by these patients, a pattern quickly became clear.
Greater than 70% (n=23) of patients whose phenotypes were worse than what was predicted by
our model were found to harbor truncating mutations within exons 6, 9, 40, or 41 (Figure 2b).
Although each of these mutations was considered only moderate by our model, each of these
patients presented with very severe disease. An explanation for the deleterious nature of these
particular mutations immediately became apparent when we mapped them to CEP290’s known
functional domains – exons 6 through 9 lie at the center of CEP290’s recently discovered
membrane association domain, while exons 40 and 41 make up the core of CEP290’s critical
microtubule binding domain (Figure 2c) (Chapter 2; Drivas et al., 2013). Splice variants lacking
any of these four exons might escape nonsense mediated decay and result in low levels of nearfull length protein, all of which, however, would lack regions critical to CEP290’s function. It is
interesting to note that a majority of Meckel syndrome and Meckel-like syndrome patients were
found to harbor mutations in these particular exons, suggesting that patients expressing lowlevels of CEP290 lacking critical functional regions are worse off than those expressing no
CEP290 at all. Taking the critical nature of exons 6,9,40, and 41 into account, we modified our
model to predict functional, rather than absolute, levels of CEP290. Applying this model to all
published CEP290 patients predicted functional protein levels were again significantly associated
with disease severity with p < 0.0001 (Fisher’s exact test).

116

Validating the model
To more rigorously interrogate our model we assembled a cohort of CEP290 patients with
diverse genotypes and symptoms. These patients and their records were carefully examined by
a single clinician masked to the patients’ genotypes (Figure 2a). We applied our modified model
to each of the patients and saw that, again, predicted functional CEP290 levels accurately
correlated with patient phenotype. All patients predicted to have high to medium levels of
CEP290 were diagnosed only with LCA, while patient 582, predicted to have very low levels of
CEP290 protein, carried a diagnosis of Joubert syndrome with retinal degeneration.
Interestingly, this small but well characterized cohort of patients revealed an even finer
correlation between predicted protein levels and patient phenotypes. Patient 54, predicted to
have high levels of CEP290, was found to have a visual acuity of 20/80, the best of the patients
we looked at. Similarly, patients 62, 619, and 620, all predicted to have medium levels of CEP290
(with a mild/moderate genotype), were found to have at least some residual light perception
despite having advanced retinal degeneration. On the other hand, patients 294 and 182, both
predicted to have medium levels of CEP290 protein, but with mild/severe genotypes, were
found to have no residual light perception.

Accurate prediction of CEP290 protein levels
To confirm that the protein levels predicted by our model correlated with actual CEP290 protein
levels, we analyzed CEP290 levels in primary dermal fibroblasts from each of these patients and
from three normal controls by western blotting (Figure 3b, c). Strikingly, CEP290 protein levels
perfectly correlated with the levels predicted by our model – patient 54, predicted to have high
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protein levels, was found to have roughly 50% of normal levels of CEP290. Patients predicted to
have medium protein levels were found to have roughly 33% of normal levels of CEP290. Patient
582, predicted to have very low protein levels, was found to have only 8.5% of normal CEP290
levels (Figure 3d).

CEP290 basal exon skipping is a common occurrence
To test whether the mechanism of NAS could be the cause of the low levels of CEP290 protein
detected in our experiments we designed nested PCR primers to selectively amplify across the
exon junctions between CEP290 exons 5, 6, and 7. Suspecting that patient 182 (known to
harbor a truncating mutation in CEP290 exon 6) might produce small amounts of CEP290
transcript skipping exon 6, as per our model, we used these primers to amplify through the exon
6 splicing junctions for each of our patients and controls. To our surprise, we discovered that for
each patient and control a small amount of CEP290 transcript lacking exon 6 was detectable
(Figure 3.4), indicating that basal-level exon skipping (BES) is a common occurrence, even
outside of the context of nonsense mutations. Such basal exon skipping is a plausible
mechanistic explanation for the levels of full-length and near-full-length CEP290 protein we
detected in our patients, suggesting that the basal skipping of exons occurs with some
frequency in all the CEP290 patients that we investigated.
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Applying the model to other ciliary disease proteins
To determine if the implications of BES and our findings extended beyond CEP290 and to other
disease genes we applied our model to Coiled-Coil and C2 Domain containing 2A (CC2D2A), a
ciliopathy gene that, similar to CEP290, is associated with a spectrum of clinical presentations
(Bachmann-Gagescu et al., 2012; Doherty et al., 2010; Gorden et al., 2008; Mougou-Zerelli et al.,
2009; Noor et al., 2008; Tallila et al., 2008). Even without accounting for any CC2D2A functional
domains, we found that predicted CC2D2A protein levels were significantly correlated with
disease severity with p < 0.0001 (Fisher’s exact test). 100% of patients with uncomplicated
Joubert syndrome were predicted to have high to medium levels of CC2D2A. Patients with
Joubert syndrome with retinal or renal disease were found to have a more even distribution
across different predicted protein levels. 80% of patients with Meckel syndrome, on the other
hand, were predicted to have very low or absent levels of CC2D2A protein (Figure 2e).
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Discussion
To date, the pleiotropic nature of ciliary dysfunction has defied explanation despite significant
scientific investigation and analysis. In particular, how mutations in single ciliary disease genes
such as CEP290 can result in such drastically different phenotypes in different patients remained
completely unknown. Here we have presented data that, for the first time, accurately and
robustly correlates CEP290 mutations with clinical presentation and have described the
mechanism by which these mutations, through alternative splicing and exon skipping, result in
predictable levels of CEP290 protein and predictable disease phenotypes.

Our model relies on the concepts of alternative splicing and exon skipping, phenomena that
have recently been shown to occur with high frequency within the retina (Farkas et al., 2013)
and which have been overlooked as a potential source of pleiotropy. The canonical splicing of a
gene transcript to yield an annotated mRNA is often treated as a rule, leaving little room for the
exceptions of haphazard exon skipping and stochastic splicing, and imposing an artificial
uniformity on the cell transcriptome. Here we have shown this idea to be false –basal levels of
non-canonical exon skipping were found to occur in every one of the 10 human samples we
investigated, yielding abundant transcript variety and posing a potential solution to the problem
of pleiotropy.

Our data indicate that, in the face of premature stop mutations, basal exon skipping (BES) may
provide nature a potential workaround, supplying the cell with low levels of alternatively spliced
transcript lacking the mutated exon producing low levels of near-full length, functional protein.
This workaround is, of course, dependent on the affected exon – exons beginning and ending in
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different reading frames provide no benefit when skipped, as such transcripts would contain
frame shifts and almost certainly premature termination codons. We found BES to faithfully and
robustly explain the pleiotropy associated both with CEP290 mutations and with mutations in
the CC2D2A gene. With continued investigation, it will be interesting to see if this mechanism
extends beyond the ciliopathies and ciliary disease genes. In fact, the mechanism of BES may
provide a new genetic paradigm, changing our understanding of the cellular transcriptome and
helping to explain the genetics of pleiotropy and human disease.
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Methods
Mutation Analysis
Human mutations in CEP290 were compiled from published articles and from the CEP290
mutation database (http://medgen.ugent.be/cep290base/) (Coppieters et al., 2010). The coding
effect of each mutation was noted, particularly with respect to whether an exon was predicted
to be disrupted by a premature stop codon (due to either nonsense or frame shift mutations) or
skipped due to a mutation affecting splicing. Mutations were then sorted into three color-coded
groups. Mild (green) mutations were those that were predicted to have little effect on total
CEP290 protein levels (in frame deletions, missense mutations, truncating mutations occurring
within the last exon, and splicing mutations in which there is evidence for high levels of normal
transcript production). Moderate (orange) mutations were those that were predicted to
significantly reduce CEP290 protein levels (those that resulted in a premature stop codon within
(or splicing mutation likely to result in the skipping of) an in-frame exon). Severe (red) mutations
were those that were predicted to act as null alleles (those that resulted in a premature stop
codon within (or splicing mutation likely to result in the skipping of) an out-of-frame exon). The
sorted mutations are listed in figure 1B. Mutations in the gene CC2D2A were sorted in an
identical fashion. For our modified CEP290 model, mutations affecting exons 6, 9, 40, or 41 were
considered severe. These exons encode domains of the CEP290 protein critical in membrane
and microtubule binding (Chapter 2, Drivas et al., 2013).
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CEP290 patient protein level and disease phenotype prediction
A model, as in figure 1C, for predicting the amount of full-length and near-full-length CEP290
protein levels in patients for whom both CEP290 disease alleles were known was devised as
follows. Any patient with two CEP290 alleles encoding mild mutations was predicted to have
high levels of full-length or near-full-length CEP290. Patients with alleles encoding one mild
mutation were predicted to have medium levels of CEP290. Patients with alleles encoding two
moderate CEP290 mutations were predicted to have low levels of CEP290. Patients with alleles
encoding one moderate and one severe mutation were predicted to have very low levels of
CEP290. Patients with two severe alleles were predicted to produce no CEP290. The same model
was applied to CC2D2A patients.

Cells and cell culture
Primary dermal fibroblasts were isolated from patient skin punches and grown in DMEM
supplemented with 10% FBS and 1% pen-strep at 37˚ C in a humidified 5% CO2 atmosphere.
Fibroblasts were passaged fewer than 10 times before analysis.

Patient Assessment
Patients were see in either the University of Iowa or the Children’s Hospital of Philadelphia
retinal degenerations clinic where a family history was ascertained and the individuals received
standard clinical examinations including assessments of visual acuity, visual fields, and retinal
structure. The diagnosis of LCA was made by electroretinogram. Molecular genetic testing was
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carried out after appropriate IRB-approved consent/assent (plus parental permission) was
obtained.

CEP290 protein levels
Patient fibroblasts were washed with PBS and 5x106 cells were lysed by incubation in 50 µL of
RIPA buffer () supplemented with a protease inhibitor cocktail for 30 minutes at 4˚ C. Cell lysates
were centrifuged at 20,000x g for 15 minutes to remove insoluble material and the resulting
supernatant was analyzed by SDS PAGE and immunoblotting using standard techniques. Blots
were probed with antibodies against CEP290 (Abcam, AB105383) and α-tubulin (Abcam,
AB7291) and imaged with a Typhoon 9400 instrument (GE).

Exon junction detection
cDNA was isolated from patient fibroblasts using Qiagen’s RNeasy kit and Invitrogen’s
SuperScript III First-Strand Synthesis kit, following the manufacturers’ protocols. A set of primers
was designed to amplify across the exon junctions from CEP290 exons 4 to 8. A nested primer
set was designed to amplify across the exon junctions from CEP290 exons 5 to 7. 10 cycles of
amplification were run using the initial primer set with patient/control cDNA as template.
Subsequently, 30 cycles of amplification were run using the nested primer set and 2 µL of the
initial reaction as template. The resulting PCR products were resolved by agarose gel
electrophoresis, imaged, gel excised, and submitted for Sanger sequencing.
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Statistical Analysis
The statistical significance of the difference between three or more means was determined
using a two-way ANOVA and Tukey’s HSD test. Statistical analysis was performed using
GraphPad Prism Software 5.0b. p-values < 0.05 were considered significant.
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Figure 3.1. A model to predict
CEP290 protein levels
(a) A schematic of nonsense-induced
alternative splicing (NAS), illustrating
the combined effects of nonsense
mutations, alternative splicing and
nonsense-mediated decay (NMD) on
protein levels. (I and III) The coding
sequence of a gene containing a
nonsense mutation (red line) is
spliced together to yield the fulllength transcript. In both cases, the
inclusion of the exon harboring the
nonsense mutation targets the
transcript for NMD. (II) Alternative
splicing yields a transcript lacking
exon 2 and the premature stop
codon. The message persists and
results in a slightly truncated protein
product. (IV) Alternative splicing
yields a transcript lacking exon 3 and
the premature stop codon but
containing a frame-shift from the
splicing together of incompatible
exon ends. The frame shift results in
premature
stop
codons
and
nonsense-mediated decay.
(b) Human CEP290 mutations were
classified based on their predicted
coding effects. In green are
mutations predicted to result in
medium to high levels of CEP290
protein. In orange are mutations that,
through the mechanism described in
panel A.II, are predicted to result in
low levels of CEP290 protein. In red
are mutations that, through the
mechanisms described in panel A.III-IV, are predicted to act as null mutations.
(c) A model for predicting CEP290 protein levels in individual patients for whom both CEP290
disease alleles are known. Listed below are the CEP290 disease phenotypes predicted to be
associated with each protein level. LCA, Leber congenital amaurosis; SLS, Senior Loken
syndrome; JSRD, Joubert syndrome and related disorders; ML, Meckel-like syndrome; MKS,
Meckel syndrome.
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Figure 3.2. Predicted CEP290
protein
levels
strongly
correlate
with
patient
phenotype
(a) Predicted CEP290 protein
levels were determined, using
our model, for all published
patients for whom both
CEP290 disease alleles were
known. Patients were sorted
by phenotype and predicted
protein levels were plotted as
a percent of total cases for
each
phenotype.
Leber
congenital amaurosis (LCA),
n=140.
Senior
Løken
syndrome
(SLS),
n=16.
Joubert
syndrome
and
related disorders (JSRD),
n=58. Meckel-like syndrome
(ML), n=4. Meckel syndrome
(MKS), n=13.
(b) Of those patients whose
phenotypes were more
severe than predicted by our
model, 70% harbored mutations in exons 6, 9, 40, or 41.
(c) A scale representation of the CEP290 protein indicating the location of the mutations
identified in panel B. The mutations within exons 6 and 9 fall within CEP290’s membrane binding
region. The mutations within exons 40 and 41 fall within CEP290’s critical microtubule binding
region (Chapter 2; Drivas et al., 2013).
(d) Predicted functional CEP290 protein levels were determined using a modified model taking
into account the critical nature of exons 6, 9, 40 and 41 for all published patients for whom both
CEP290 disease alleles were known. Patients were sorted by phenotype and predicted
functional protein levels were plotted as a percent of total cases for each phenotype as in panel
a.
(e) Our model for predicting protein levels applied to a different ciliopathy disease gene,
CC2D2A. Patients were sorted by phenotype and predicted protein levels were plotted as a
percent t of total cases for each phenotype. Joubert syndrome (JS), n=23. Joubert syndrome
with extra-CNS involvement (JSRD), n=14. Meckel syndrome (MKS), n=15.
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Figure 3.3. Actual CEP290 protein levels robustly correlate with predicted protein levels and
are predictive of clinical phenotype.
(a) Table listing the clinical features, mutations, and predicted protein levels of seven CEP290
patients. Color coding is as in Figure 1. Boxes with orange and red stripes indicate mutations
expected to produce low levels of dysfunctional CEP290 lacking critical exons 6 or 41.
(b) Immunoblot showing relative levels of CEP290 protein in fibroblasts isolated from seven
CEP290 patients and three normal controls (A, B and C). Relevant molecular weights are
indicated in kiloDaltons.
(c) Loading control for panel B, probing for levels of αTubulin. Relevant molecular weights are
indicated in kiloDaltons.
(d) Densitometric analysis of CEP290 protein levels from seven CEP290 patients and three
normal controls as in panel B. Data are presented as mean ± SD, n=4. Means with different
letters are significantly different.
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Figure 3.4. Basal exon skipping (BES) of CEP290 exon 6 occurs in all samples
(a) Nested PCR primers were designed to amplify across the exon junctions between exons 5-7.
PCR products amplified, using these primers, from cDNA prepared from patient fibroblasts were
resolved by gel electrophoresis. Patient 182 (asterisk) is known to harbor a truncating mutation
in CEP290 exon 6. In every sample a major band of roughly 350 bp was detected (the size
expected for PCR products containing exons 5, 6, and 7) along with a minor band of roughly 200
bp (the size expected for PCR products containing only exons 5 and 7).
(b) Gel extraction and sequencing of the major band revealed that it corresponded to a PCR
product containing exons 5, 6, and 7.
(c) Gel extraction and sequencing of the minor band revealed that it corresponded to a PCR
product lacking exon 6, with exon 5 being spliced directly onto exon 7.
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LCA

Intron 26

Exon 10 FS

LCA

Intron 26

Exon 40 FS

JSRD

Intron 12

Exon 39 FS

LCA

Intron 26

Exon 10 P

LCA

Intron 26

Exon 40 FS

JSRD

Intron 28

Intron 45

LCA

Intron 26

Exon 14 FS

LCA

Intron 26

Exon 40 FS

JSRD

Exon 40

Exon 39

LCA

Intron 26

Exon 14 FS

LCA

Intron 26

Exon 41 S

JSRD

Exon 41

Exon 41

LCA

Intron 26

Exon 14 FS

LCA

Intron 26

Exon 41 S

JSRD

Exon 41

Exon 41

LCA

Intron 26

Exon 14 S

LCA

Intron 26

Exon 41 S

JSRD

Exon 41

G397 P

LCA

Intron 26

Exon 14 S

LCA

Intron 26

Exon 42 FS

JSRD

Exon 41

Exon 3

LCA

Intron 26

Exon 16 S

LCA

Intron 26

Exon 42 FS

JSRD

Exon 46

Exon 38

LCA

Intron 26

Exon 16 S

LCA

Intron 26

Exon 42 FS

JSRD

Exon 41 S

Exon 41 S

LCA

Intron 26

Exon 19 FS

LCA

Intron 26

Exon 42 FS

JSRD

Exon 42 S

Exon 42 S

LCA

Intron 26

Exon 19 FS

LCA

Intron 26

Exon 42 P

Intron 26

Exon 19 FS

LCA

Intron 26

Exon 43 FS

JSRD

Exon 42 S

Exon 42 S

LCA

JSRD

Exon 37 S

Exon 41 FS

LCA

Intron 26

Exon 20 FS

LCA

Intron 26

Exon 43 S

JSRD

Exon 41 S

Exon 41 S

LCA

Intron 26

Exon 21 FS

LCA

Intron 26

Exon 48 FS

JSRD

Exon 42 S

Exon 42 S

LCA

Intron 26

Exon 22 S

LCA

Intron 26

Exon 48 FS

JSRD

Exon 42 S

Exon 42 S

LCA

Intron 26

Exon 24 FS

LCA

Intron 26

Exon 48 FS

JSRD

Exon 17 FS

Exon 31 S

LCA

Intron 26

Exon 25 S

LCA

Intron 26

Exon 48 FS

JSRD

Exon 17 FS

Exon 44 S

LCA

Intron 26

Exon 28 FS

LCA

Intron 26

Exon 48 FS

JSRD

Exon 36 S

Exon 36 S

LCA

Intron 26

Exon 28 FS

LCA

Intron 26

Exon 5 FS

JSRD

Exon 36 S

Exon 36 S

LCA

Intron 26

Exon 28 FS

LCA

Intron 26

Exon 54 FS

JSRD

Exon 36 S

Exon 36 S

LCA

Intron 26

Exon 28 S

LCA

Intron 26

Exon 6 FS
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LCA

Intron 26

Exon 6 FS

MKS

Exon 28 FS

Exon 28 FS

LCA

Intron 26

Exon 6 FS

MKS

Exon 40 FS

Exon 40 FS

LCA

Intron 26

Exon 6 S

MKS

Exon 40 FS

Exon 40 FS

LCA

Intron 26

Exon 9 S

MKS

Exon 40 FS

Exon 40 FS

LCA

Intron 26

Intron 13

MKS

Exon 40 FS

Exon 40 FS

LCA

Intron 26

Intron 13

MKS

Exon 6 FS

Exon 19 FS

LCA

Intron 26

Intron 19

MKS

Exon 6 FS

Exon 6 FS

LCA

Intron 26

Intron 21

MKS

Exon 6 FS

Exon 6 FS

LCA

Intron 26

Intron 26

MKS

Exon 9 S

Exon 9 S

LCA

Intron 26

Intron 26

MKS

Exon 9 S

Exon 9 S

LCA

Intron 26

Intron 26

MKS

Intron 3

Exon 6 FS

LCA

Intron 26

Intron 26

MKS

Intron 3

Exon 6 FS

LCA

Intron 26

Intron 26

ML

Exon 26 S

Exon 31 S

LCA

Intron 26

Intron 26

ML

Exon 41 FS

Exon 42 FS

LCA

Intron 26

Intron 26

ML

Exon 41 FS

Exon 42 FS

LCA

Intron 26

Intron 26

ML

Exon27 S

Intron 27

LCA

Intron 26

Intron 26

SLS

Exon 2 P

Exon 2 P

LCA

Intron 26

Intron 26

SLS

Exon 2 P

Exon 15 S

LCA

Intron 26

Intron 26

SLS

Exon 26 P

Exon 26 P

LCA

Intron 26

Intron 26

SLS

Exon 36 S

Exon 34 S

LCA

Intron 26

Intron 26

SLS

Exon 36 S

Exon 34 S

LCA

Intron 26

Intron 26

SLS

Exon 41 FS

Intron 32

LCA

Intron 26

Intron 26

SLS

Exon 41 FS

Exon 42

LCA

Intron 26

Intron 26

SLS

Intron 21

Intron 21

LCA

Intron 26

Intron 26

SLS

Intron 21

Intron 21

LCA

Intron 26

Intron 26

SLS

Exon 2 P

Intron 38

LCA

Intron 26

Intron 26

SLS

Exon 20 S

Exon 36 S

LCA

Intron 26

Intron 26

SLS

Exon 20 S

Exon 36 S

LCA

Intron 26

Intron 26

SLS

Exon 31 S

Exon 36 S

LCA

Intron 26

Intron 26

SLS

Exon 35 FS

Exon 36 S

LCA

Intron 26

Intron 26

SLS

Intron 13

Exon 36 S

LCA

Intron 26

Intron 26

SLS

Exon 5 FS

Exon 46 FS

LCA

Intron 26

Intron 26

LCA

Intron 26

Intron 26

LCA

Intron 26

Intron 26

LCA

Intron 26

Intron 26

LCA

Intron 26

Intron 26

LCA

Intron 26

Intron 28

LCA

Intron 26

Intron 28

LCA

Intron 26

Intron 28

LCA

Intron 26

Intron 3

LCA

Intron 26

Intron 38

LCA

Intron 26

Intron 4

LCA

Intron 26

Intron 40

LCA

Intron 26

Intron 40

LCA

Intron 26

Intron 40

LCA

Intron 26

Intron 40

LCA

Intron 26

Intron 40

LCA

Intron 40

Exon 13 S

MKS

Exon 14 FS

Exon 32 FS

Table 1. Genotype and
diagnosis for all reported
CEP290 patients.
Disease
diagnoses
in
green agree with our
model. Disease diagnoses
in red do not agree with
our model. Color coding of
alleles and abbreviations
are identical to those in
Figure 1, taking into
account the effect of
mutations affecting exons
6, 9, 40, or 41.
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Introduction
Dysfunction of the centrosomal and ciliary protein CEP290 is the chief cause of the devastating
blinding disease Leber congenital amaurosis (LCA), with more than 20% of LCA cases being
linked directly to mutations in the CEP290 gene (Perrault et al., 2007). LCA as a disease stands
out as being one of the first genetic disorders to be successfully and safely treated by gene
therapeutic approaches utilizing adeno-associated virus (AAV) vectors (Maguire et al., 2009), but
the extension of recombinant AAV-based therapeutics to CEP290 patients has been hindered by
CEP290’s large size.

The natural DNA capacity of the AAV virus is 4.7 kb, with therapeutic cassettes of up to 5.0 kb
having been successfully packaged within the viral capsid (Wu et al., 2010). CEP290, however,
with an open reading frame of 7.8kb, is much too long for AAV packaging (Chang et al., 2006). A
considerable amount of effort in the gene therapy community has been spent trying to package
larger-than-normal genomes within AAV – in 2008 it was reported that full length CEP290 cDNA
had been successfully packaged within AAV serotype 5 (Allocca et al., 2008), but to date no
group has been able to successfully replicate these results and CEP290 patients remain without
any effective treatments.

The recent discovery of novel autoinhibitory regions within the CEP290 gene, however, may
present an alternative approach to the development of CEP290 therapeutics (Chapter 2; Drivas
et al., 2013). Perhaps CEP290 truncation mutants lacking these inhibitory domains but
maintaining the other important functional regions of the protein would exhibit normal, or even
enhanced, CEP290 function while at the same time being small enough to fit within AAV. The
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delivery of such a therapeutic to terminally differentiated tissues, such as the retina, where
permanent activation of CEP290 is not expected to be problematic, might prove effective in the
treatment of CEP290-related diseases such as LCA.

This is not a completely novel idea – a mini-gene approach has met some success in the
treatment of muscular dystrophy where the functionality of dystrophin, a large structural
protein that is at the root of all cases of Duchenne muscular dystrophy, was found to be
preserved in a miniDystrophin gene (Koppanati et al., 2010). The AAV-vectored delivery of

miniDystrophin to a mouse model of muscular dystrophy was able to affect at least some
improvement in the disease phenotype (Koppanati et al., 2010). With this proof-of principle
study in Duchenne muscular dystrophy and with our new-found knowledge of CEP290’s
autoregulatory and functional domains, we set out to design a miniCEP290 gene for therapeutic
intervention.
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Results
Creation of a CEP290 knockdown cell line
To test the efficacy of our miniCEP290 therapeutic we first set out to create a CEP290knockdown reporter cell line. Knockdown of CEP290 in cultured cells has been reported to result
in dramatic decreases in ciliation upon serum starvation (Gorden et al., 2008; Tsang et al., 2008),
and rescue of this phenotype could serve as a good reporter for miniCEP290 protein function.
Three CEP290 shRNA constructs were generated and transfected into hTERT-RPE1 cells to assess
their ability to knockdown levels of CEP290 protein. One week post transfection cell lysates
were collected and assayed for CEP290 by western blotting. All three constructs were found to
affect a greater than 50% reduction in CEP290 protein levels, even in only transient transfection
(Figure 4.1 A, B).

To assay the effects of each of these constructs on cell ciliation, retrovirus vectors encoding
each construct were generated and used to transduce hTERT-RPE1 cells. Control and transduced
cells were stained for acetylated tubulin and observed by fluorescence microscopy for deficits in
ciliation. Construct sh2 in particular was found to affect a profound decrease in cell ciliation,
with only 50% of cells forming primary cilia, compared to 75% of control cells, upon serum
starvation (Figure 4.1 C, D).

We decided to move forward with CEP290 shRNA construct 2 due to its efficiency in knocking
down CEP290 protein levels and ability to affect a significant ciliary phenotype. CEP290 sh2
retrovirus-transduced hERT-RPE1 cells were selected for with puromycin and individual clones
were isolated and assayed for CEP290 levels. All of the clones tested were found to exhibit
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significant knockdown of CEP290 (Figure 4.2, A), but clones 2.5, 2.7, and 2.8 were each found to
affect the greatest knockdown, with less than 30% of endogenous CEP290 remaining (Figure 4.2,
B).

To test the ciliary phenotype of such significant knockdown of CEP290 protein, clonal lines 2.5,
2.7, and 2.8 were stained for acetylated tubulin, a marker of the primary cilium, and assayed by
fluorescence microscopy for ciliation. Clone 2.8 in particular was characterized by a remarkably
severe deficit in ciliation upon serum starvation (Figure 4.2, C), with only 5% of sh2.8 cells
producing primary cilia, compared to greater than 75% of control cells (Figure 4.2, D). In the
serum fed state, sh2.8 cells formed cilia only extremely rarely, making accurate quantification
difficult (data not shown). We decided to move forward with the CEP290 shRNA 2.8 cell line as a
reporter for miniCEP290 gene rescue.

Design of a miniCEP290 gene
We next set out to design a miniCEP290 gene small enough to fit within AAV’s limited packaging
capacity. To maintain as much of the protein as possible, we decided to include CEP290 amino
acids 130-380, 700-1040, 1260-1605, and 1695-1990, making for a total open reading frame of
only 3.7 kb, small enough for AAV packaging (Figure 4.3, A, B). miniCEP290 was thus strategically
designed to include CEP290’s membrane and microtubule binding domains (Chapter 2; Drivas et
al., 2013) and almost all of CEP290’s PCM-1, NPHP5, CC2D2A, and Rab8A binding domains
(Chang et al., 2006; Gorden et al., 2008; Kim et al., 2008; Schäfer et al., 2008), while leaving out
as much of CEP290’s known autoregulatory domains as possible (Chapter 2; Drivas et al., 2013).
The mini gene was codon optimized, both to increase expression levels and to harder the
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transcript against the affects of the shRNA used to generate the CEP290 knockdown reporter
cell line, and synthesized by DNA 2.0.

miniCEP290 localizes correctly in hTERT-RPE1 cells
As a preliminary test of miniCEP290’s ability to recapitulate CEP290 functionality, we generated
a GFP-fused miniCEP290 expression construct. Upon transfection into hTERT-RPE1 cells,
miniCEP290 was found to localize to discrete puncta throughout the cytoplasm (Figure 4.3, C), a
pattern similar to that observed for overexpressed full-length CEP290 (Chapter 2; Drivas et al.,
2013). In cells where primary cilia were present, a punctus of miniCEP290 was always found
exactly at the ciliary transition zone, immediately between the ciliary axoneme and centrosome
(as indicated by acetylated tubulin and pericentrin staining, respectively; Figure 4.3, C),
indicating that, at least in cells with endogenous CEP290 expression, miniCEP290 was capable of
correctly localizing to the same compartment as its full-length counterpart.
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Discussion
The work presented in this chapter represents the very beginning of an exciting attempt to
apply what we have learned about the basic biology of CEP290 to the creation of a novel and
inventive therapeutic. In the past few years it has become clear that CEP290 can be divided into
a number of discrete functional domains, some of which promote the protein’s function at the
primary cilium and others which actively work to inhibit the protein (Drivas et al., 2013; Tsang et
al., 2008). The generation of an intelligently engineered truncated version of the protein small
enough to deliver using AAV-based viral vectors but large enough to retain some of the original
protein’s function is now a real possibility. Whether or not the miniCEP290 gene we propose in
this study will ultimately prove useful to this end remains to be seen, but the general strategy
seems to be the most promising one currently available.

A number of additional studies on the miniCEP290 gene described are needed to determine
whether or not it will prove to be of any utility in rescuing CEP290 deficiency. Many of these
studies are currently underway –we have already shown that miniCEP290 localizes appropriately
in hTERT-RPE1 cells (although it is a possibility that miniCEP290 localizes to the ciliary transition
zone through homotypic interactions with endogenous CEP290, and not though an innate ability
of the mini gene to correctly localize), and, perhaps more importantly we have shown that
miniCEP290 doesn’t seem to interfere with ciliogenesis (an important concern when
overexpressing truncation mutants). We are now actively working to determine whether
miniCEP290 is also capable of binding to microtubules and cellular membranes, two functions
recently discovered to be critical to full-length CEP290’s role in cilium formation. A panel of
immunoprecipitation experiments will be performed to confirm that the mini gene is capable of
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interacting with known CEP290 binding partners, an aspect of CEP290 biology likely critical to
the protein’s function at the cilium.

The next most logical step will be to assay miniCEP290’s ability to rescue the ciliogenesis
phenotype of the sh2.8 cell line described here. We are currently subcloning the miniCEP290
gene into a lentiviral vector for this exact purpose. Any promising results in cell culture will, of
course, have to be validated in animal models to demonstrate a potential for therapeutic use.
We could test the lentiviral vectors in early postnatal rd16 mice as this will lead to transduction
of at least some photoreceptor precursor cells (Auricchio et al., 2001; Kong et al., 2008).
Alternatively, AAV vectors encoding the miniCEP290 gene can be generated and subretinally
administered to rd16 mice. If miniCEP290 does, in fact, recapitulate even some of full-length
CEP290’s function, we would expect to see at least partial correction of the rd16 retinal
degeneration phenotype in the treated eyes.

It is too early to tell when miniCEP290 will make it out of the culture dish and into preclinical
testing, but what is certainly clear is that novel therapeutic approaches are sorely needed for
people suffering from CEP290-based disease. Regardless of whether or not miniCEP290 pans out
as a therapeutic tool, it is undeniable that whatever we may learn in our examination of
miniCEP290 activity will be invaluable to the development of therapeutic interventions in the
future.
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Methods
Cell culture and treatments
hTERT RPE-1 cells were grown in DMEM:F12 supplemented with 10% FBS and 0.075% sodium
bicarbonate. All cells were grown at 37˚ C in a humidified 5% CO2 atmosphere. Transfections
were performed with FuGENE 6 reagent (Promega) according to the manufacturer’s protocol.
Cells were induced to form primary cilia by serum starvation with Opti-MEM I (Invitrogen) for
48-72 hours.

miniCEP290 synthesis
The miniCEP290 construct was codon optimized, synthesized, and sequenced by DNA2.0.

Plasmid construction
shRNA constructs were created as follows. Three regions of the human CEP290 coding sequence
without homology to other transcripts were selected as shRNA targets. Oligonucleotides
encoding the target sequence in the context of a DNA hairpin were synthesized, annealed, and
ligated into the pSIREN-RetroQ retrovirus vector (Clontech). Efficiency of knockdown was
assayed as described in the results section.

The mammalian expression vector encoding GFP-fused miniCEP290 was created by the
amplification of the miniCEP290 gene by PCR using primers compatible with Gateway® cloning
(Invitrogen). Amplified products were cloned into pDONR221 (Invitrogen) by Gateway® cloning
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to generate entry clones and subsequently shuttled into the plasmid pcDNA-DEST53 (Invitrogen)
by Gateway® LR clonase reactions to create N-terminally-tagged GFP fusions.

Retrovirus production and transduction
Retroviral vectors were produced by transfection of 80% confluent 293T cells in 100mm culture
dishes with 10 µg of retrovirus construct and 10 µg of pCL10A1 packaging plasmid. Media was
replaced after 24 hours, and retroviral supernatants were harvested at 48 and 72 hours,
combined, filtered through a 0.45 µm filter, and snap-frozen at -80° C. For retrovirus
transduction, hTERT RPE-1 cells were plated in media containing 8 µg/mL polybrene. Filtered
media containing the appropriate retroviral particles was added and 24 hours after transduction
cells were switched to selective media containing 10µg/mL puromycin.

Antibodies, immunoblotting, and immunofluorescence
Antibodies used in this study were rabbit anti-human CEP290 (Abcam, ab105383), rabbit antipericentrin (Abcam, AB4448), rabbit anti-GAPDH (Sigma, SAB2103104), mouse anti-Acetylated
α-tubulin (Sigma, T7451), HRP-conjugated goat anti-mouse (GE, NA931V), HRP-conjugated goat
anti-rabbit (GE, NA934V), Cy5 conjugated goat anti-rabbit (KPL, 072-02-15-06), and AlexaFluor
594-conjugated goat anti-mouse (Invitrogen, A1100S).

For immunofluorescence, cells were grown in chamber slides and fixed with 3% PFA in PBS for
20 minutes at 37˚ C. Cells were permeabilized with 1% Triton X-100 in PBS for 5 minutes, and
blocked in 2% BSA in PBS for 30 minutes prior to incubation with primary antibody. Secondary
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antibodies used were donkey anti-mouse or anti-rabbit, conjugated to Cy5 or AlexaFluor 594.
Slides were mounted in mounting medium containing DAPI. Images were acquired with an Axio
Imager.M2 microscope using either an EC Plan-Neofluar 40x/0.75 M27 or an EC Plan-Neofluar
63x/1.25 Oil M27 objective and captured using an AxioCamMR3 camera and the AxioVs40
software, version 4.8.2.0.

For immunoblotting, samples were subjected to SDS-PAGE and transferred to nitrocellulose
membrane using standard techniques. Membranes were blocked in 5% nonfat milk for 1 hour at
room temperature and subsequently incubated in primary antibody overnight at 4° C.
Membranes were washed three times with PBST (0.1% Tween-20 in PBS), incubated with HRPconjugated secondary antibody for 1 hour at room temperature, washed, and developed using
ECL2 reagent (Pierce), and scanned on a Typhoon 9400 instrument (GE). Immunoblots were
densitometrically quantified using ImageJ 1.44p.
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Figure 4.1. Generation and testing of CEP290 shRNA constructs
(A) hTERT-RPE1 cells transiently transfected with three different CEP290 shRNA constructs were
lysed and analyzed by western blotting for CEP290 levels. Blots were reprobed for GAPDH as a
loading control.
(B) Densitometric quantification of CEP290 protein levels in hTERT-RPE1 cells as in panel A.
CEP290 levels were normalized using GAPDH as a loading control and the percent of CEP290
remaining, compared to untransfected hTERT-RPE1 cells, was determined.
(C) Immunofluorescence microscopy images of fields of hTERT-RPE1 cells, either untransfected
or transfected with CEP290 shRNA construct 2, stained for acetylated tubulin (red) as a marker
of the primary cilium.
(D) The percent of control and sh2 transfected hTERT-RPE1 cells, as in panel C, that formed cilia
upon serum starvation.
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Figure 4.2. Isolation and testing of clonal CEP290 knockdown cell lines
(A) Clonal retrovirus-transduced hTERT-RPE1 cell lines expressing CEP290 shRNA 2 were lysed
and analyzed by western blotting for CEP290 levels. Blots were reprobed for GAPDH as a loading
control.
(B) Densitometric quantification of CEP290 protein levels in hTERT-RPE1 cells as in panel A.
CEP290 levels were normalized using GAPDH as a loading control and the percent of CEP290
remaining, compared to untransfected hTERT-RPE1 cells, was determined.
(C) Immunofluorescence microscopy images of fields of control and sh2.8 hTERT-RPE1 cells
stained for acetylated tubulin (red) as a marker of the primary cilium.
(D) The percent of control and sh2.8 hTERT-RPE1 cells, as in panel C, that formed cilia upon
serum starvation.
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Figure 4.3 Construction and testing of a miniCEP290 construct
(A) Schematic representation of the CEP290 protein with identified functional domains,
interacting domains, and protein motifs labeled. Grayed areas represent regions of the protein
not included in the miniCEP290 construct.
(B) A schematic representation of miniCEP290. Color coding of functional domains is identical to
panel A.
(C) Immunofluorescence images of hTERT-RPE1 cells transiently transfected with GFP-fused
miniCEP290 and stained for acetylated tubulin (red) and pericentrin (magenta), and with DAPI
(blue). The lower right panel represents a magnified view of a primary cilium, showing the
localization of miniCEP290 to the ciliary transition zone.
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Putting the pieces together
The work presented in the previous chapters represents an in-depth look at the function of
CEP290 in ciliogenesis and in human disease. I presented data showing CEP290 to be both a
membrane and microtubule binding protein, identified novel autoregulatory domains within
CEP290 that appear to regulate the protein’s activity and the initiation of ciliogenesis (Chapter
2), and described a novel model for CEP290 disease pathogenesis that, for the first time,
accurately and robustly links specific CEP290 mutations with specific clinical diagnoses, while at
the same time independently corroborating the critical nature of CEP290’s membrane and
microtubule binding domains (Chapter 3). Using the knowledge I gained in the first two
chapters, I describe, in studies which are still ongoing, my attempt to create a miniCEP290 gene
with the ultimate goal of using such a gene as a novel therapeutic for the numerous patients
living with CEP290-based disease (Chapter 4).

As it turns out, however, picking the problem apart has proved much easier than putting
everything back together. Whether reconstructing a mini gene from scraps and fragments,
assembling a model from hypothesis and databases, or synthesizing years of work into a single
chapter, it’s not always obvious how all the pieces fit together, even when one begins to
recognize the broader picture that the pieces will ultimately paint. Often times the portrait of
CEP290 that I thought I saw in the jumble turned out to be illusions – tightly-wound rings of
microtubules masquerading as the nuclear envelope; unambiguous nuclear localization signals
producing anything but unambiguous results – while at other times the most obvious pieces –
bright, beckoning puncta of vesicular staining, for instance – lay on the top of the pile, in plain
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view, completely overlooked or brushed aside in the pursuit of other seemingly more interesting
stories.

Regardless of how the pieces were won or how they were fit together, they ultimately paint a
picture and tell a story that is their own. The full, unabridged, and definitive version of CEP290’s
story is certainly still years in the making. While we wait, however, we have the exciting
opportunity to tell our own versions of the CEP290 story. Hopefully we will all agree on the most
important facts and, collectively, come close to approximating the true plotline. There is
certainly room for multiple viewpoints, but what follows is the story of CEP290 that, based on
my data and the data of other fantastic groups, I believe to be an accurate reflection of the
protein’s true identity.
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CEP290: a primary player in the primary cilium
The story of CEP290 is undoubtedly a story of the protein’s function (and dysfunction) at the
primary cilium. Other groups have investigated the protein’s putative role in the nucleus (Guo et
al., 2004), at the centriolar satellites (Kim et al., 2008), and as a transcriptional activator (Sayer
et al., 2006), but it seems to me (and to the field in general) that these excursions into poorlycharted CEP290 territory have been mostly diversions. At the very least, any role that CEP290
might be playing elsewhere in the cell has certainly taken a backseat to the protein’s role in
ciliogenesis and cilium function (Coppieters et al., 2010). This is not to say that the other
functions ascribed to the protein are inconsequential to CEP290’s role in the cell, but only that
the protein’s most important function, based on the data we currently have, appears to lie in
promoting and maintaining cilium formation and function. We are now finally beginning to gain
a firm grasp on the role that the protein plays in these processes, and as we have learned more
about what CEP290 is doing we have begun to appreciate how important and central the
protein is to the integrity of the cilium.

Bridging the gap
With the publication of the work presented in this thesis, and with consideration of the work
published by other groups, we have finally defined the critical role that CEP290 plays at the
primary cilium. We can now say with confidence that CEP290 directly bridges the gap between
the ciliary membrane and microtubule axoneme at the transition zone of the organelle.

Since Craige et al.’s publication in 2010, CEP290 had been known to be a critical component of
the ciliary Y-links, the dense, proteinaceous structures that appear to span the distance between
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the transition zone membrane and axoneme. A Chlamydomonas mutant lacking CEP290 was
found to exhibit significant deficits in ciliary Y-link formation, resulting in severe dysregulation of
the protein components of the ciliary compartment. But in what capacity does CEP290 serve to
stabilize or promote Y-link formation? It had been postulated, since CEP290’s discovery, that the
predominantly coiled-coiled nature of the protein might lend itself well to the structural
bolstering of the cilium (Chang et al., 2006). But whether CEP290 serves merely as a structural
connector, acting as a scaffold for the assembly of other Y-link components, or whether it plays
a direct role in riveting the axoneme to the membrane has been up for debate. In fact, as
recently as June of this year it had been proposed that CEP290 acts as nothing more than an
adapter, serving to connect microtubule binding proteins at the axoneme to membrane binding
proteins at the ciliary membrane (Wang et al., 2013).

The work on CEP290 presented in this dissertation lays that notion to rest. It is now clear that
CEP290 itself directly anchors the microtubule core of the cilium to the overlying membrane.
CEP290 contains a membrane binding domain within its N-terminus and a microtubule binding
domain near its C-terminal end. The proper function of both of these domains is absolutely
critical to the function of the protein – deletion of the microtubule binding domain in the rd16
mouse leads to profound and rapid retinal degeneration; human patients producing low levels
of CEP290 lacking either domain were found to fare far worse than even those patients lacking
CEP290 altogether. The fact that dysfunction of CEP290 and its membrane/microtubule binding
domains leads to such significant disease and such dramatic disintegration of the ciliary Y-links
speaks to the fact that CEP290’s function at the cilium is completely indispensible. There
appears to be no redundancy where CEP290 is concerned – no protein has yet been discovered
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capable of masking CEP290 deficiency. This may be due to the unique, bispecific nature of the
CEP290 protein – CEP290 is so far the only protein component of the transition zone shown
capable of directly linking the ciliary membrane to the ciliary axoneme, and the protein’s
uniqueness in this regard may be at the root of its indispensability.

But why are the membrane-to-microtubule bridges of the ciliary Y-links so important for ciliary
function? There are certainly a number of hypotheses, each of them valid. It has been suggested
that the ciliary Y-links act as a pore, selectively allowing for the transport of ciliary cargo (Kee et
al., 2012). Or perhaps the Y-links act, more simply, as a diffusion barrier, passively separating the
ciliary compartment from the cytosol (Hu and Nelson, 2011). Some have even proposed that the
ciliary Y-links are the site of IFT initiation, serving as specialized structures for the loading of IFT
particles onto the intraflagellar highway (Craige et al., 2010).

But there are certainly other protein components of the ciliary Y-links, many of which bind
either the ciliary membrane or axonemal microtubules, and many of which are known CEP290interactors, yet none of these proteins is capable of rescuing CEP290 dysfunction (Gorden et al.,
2008; Kim et al., 2008; Schäfer et al., 2008). Additionally, it is only CEP290 dysfunction that has
been shown to result in the complete dissolution of the ciliary Y-links (Craige et al., 2010). Why
is it that CEP290, in particular, is so essential to Y-link formation? I would propose that CEP290,
always present and primed for ciliogenesis at the mother centriole (Tsang et al., 2008), forms
the initial link between the axoneme and ciliary membrane – the grappling hook of the
transition zone, if you will. Once CEP290 securely attaches itself to both components of the
organelle it might then act as a scaffold for the elaboration of the structures we know as the
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ciliary Y-links (Figure 5.1). Thus, disruption of CEP290 function leads to complete collapse of the
Y-links and severe disease, while dysfunction of other Y-link components produces a less
dramatic phenotype. This hypothesis will of course require significant experimental validation,
but all the data that the field has gathered so far is at least in support of the notion.

Bending over backwards to stop ciliogenesis
It became clear from our studies of CEP290 function that the full-length CEP290 protein was
significantly inhibited in both its membrane and microtubule binding activities when compared
to truncation mutants lacking either CEP290’s N- or C-terminus. Investigating this phenomenon
further, we went on to discover that the N- and C-termini of the protein do indeed contain
autoregulatory domains that act to inhibit CEP290 function and ciliogenesis. The natural
inhibition of the protein may, in fact, be the reason why so many groups overlooked CEP290 as a
membrane or microtubule binding protein in the first place – overexpressed full-length CEP290
does not obviously associate with either microtubules or membrane.

It had been known for some time that the N- and C- termini of the protein, each containing one
of the autoregulatory domains we had identified, are both capable of homo- and
heterodimerization (Schäfer et al., 2008). Additionally, in all cases examined, full-length CEP290
seemed to be intrinsically inhibited, suggesting that, whatever the mechanism, CEP290
inhibition is an inherent quality of the protein itself. Finally, we went on to show that
overexpression of either terminal autoregulatory domain paradoxically increases, rather than
decreases, CEP290 function and ciliogenesis. All of these data led me to the hypothesis that the
N- and C-termini of the protein were interacting, cooperating to inhibit CEP290 function.
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Perhaps the termini tightly bind to each other, folding the protein over on itself, obscuring
important functional domains and inhibiting ciliogenesis (Figure 5.1).

As noted in the discussion of Chapter 2, this particular mechanism of protein inhibition is not
novel – it is, in fact, employed by a multitude of human proteins. The ERM domain-containing
proteins, for instance, which function to link the cell membrane to the actin cytoskeleton,
depend upon this same mechanism to regulate their actin and membrane binding activities
(Smith et al., 2003). In fact, the actin- and membrane-binding domains of these proteins aid in
their autoinhibition, with the two domains binding to each other in the inhibited state, inhibiting
their respective functions, and shutting the protein off (Cornell and Taneva, 2006). It is not
surprising, then, that CEP290’s membrane binding domain lies in the middle of the N-terminal

A

B

C

D

Figure 5.1 A model for CEP290 regulation
(A) The centrioles, each capped by a ring of CEP290, migrate towards the cell surface
(B) The distal appendages make contact with the membrane and form the thick transition fibers
(C) CP110 (purple) is removed from CEP290 at the mother centriole, allowing the protein to
spring open and bridge the gap between the membrane and axoneme
(D) CEP290 recruits other transition zone proteins (red/orange), creating the ciliary Y-links,
initiating axoneme extension, and establishing the distinct ciliary compartment
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autoregulatory domain I identified, and that its microtubule binding domain lies immediately
adjacent to the identified C-terminal inhibitory domain. It is likely that CEP290’s membrane and
microtubule binding domains play similar roles in inhibiting the protein’s function.

Reviewing the literature, it became clear that there had been hints of this mechanism of
regulation all along. It has been demonstrated that the protein CP110 is capable of binding to
and inhibiting CEP290. In fact, CP110 binds CEP290 squarely in the middle of its membrane
binding/N-terminal autoregulatory domain (Tsang et al., 2008). It is tantalizing to think that the
binding of CP110 causes a conformational change within CEP290’s membrane binding domain,
rendering it incapable of binding membranes and promoting and stabilizing its binding to the Cterminal microtubule binding/autoregulatory domain. CP110 would thus keep the protein
inhibited, folded head-to-tail, at the mother centriole throughout the cell cycle. The removal of
CP110 at the initiation of ciliogenesis (Goetz et al., 2012) might allow CEP290 to spring open,
freeing its membrane and microtubule binding domain to bridge the transition zone gap and
promote Y-link formation (Figure 5.1).

A second hint to the existence of this mechanism of CEP290 inhibition came from the initial
study of the rd16 mouse. When the rd16 Cep290 mutation was first described, the authors
noted that rd16 Cep290 had a significantly higher affinity for its binding partners than full-length
Cep290 did itself (Chang et al., 2006). The rd16 Cep290 deletion encompasses much of the
protein’s microtubule binding domain, which, as I have noted, may be playing a critical role in
mediating Cep290 autoinhibition. The rd16 Cep290 deletion might thus be interfering with
CEP290’s innate regulation, preventing the protein from shutting off, and paradoxically
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increasing its apparent affinity for its binding partners. The difficult-to-explain increase in affinity
of rd16 Cep290 for its binding partners now makes perfect sense in the context of CEP290
autoregulation.

However, one last piece of the model is missing. One would hypothesize that CEP290 must
contain some kind of a hinge, allowing the two autoregulatory domains at either end of the
protein to come in contact with each other to affect CEP290 inhibition. As it turns out, we may
have, unknowingly, already identified CEP290’s hinge. CEP290 has long been known to contain,
at its center, a Structural Maintenance of Chromosomes (SMC) homology domain (Coppieters et
al., 2010). The SMC proteins themselves are composed of two coiled coil arms on either side of a
molecular hinge that can be selectively swung open or closed to bind to and gather the cell’s
chromosomes (Melby et al., 1998). It had been assumed that CEP290’s SMC homology domain
was playing some kind of role in DNA binding (presumed, it seems, only because of the
“chromosomes” part of the SMC name and not because of any evidence that CEP290 can
actually bind DNA). The SMC homology domain now suddenly makes much more sense,
potentially providing a hinge for the opening and closing – activation and inactivation – of
CEP290.

To me, at least, this model for CEP290 inhibition makes perfect sense. It helps to explain so
many pieces of previously difficult-to-explain data and synthesizes many aspects of CEP290
biology, both on a real and abstract level, into a compelling story, leaving very few loose ends.
Significant experimentation is clearly needed to validate this hypothesis, but I eagerly anticipate
any advances that may be made on this front.
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CEP29opathy
Throughout this thesis I have belabored the point that CEP290 dysfunction results in significant
and devastating disease, but this point cannot be stressed enough – accounting for up to 20% of
all cases of Leber congenital amaurosis (LCA), CEP290 is the single biggest cause of LCA yet
discovered (den Hollander et al., 2008; Perrault et al., 2007). CEP290 is also the only gene known
to be involved in the pathogenesis of such a broad spectrum of ciliopathy disease, with
mutations in the gene resulting in at least 7 distinct ciliopathy phenotypes, ranging in severity
from isolated retinal degeneration to embryonic lethality (Coppieters et al., 2010). Up until now,
however, we were at a loss when it came to describing the molecular mechanisms of CEP290
disease pathogenesis. The work presented in this thesis has begun to elucidate some of these
mechanisms, and we are now finally beginning to get a handle on the molecular mechanisms of

CEP290 disease.

Molecular mechanisms of CEP290 disease pathogenesis
Over the past 10 years, the number of reported disease-causing mutations in the human CEP290
gene has exploded, with over 140 deleterious mutations identified throughout the gene’s open
reading frame (Coppieters et al., 2010). But even as the number of reported mutations
increased, the effects that these mutations were having on CEP290 function remained
unknown; in fact, CEP290’s function in general continued to remain somewhat of a mystery. It is
now clear that mutations in CEP290, in one way or another, interfere with the protein’s critical
role in bridging the gap between the ciliary membrane and axoneme: we found that the retinal
pathology of the rd16 mouse, a model of CEP290 disease characterized by a large in-frame
deletion of the Cep290 gene, was ultimately due to the complete disruption of Cep290
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microtubule binding (Chapter 2); numerous human mutations in the CEP290 gene map to this
same critical microtubule binding domain, suggesting a potential molecular mechanism for
human CEP290 disease.

But on closer inspection it becomes clear that the story isn’t quite so simple. Of all the 142
identified human CEP290 mutations, fewer than 10 are of the missense variety (Coppieters et
al., 2010). All of the others are predicted to result in premature termination codons, either
directly, through nonsense mutations, or indirectly, through deletions/insertions resulting in
frame-shifts. The effects of these truncating mutations on CEP290 protein levels has not been
thoroughly investigated, but it is reasonable to assume that, through the mechanism of
nonsense-mediated decay (NMD), many of these mutations should act as null alleles (Baker and
Parker, 2004), producing little if any CEP290 protein. Suddenly the mechanistic relevance of
mutations in the microtubule and membrane binding domains of CEP290 seems greatly
diminished – certainly these mutations should significantly interfere with CEP290 function, but
so should truncating mutations affecting any other region of the protein, each of them acting,
through NMD, to decimate CEP290 protein levels and eliminate CEP290 function.

These important observations and implications have received minimal discussion in the
literature, but seem integral to CEP290 disease pathogenesis. If nearly every known CEP290
mutation should result in absent CEP290 protein, how can different CEP290 mutations result in
such drastically different phenotypes?
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While a number of hypotheses and models to explain the mechanisms and spectrum of CEP290
disease have been proposed, none have held up to scientific scrutiny. In Chapter 3 of this
dissertation, however, we propose a model for CEP290 disease pathogenesis that, for the first
time, robustly and accurately illustrates how different CEP290 mutations result in different
diseases. The model is based on a simple concept: through the mechanisms of NMD and basal
exon skipping (BES), different CEP290 mutations result in different CEP290 protein levels, with
decreasing protein levels correlating with increased disease severity (Chapter 3).

Our model explains many of the inconsistencies the field has encountered in describing CEP290
disease pathogenesis but, perhaps more importantly, it surprised us by highlighting the
importance of CEP290’s microtubule and membrane binding domains in disease pathogenesis. A
number of patients with severe CEP290 disease did not, at first glance, neatly fit our model. On
closer inspection, it was discovered that the pathology seen in these patients stemmed from
their production of low levels of CEP290 (levels high enough to potentially ameliorate disease),
but of CEP290 lacking either the microtubule or membrane binding domain. In fact, these
patients were found to fare worse than those patients producing no CEP290 at all. Disruption of
CEP290’s membrane or microtubule domains again proved to be the critical mechanism in the
progression of CEP290 disease.

And so our inquiry into CEP290 disease pathogenesis has come full circle. The membrane and
microtubule binding functionality of the protein does, in fact, lie at the heart of CEP290 disease;
it is this dual functionality that is critical to the protein’s role in ciliary biology and human health.
However, it is not mutations in these critical regions that are responsible for CEP290 pathology,
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but rather mutations, in general, that diminish the levels of functional CEP290 protein. As
CEP290 protein levels drop, the structural integrity of the ciliary Y-links is jeopardized.
Eventually, the integrity of the ciliary compartment itself is compromised – trafficking into the
organelle is hindered and normally excluded proteins begin to leak in. Thus, without enough
CEP290 to bridge the gap between the transition zone membrane and axoneme, disease begins
to manifest – first, with moderately reduced levels of CEP290, in the retina; with lower CEP290
levels, in the kidneys; finally, with lower CEP290 levels still, throughout the body. With this new
understanding of the mechanisms underlying CEP290 pathology we can finally begin to consider
novel therapeutic strategies to help those suffering from CEP290 disease.

Implications for therapeutic intervention
As illustrated in the work presented in this thesis, it is inevitable that any new understanding we
gain of CEP290’s basic biology will be critical in the development of innovative CEP290
therapeutics. In our studies, the identification of novel CEP290 functional domains immediately
suggested new avenues towards therapeutic approaches. For instance, it is now clear that any
gene transfer strategy delivering CEP290 or a miniCEP290 gene must take into consideration the
critical role the protein plays in bridging the transition zone gap, taking special care to preserve
CEP290’s membrane and microtubule binding functionality (Chapter 2). On the other hand, the
identification of novel inhibitory domains within the protein presents numerous possibilities for
therapeutic approach of a different sort. If these inhibitory domains are truly dispensable for
CEP290 function in the retina, we may be one step closer to the design and delivery of a

miniCEP290 gene capable of replacing the full-length protein’s function while being small
enough to fit within the AAV class of viral vectors (Chapters 3, 4). Regardless of whether such a
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mini gene strategy ultimately pays off, learning more about the regulation of CEP290 through
the continued study of its inhibitory domains may present completely new paradigms for the
treatment of CEP290 disease. With a finer understanding of how CEP290 is activated, the
possibility exists that we might be able to potentiate what little CEP290 may still be present in
the tissues of CEP290 patients by manipulating endogenous CEP290 regulation for therapeutic
gain.

The activity of residual CEP290 protein levels is not only relevant to the design of therapeutics –
it is now clear that CEP290 protein levels are critically important to human health. The sliding
scale of CEP290 disease (CEP29opathy, to coin a new term) indicates that there is no
CE29opathy tipping point – incremental decreases in CEP290 protein levels result in incremental
decreases in ciliary function. These findings have major, and not necessarily favorable,
implications for therapeutic intervention. In Chapter 3 we discovered that even high levels of
CEP290 protein (up to 50% of normal) were still associated with significant retinal degeneration.
Low to absent levels of CEP290, on the other hand, were uniformly associated with severe
disease. In terms of therapeutic approach, these data seem to indicate that relatively high levels
of CEP290 expression will have to be achieved in the retina if there is any hope of halting the
progression of CEP290-associated LCA. The renal disease common to so many CEP29opathies,
on the other hand, may be rescuable with lower levels of CEP290 protein, as it is only at medium
to low levels of CEP290 that renal symptoms are manifest. Unfortunately, the CNS and systemic
deficits of Joubert syndrome and Bardet-Biedl syndrome will likely be refractory to any gene
therapeutic approach since much of the pathology in these diseases occurs during the very
earliest stages of embryonic development (Chen, 2007).
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Regardless of how effective a gene transfer approach to CEP290 disease might or might not be
in ameliorating the pathology seen in different organ systems, the fact remains that we are still
without any CEP290 therapeutic. Some of the findings presented in this dissertation may
someday aid in the development of such an intervention, perhaps through the use of a

miniCEP290 gene, as discussed, or perhaps through some as-of-yet undreamt of approach.
Either way, I am glad to have contributed to the work towards this end. I can only hope that
some small part of this thesis will go on to make difference in the lives of those CEP290 patients
and supporters who have already made a difference in mine.
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